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GENERAL INTRODUCTION
Hidradenitis suppurativa (HS), also known as acne inversa, is an infl ammatory, debilitating 
follicular skin disease with natural fl are ups. It usually presents after puberty with painful, 
deep-seated, infl amed lesions in the inverse areas of the body, most commonly the axillary, 
inguinal and anogenital regions (Figure 1). HS is not a rare disease since estimated prevalence 
rates range between 1% and 4%1,2 in European countries. HS prevalence rates in other parts of 
the world are unknown. The historic fi gure and founder of communism Karl Marx is thought 
to have been a HS suff erer3. Generally, HS develops almost always after puberty, usually in the 
second decade of life at a median age of 20 years4. Women are more frequently aff ected than 
men with a sex ratio of 3:11,4. In a study of 302 HS patients the most frequently aff ected area 
was the inguinofemoral area in 90%, hereafter, the axillary region in 69%, perineal/perianal 
involvement in 37%, buttocks in 27% and the breasts in 18% of cases4. Due to its frequent 
Figure 1. Prototypical hidradenitis suppurativa
 
Axillary HS in a man (source Dept. Dermatology, Erasmus MC). (See also Color section, p. 193.)
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occurrence, patients with HS are seen or being treated by a variety of medical specialists 
such as general practitioners, dermatologists, surgeons, plastic surgeons, gynaecologists and 
urologists. However, many physicians are not familiar with the disease, which is indirectly 
illustrated by the reported mean time till diagnosis of 7 years5, the misconception that HS is a 
bacterial infection of the apocrine glands, and the assumption that HS is an ectopic variant of 
acne vulgaris. The latter has frequently resulted in fruitless treatment with isotretinoin. HS is 
associated with frequent and long-term sick leave6, suggesting a substantial underestimated 
socio-economic impact. Furthermore the development of the life-threatening squamous cell 
carcinoma, triggered by persistent infl ammation, has been reported in chronic HS lesions, 
especially on the buttocks of men7.
Despite its common occurrence, its profound eff ect on quality of life and its socio-econom-
ic impact, HS is a scientifi cally relatively neglected disease. The limited research so far has 
yielded few novel insights into the pathomechanisms of the disease and hence little basis 
for rational improvement of therapy. Consequently, there is a large unmet medical need in 
patients with HS. Fortunately, in the last decade, HS has gradually gained more attention, 
and has become a more attractive topic of research, illustrated by the increasing numbers 
of scientifi c publications each year (Figure 2). This indicates that this devastating disease is 
fi nally receiving more attention.
Figure 2. Number of publications on HS is increasing
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Number of hits in Pubmed (www.pubmed.org) per year using the search terms hidradenitis suppurativa, 
acne inversa, ectopic acne, Verneuil’s disease, pyoderma fi stulans signifi ca, and fox den disease.
Historical perspective and nomenclature
Literally translated, hidradenitis suppurativa means ‘pussing sweat gland infl ammation’ and 
is derived from the Greek hidros, meaning sweat and aden meaning glands. Concepts on HS 
pathogenesis changed over time, but at very slow pace. In 1854, the French surgeon Verneuil 
associated the symptoms with infl ammation of areas characterized by many sweat glands 
and named it HS8. In 1955, Shelly and Cahn experimentally obstructed the sweat glands in 
the axilla and saw HS like lesions develop, supporting the concept that obstructed sweat 
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ducts result in HS9. With plugging as the primary pathogenic mechanism, HS was classifi ed 
with three other follicular occlusion diseases in the follicular occlusion tetrad10. The follicular 
occlusion tetrad consists of acne conglobata, dissecting cellulitis of the scalp or perifolliculitis 
capitis et suff odiens, pilonidal sinus and hidradenitis suppurativa (Box 1). Acne conglobata is 
a form of acne vulgaris characterized by severe, eruptive nodulocystic acne without systemic 
manifestations (Figure 3). Dissecting cellulitis of the scalp is characterized by scarring alope-
cia with suppurating nodules and fi stulas (Figure 4) and pilonidal sinus is characterized by 
infl ammatory nodules and fi stulas caused by ingrown hairs, usually in the gluteal cleft (Figure 
5). It is unknown how often these diseases co-occur and what their pathogenic interrelations 
are. With plugging of the acrosyringium as the suspected primary event, Plewig and Steger 
introduced the name acne inversa in 198911. But it was not until 1990 that Yu and Cook, in a 
small histological study, demonstrated that apocrinitis was present only in a minority of HS 
specimens and follicular occlusion was a far more constant histopathological feature12. Over 
Box 1. The follicular occlusion tetrad
Acne conglobata
Dissecting cellulitis of the scalp
Hidradenitis suppurativa
Pilonidal sinus
Figure 3. Acne conglobata on the back of a man
Acne conglobata is characterized by severe eruptive nodulocystic acne without systemic manifestations 
(source Dept. Dermatology, Erasmus MC). (See also Color section, p. 193.)
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the years, several synonyms for the disease emerged, but none suffi  ciently covers the patho-
genesis (Box 2). Synonyms used are: acne inversa (generally German Literature), ectopic acne 
(Dutch literature), Verneuils´s disease (French literature), pyoderma fi stulans signifi ca and fox 
Figure 4. Dissecting cellulitis of the scalp or perifolliculitis capitis et suff odiens
 
Dissecting cellulitis of the scalp is characterized by scarring alopecia with suppurating nodules and 
fi stulas (source Dept. Dermatology, Erasmus MC). (See also Color section, p. 194.)
Figure 5. Pilonidal sinus at the gluteal cleft
Pilonidal sinus characterized by infl ammatory nodules and fi stulas caused by ingrown hairs (source Dept. 
Dermatology, Erasmus MC). (See also Color section, p. 194.)
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den disease, according to the resemblance of the fi stula network with the underground maze 
of tunnels of fox holes. Today, HS experts agree HS is a misnomer, but since none of these 
synonyms suffi  ciently cover the pathogenesis, most experts prefer to use the term HS at the 
current time.
Disease severity classifi cation
In 1989, a severity classifi cation was fi rst proposed by Hurley13 (Box 3 and Figure 6). Fortu-
nately the stage I disease is the most common (68% of patients), while stage II occurs in 28% 
of patients, and 4% of HS patients have stage III4. All HS patients initially start in stage I, but 
data on prognosis are limited and consequently it is unpredictable which patients progress 
to the more severe stage of the disease. Today, the Hurley classifi cation is still useful for the 
classifi cation in three severity groups but the classifi cation has limitations. The Hurley clas-
sifi cation is a not very quantitative one, consisting of only 3 stages and based on rather static 
disease characteristics such as scarring and fi stulas. Hence, it is not suitable for monitoring 
the effi  cacy of interventions in clinical trials. A more detailed and dynamic HS severity score 
was created by Sartorius et al. and was later modifi ed and validated14-16 (Figure 7). The main 
parameter in the modifi ed Sartorius score is the counting of individual nodules and fi stulas. 
This modifi ed Sartorius score is diffi  cult to use and its usability is limited especially in severe 
cases in which lesions become confl uent.
Box 3. HS severity staging according to Hurley13
Hurley stage Clinical description
Stage I Abscess formation, single or multiple, without sinus tract and cicatrization.
Stage II Recurrent abscesses, with tract formation and cicatrization. Single or multiple, widely separated lesions.
Stage III Diff use or near diff use involvement, or multiple interconnected tracts and abscesses across entire area.
Quality of life
HS can have a great impact on the patient’s quality of life6,17-21. This reduction in quality of 
life is even more signifi cant than in other recalcitrant dermatologic diseases such as severe 
psoriasis or hand eczema21,22. This decline in quality of life is easy to comprehend. First, the 
infl ammatory lesions can be extremely painful leading to impairment of daily activities. 
Second, the purulent discharge can be foul-smelling, require multiple changes of clothing 
Box 2. Synonyms for hidradenitis suppurativa
Acne inversa
Ectopic acne
Verneuils disease
Pyoderma fi stulans signifi ca
Fox den disease
Hessel BW.indd   13 11-Oct-11   10:36:31 AM
Chapter 1
14
Figure 6. Examples of HS by Hurley stage
a
b
c
a)  Hurley stage I HS in the axilla of a woman
b)  Hurley stage II HS in the axilla of a woman
c)  Hurley stage III HS in the groin of a man 
All images: source Dr. J. Boer, Deventer 
Hospital, The Netherlands.  (See also Color 
section, p. 195.)
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Figure 7. Modifi ed Sartorius score15
Hessel BW.indd   15 11-Oct-11   10:36:32 AM
Chapter 1
16
during the day and in extreme cases the use of diapers or ladies bandages. Third, HS mainly 
occurs at private areas of the body. This infl uences sex life and induces fear of entering new 
relationships22. Separately and jointly, all these aspects result in embarrassment, shame and 
low self-esteem22.
Pathogenic factors
The pathogenesis of HS is poorly known. Yet, it is generally accepted that the hair follicles 
are the primary origin of the pathological process rather than the apocrine glands. Genetic 
predisposition, cigarette smoking, shear forces, obesity, a deregulated immune response and 
hormonal abnormalities are all suspected risk factors23. In our own experience patients report 
psychosocial stress as an exacerbating factor; however its eff ect on HS severity has not been 
studied. These six putative factors are concisely discussed below.
Genetic predisposition
Genetic predisposition is considered an important HS disease factor. Up to 40% of HS patients 
know a family member with similar symptoms24. This percentage is probably an underestima-
tion, since boils in the groin is not something to discuss at family meetings or birthday parties. 
Moreover, as symptoms of severe disease cannot be concealed or ignored, patients are more 
likely only to know family members with severe HS. Table 1 provides an overview on genetic 
Table 1. Genetic studies in HS
Conclusion Critical comment Reference #
Autosomal dominant inheritance Vague HS defi nition, short of expected 50% mendelian value 26
Autosomal dominant inheritance Short of expected 50% mendelian value 27
Not linked to HLA -A, -B, or -DR Limited population size n=42 28
Linked to D6S440-D6S442 LOD 2.83 Not published other than abstract 29
Linked to D19S911-D19S1170 LOD 3.66 Not published other than abstract 30
Linked to D1S248-D1S2711 LOD>3 Follicular occlusion tetrad rather than solitary HS 30
Not linked to 1p21.1-1q25.3 region 31
Not linked to P450 1A1 (CYP1A1) SNPs Limited population size n=51 32
Not linked to NOD2 mutations Limited population size n=10 33
Not linked to NOD2 mutations Limited population size n=51 34
Linked to heterozygous point mutation (C119T) One patient with follicular occlusion triad and keratitis-
ichthyosis-deafness syndrome
35
Linked to PSENEN NCSTN mutations in 
γ-secretase signaling
Follicular occlusion tetrad phenotype rather than solitary HS 36
Linked to PSENEN NCSTN mutations in 
γ-secretase signaling
In 5 out 7 pedigrees no mutation was found 37
Linked to NCSTN mutations in γ-secretase 
signaling
Follicular occlusion tetrad rather than solitary HS 38
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HS studies. In 1968, the fi rst HS family history was described25 followed by the fi rst structured 
family investigation in 198526. Despite uncertainties about the diagnosis, an autosomal domi-
nant pattern of inheritance was postulated26. In 2000, these previously studied families were 
re-examined and again the results supported the concept of familial inheritance of HS with 
an autosomal dominant mode, despite a less than 50% mendelian value27. HS does not seem 
to be associated with HLA genotypes. In 1988, a signifi cantly diff erent frequency of HLA-A19 
was found in HS patients using serological tissue-typing techniques but later, using genomic 
methods, Lapins et al. found no association with HLA in another HS population28. The fi rst 
HS-associated loci were defi ned at 6q25.2 and chromosome 19, but these results were only 
reported in an abstract29. Another HS locus was claimed at 1p21.1-1q25.3 in a Chinese family 
comprising 10 patients across four generations30. However, this locus could not be confi rmed 
in another family31. Since another HS pathogenic factor is smoking, Ludowsky et al. studied 
SNPs (single nucleotide polymorphisms) in the P450 1A1 (CYP1A1) gene32. This cytochrome 
metabolizes the xenobiotic compounds of tobacco. Overall, similar SNP were found between 
HS patients and healthy controls32. Two other studies found no correlation with HS and SNPs 
of the innate immunity pattern recognition receptor NOD233,34. In one case, a possible ge-
netic locus for the follicular occlusion tetrad, of which HS is part, was determined to be the 
heterozygous point mutation C119T35. However, this patient had comorbid keratitis-ichtyosis 
deafness syndrome35. More recently, a study investigated six large Chinese families with sup-
posedly HS, inherited in an autosomal dominant mode. In this study mutations in γ-secretase 
genes were revealed36. However, these results should be interpreted with caution, because 
the phenotypes of the investigated patients did not represent classic HS, but rather the rare 
follicular occlusion tetrad. Therefore, the results of this study are representative for the fol-
licular occlusion tetrad as a disease entity, but are not convincing for pure HS. Conversely, 
these defects in γ-secretase signalling were rapidly confi rmed in a Caucasian family revealing 
a haploinsuffi  ciency of the γ-secretase genes37. In another report demonstrating γ-secretase 
mutations in a large Chinese family, the provided clinical photographs again suggested the 
follicular occlusion tetrad rather than solitary HS38. Gamma-secretase is a transmembrane 
protease consisting of four essential protein subunits: one catalytic presenilin subunit and 
three cofactor subunits presenilin enhancer 2 (PEN2), nicastrin (NCT), and anterior pharynx 
defective 1 (APH1) mediates intramembranous cleavage of various type I membrane pro-
teins, including amyloid precursor protein and Notch36. In mice the genetic inactivation of 
γ-secretase produces epidermal cysts and spontaneous squamous cell carcinomas (rare in 
HS) or basal cell carcinomas (not associated with HS). In humans, mutations in the two prese-
nilin genes (PSEN1 and PSEN2), but not the other γ-secretase component genes, cause early-
onset familial Alzheimer dementias and non-Alzheimer dementias36. Yet, the co-occurrence 
of dementias in HS has not been reported.
In conclusion, HS is probably a genetic heterogeneous disease of which rare clinical pheno-
types can be inherited in an autosomal dominant mode.
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Smoking
A striking HS behavioural risk factor is tobacco smoking. A matched-pair case control study 
showed that 88.9% of HS patients were active smokers compared to 46% in the control 
group; odds ratio (OR) 9.4; 95% confi dence interval (CI) 3.7-23.739. In a large French popu-
lation survey more than 70% of self-assessed HS suff erers were smokers; OR 12.55; 95% CI 
8.58-18.382. Furthermore, in a cohort of 302 HS patients, 76% was a current smoker and 
15% a former smoker4. HS smokers were more severely aff ected according to the modifi ed 
Sartorius score than non-smokers15. As discussed above, Lukowsky et al. studied SNPs in the 
tobacco-compound metabolizing cytochrome P450 in HS patients32. No SNPs related to HS 
were detected32. Cigarette smoke contains more than 4,500 components in its gaseous and 
particulate phases40 which all theoretically could contribute to HS pathogenesis.
Potential pathogenic eff ects of smoking in HS pathogenesis are discussed here briefl y. 
(Table 2). First, cigarette smoke can promote follicular occlusion. Hana et al. were the fi rst 
to study the eff ect of nicotine on a cultured epidermis equivalent41. They concluded that 
nicotine and the non-neuronal cholinergic system play a signifi cant role in the pathogenesis 
of HS by promoting infundibular epithelial hyperplasia and thus follicular plugging41. Sec-
ond, cigarette smoke aff ects a wide range of host defence mechanisms42, such as increased 
chemotaxis of polymorphic neutrophils since smoking has been shown to induce expression 
of IL-8 in the lungs43. Smoking increases the secretion of tumor necrosis factor alpha (TNF-α) 
by human keratinocytes44. Recently in the blood of smoking psoriasis patients increased rates 
of Th17 cells were demonstrated compared to non-smoking psoriasis patients45. Moreover, 
it was demonstrated that tobacco smoking generated Th17 cells ex vivo45. Third, bacteria 
are thought by some to be responsible for aggravating HS, and nicotine has been shown to 
stimulate Staphylococcus aureus growth46.
To understand how smoking might modulate pathogenic processes in HS, data on other 
evidently smoking associated diseases might provide useful information. Palmoplantar pus-
tulosis (PPP), also known as localised pustular psoriasis is such a skin disease associated 
with smoking with an OR of 10.5 and CI 3.3-33.547. PPP is characterized by groups of sterile 
pustules with thickened, scaly, red skin which easily develop painful cracks at the palms 
and soles. Receptors for nicotine, namely the alpha-7 nicotinic acetylcholine receptors, are 
Table 2. Putative mechanisms of smoking in HS pathogenesis
Eff ect Reference #
Promotion of follicular occlusion 41
Promotion of polymorphic neutrophil chemotaxis 43
Promotion of TNF-α secretion by keratinocytes 44
Promotion of Th17 cell development 45
Stimulation of Staphylococcus aureus growth 46
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overexpressed in the eccrine sweat glands and ducts of PPP patients48,49. But the precise 
mechanism by which these receptors can modulate infl ammation is not known.
Several studies have shown that cigarette smoke contain dioxins and dioxin-like chemi-
cals50. The aryl hydrocarbon receptor (AhR), present in the cytoplasm of all immune cells, is 
triggered by dioxin and dioxin-like chemicals and has immunomodulating properties upon 
stimulation51. AhR activation results in expansion of Th17 cells as well as cytokine produc-
tion and caused earlier and more severe disease in a mouse model for multiple sclerosis 
experimental autoimmune encephalomyelitis, (EAE)51. Recently, it was shown that abnormal 
AhR pathway activation promotes chronic infl ammation in the mucosa of Crohn’s disease 
patients52. Since HS is associated with smoking and probably with Crohn’s disease39,53 (Chap-
ter 2.2), ligation of the AhR potentially ameliorates HS infl ammation in a similar fashion. Al-
though the evidence discussed above suggests that smoking plays a role in HS pathogenesis 
it cannot formally be excluded that conversely the smoking habit is the result of HS. It is well 
established that HS patients have a decreased quality of life18 and that a low quality of life 
generally is associated with smoking habits54, which suggests that HS patients more often 
smoke due to their poor quality of life.
In conclusion, despite an evident epidemiologic association between smoking and HS, it 
remains unclear if and how pathogenic mechanisms of smoking contribute to HS disease 
initiation and/or maintenance.
Mechanical friction
Based on clinical observations it has been postulated that mechanical friction is associated 
with HS55. Predisposed HS skin areas are sites of regular mechanical stress. This becomes par-
ticularly clear in the obese in which additional HS locations include the abdominal folds and 
the medial upper leg. In the latter case, HS is induced or promoted by rubbing of the legs dur-
ing walking. Mechanical friction can also cause acne mechanica, which has been described 
as a distinct entity. Acne mechanica is considered to be a form of acne, usually infl ammatory, 
that is exacerbated by repeated friction, inducing bending and folding of hairs/hair follicles 
back and forward inducing microtrauma followed by hyperkeratinisation and occlusion of 
the follicle, and fi nally by rupture of microcomedones56.
Causes of friction resulting in acne mechanica are diverse. They include clothing (tight 
straps and belts), and occupational pressure (rubbing of back, buttocks in truck drivers). Acne 
mechanica also occurs at sites of mechanical stress due to leg stump prostheses57. Another 
friction related disorder is jeep disease58. During World War II, riding jeeps, trucks and tanks 
caused considerable morbidity in US army personnel. This jeep disease was characterized 
by abscesses, fi stulas and pilonidal sinuses and cysts of the buttocks, and was presumably 
caused by frictional forces induced by long bumpy rides58. In 2010, Dufour et al. postulated 
a hypothesis on how mechanical stress could contribute to HS development. An infant de-
veloped hidradenitis-like lesions in an inguinal naevus comedonicus, when the child started 
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to move around, thereby increasing shear forces59. The authors proposed that the degree of 
strain on a hair follicle increases with its diameter, leading to follicle wall ruptures59.
In summary, mechanical stress could promote HS in two ways. First, it may promote follicu-
lar occlusion similar to acne mechanica. Second, it may trigger rupture of the fragile dilated 
follicles.
Obesity
There is strong evidence that HS is associated with a high body mass index (BMI)60-64. More-
over it has been shown that a positive correlation exists between BMI and disease severity4. 
However, there are individual cases, in which the patient has a normal stature or even a low 
BMI evidencing that high BMI is not a requirement for HS. Clinically, in the obese, additional 
predilection sites for HS are the extended skinfolds, mainly the abdominal folds and the 
medial upper leg. The mechanisms by which a high BMI infl uences HS likely are complex 
since several features of obesity can aff ect HS pathogenesis (Table 3). First, the obese have 
more and larger skinfolds, especially the abdominal folds, in which skin on skin contact 
occurs, enhancing mechanical friction. Second, the higher than usual skin temperature and 
humid microclimate in skinfolds favour bacterial growth. Third, obesity brings along the 
concept of immunometabolism. Immunometabolism is the interplay between immunologi-
cal and metabolic processes. Nowadays, adipose tissue is not only considered as an energy 
storage site, but additionally as an endocrine and an immune organ capable of producing 
adipokines, cytokines and chemokines65. Pro-infl ammatory adipokines include TNF-α, IL-6, 
resistin, retinol binding protein 4 (RBP4), lipocalin 2, CCL2, IL-18, nicothiamide, nicotinamide 
phosphoribosyltransferase (NAMPT), and CXCL5. Anti-infl ammatory adipokines include 
adiponectin and IL-10. In addition, production of the anti-infl ammatory SFRP5 (secreted 
frizzled-related protein 5) decreases when fat mass increases. Moreover, obesity is causally 
linked to a low-grade, sub-acute, infl ammatory state65,66.
In conclusion, obesity might infl uence HS pathogenesis by creating a bacteria friendly 
environment, enhance shear forces and modulate immunity to a more pro-infl ammatory 
state. Quite surprisingly, it is unknown whether or not HS activity wanes or disappears when 
patients lose weight.
Table 3. Putative pathogenic mechanisms of obesity in HS
Mechanism Reference #
Larger and more skinfolds
Enhanced mechanical friction
Microclimate in skin folds favours bacterial growth
Production of pro-infl ammatory adipokines 65
Pro-infammatory state 65,66
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Bacteria
Frequently, HS patients fear their affl  iction is contagious. Some assume it is the result of a 
persistent bacterial infection, contracted after visiting a swimming pool or sauna. The fear of 
being contagious can isolate patients from participating in social activities and is therefore 
a factor negatively aff ecting quality of life and self-esteem. There is no evidence that viral or 
fungal infections cause or contribute to HS pathogenesis. The role of bacteria in HS patho-
genesis is far from clarifi ed. At fi rst sight the clinical aspects of HS do suggest infection. But 
results of bacterial cultures, despite the volume of discharge, are often negative or do only 
yield skin commensal microbiota67,68. In a retrospective study, axillary bacterial cultures from 
HS patients demonstrated that the most prevalent aerobic bacteria species were Staphy-
lococcus aureus, Streptococcus pyogenes, and Pseudomonas aeruginosa, the most frequent 
anaerobic bacteria were Peptostreptococcus species, Prevotella species, microaerophilic 
streptococci, Fusobacterium species, and Bacteroides species67. However, these bacteria were 
collected by epidermal swabs which were potentially contaminated with skin commensals. 
Later, this contamination factor was circumvented in a study aspirating pus from the deeper 
parts of HS lesions68. Using this method bacteria were cultured in only half of the samples68. 
The most frequently cultured bacteria were S. aureus and coagulase-negative staphylococci 
(S. epidermidis and S. hominis), so again skin commensals68.
In conclusion, there are several hypotheses on possible pathogenic roles of bacteria in 
HS. First, bacteria are not the initial causative factor, but are able to aggravate the disease 
by creating a chronic wound infection or augmenting innate infl ammatory pathways by 
engagement of for instance Toll like receptors (TLR), NOD-like receptors (NLR) and the infl am-
masome. Second, the composition of the commensal skin microbiota in HS patients may be 
altered to more pathogenic species, triggering the disease. Third, the immune response to 
commensals may be altered and easily triggered similar to the pathogenic concept of Crohn’s 
disease as a response to the gut microbiota69.
Immunology
The chronic infl ammatory nature combined with the frequent absence of pathogenic bacte-
ria is suspect for a key role of aberrant immunity in HS. This suspicion is further supported by 
the reported co-occurrence with sterile arthritis and the assumed association and similarities 
with Crohn´s disease53. 1977, Dvorak studied immune mechanisms in HS and concluded that 
there were no abnormalities in granulocyte function (chemotaxis, phagocytosis and intra-
cellular killing) nor immune globulin levels, but complement levels were elevated70. Vasey 
et al. demonstrated elevated levels of immunoglobulins, C3, C4 and circulating immune 
complexes in patients with combined arthritis and HS71. Bylaite et al. studied the epidermal 
expression of the lysosomal proteinase Cathepsin (Cat) L and its inhibitor hurpin in several 
infl ammatory and neoplastic skin diseases72. Cathepsin (Cat) L is an important lysosomal 
proteinase involved in a variety of cellular functions including intracellular protein turnover, 
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epidermal homeostasis and hair development. HS epidermis showed increased expression 
of Cat L and Hurpin, however, lower than in lesions of psoriasis, atopic dermatitis (AD) and 
squamous cell carcinoma72. Because of the vast numbers of neutrophilic granulocytes in HS 
lesions, their function has been studied to some extent. In 1982, Ginder et al. demonstrated in 
a single case of HS a defect in polymorphonuclear leukocyte killing of bacteria accompanied 
by low levels of cyclic GMP73. However, this patient experienced various additional infections, 
suggesting the defect was not HS-related73. Lapins et al. demonstrated a signifi cantly higher 
generation of free oxygen radicals by neutrophilic granulocytes than healthy controls upon 
stimulation with phorbol myristate acetate74. Giamarellos-Bouboulis et al. demonstrated an 
impaired secretion of TNF-α and IL-6 upon stimulation of monocytes to bacterial compounds 
in patients with HS75. They also demonstrated a diminished percentage of natural killer cells 
in the blood when patients had HS for a longer period75.
Toll-like receptors (TLR) are important pattern recognition receptors of innate immunity 
that play a crucial role in inducing immune responses, including the production of various 
cytokines. Hunger et al. demonstrated enhanced expression of TLR2 at both mRNA level and 
protein level on macrophages and dendritic cells (DC) within the HS infi ltrate compared to 
healthy control skin76.
Sartorius et al. assumed HS worsens in response to psychological stress and studied neu-
roendocrine involvement in HS in a limited immunohistochemical study. They observed an 
overall decreased density of nerve fi bers in the epidermis expressing protein gene product 
9.5 (PGP9.5)77. No diff erence was observed in the dermis77. This study did not clarify whether 
or not PGP9.5 positive cells play a pathological role in HS77. In 2010, the expression of several 
anti-microbial peptides (AMP) in HS lesions were studied78. The study demonstrated on the 
mRNA level in HS skin biopsies a relative defi ciency of several AMP including defi ciency of 
HBD1, HBD2, HBD3, S100A7, S100A8 and S100A978. Regulators of AMP expression include 
IL-22 and IL-20 mRNA levels of IL-22 and IL-20 were reduced compared to psoriasis and 
atopic dermatitis (AD), as well as its receptors IL-22R1, IL-20R1 and IL-20R2 whereas IL-22BP 
was expressed higher in HS than in psoriasis lesions78. IL-22 is produced by several T helper 
subsets but Th1, Th17 and Th22 cells were not altered in number in the peripheral blood of 
HS patients compared to psoriasis78. It was proposed that the relative IL-22 defi ciency could 
be induced by a defi ciency of cytokines essential for the generation and activation of IL-22 
producing cells. However, no defi ciency in mRNA of IL-12-p35, IL-12/IL-23p40, IL-23p19 IL-6 
or TNF-α was found78. The expression of the major immunosuppressive anti-infl ammatory 
mediator IL-10 showed a signifi cant negative correlation with IL-22 levels78. No diff erence in 
lesional Foxp3 expression as a marker for regulatory T cells between psoriasis and HS was 
observed78. Since IL-10 expression and IL-1 were signifi cantly correlated, the data suggests 
that IL-1β plays an important role in IL-10 expression78. A limitation of this study, however, 
was that only mRNA levels were measured and not the proteins levels78.
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Sex hormones
Whether or not sex hormones are involved in HS pathogenesis is not clear. Several disease 
characteristics seem to indicate that sex hormones infl uence the disease course. First, women 
are overall three times more often aff ected than men1,4. Second, the disease seems to fade 
out around the menopause79,80. Third, premenstrual fl are ups have been reported in 57% of 56 
female HS patients79. This ratio was 44% in another study including 110 females24. Moreover, 
the reported effi  cacy of anti-androgen therapy (cyproterone acetate) and oral contraceptives 
supports a sex hormonal role in HS81-83. However, there are just as many arguments against 
sex hormone involvement. First, the onset of HS is usually after puberty. Second, in HS there is 
no androgen-associated hyperseborrhea, and sebaceous glands are reduced in number and 
size84. Third, hyperandrogenic polycystic ovarian syndrome (PCOS) was reported in 12.5% of 
64 HS cases, while 10% was expected in the healthy population. This rate suggests there 
is no association, although the authors concluded otherwise83. Fourth, pregnancy does not 
seem to infl uence disease severity. One study reported improvement during pregnancy in 
2% of 110 females24. In a series of Jemec et al. 9/32 females reported improvement and 6/32 
worsening, while 17/32 reported no severity change during pregnancy80. Fifth, most impor-
tantly, no aberrant hormonal balance has been demonstrated in the serum80,85 or in apocrine 
glands86 of HS patients.
Treatment
HS is notoriously diffi  cult to treat. Most patients respond only partially or the disease rapidly 
re-occurs after drug cessation. The number of clinical trials in HS is limited. There are few 
studies with more than 10 patients (Table 4). Moreover, most clinical studies on HS treat-
ment are of observational type rather than randomized controlled, resulting in a low level 
of evidence based medicine. Moreover, current HS clinical research still suff ers from severe 
shortcomings. First is the lack of a uniform outcome measurement. Most studies use a type of 
a global physician assessment as primary outcome measurement. Second, since HS is a clini-
cally highly heterogeneous disease, patient groups, especially in older studies, are ill-defi ned 
and results are therefore not comparable. Third, HS is a disease with spontaneous fl are ups 
and remissions. Many studies lack a follow-up or have an insuffi  cient follow-up duration. 
Moreover, since HS can reoccur at the same location but also at new locations, reoccurrence 
is not clearly defi ned. These complications evidently hamper generalisation of study out-
comes and severely limit comparisons of studies. Only treatment modalities that have been 
investigated in studies including 10 or more patients will be briefl y discussed below. These 
studies include oral and topical antibiotics, anti-TNF-α biologics, anti-androgens, retinoids 
and light therapy, including the neodymium-doped yttrium aluminium garnet laser (Nd-Yag), 
zinc substitution and the topical peeling agent resorcinol. In addition, surgery is often inevi-
table in more severe HS. Radical excision, whereby all fi stulas and subcutaneous abscesses 
are removed, is considered the only method providing long term cure. Table 4 provides an 
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overview of clinical trials with a minimum of 10 patients studying pharmaceuticals and light/
laser therapy in HS.
Antibiotics
Antibiotic therapy is as a prominent form of HS treatment. This is probably because the 
fi rst clinical impression of HS is that of infection although bacterial cultures are frequently 
negative. Interestingly the literature reveals only a handful of studies on the use of antibiotics 
including only two randomized controlled trials (RCT)87,88. A small RCT demonstrated that 
topical clindamycin was superior to placebo in mild forms of HS. Another RCT showed no 
Table 4. Clinical HS trials with pharmaceuticals and light/laser therapy (minimum 10 patients)
Trial type n Outcome Ref. #
Antibiotics
Topical clindamycin 1% QD for 12 weeks RCT 27 Clindamycin was superior to placebo 87
Oral 500 mg tetracyclin BID vs. topical BID 
clindamycin 1% for 16 weeks
RCT 46 Equally eff ective, both drugs showed 
slight improvement in lesion count
88
Oral combination of clindamycin 300 mg BID and 
rifampicin 300 mg BID for 10 weeks
Retrospective case 
series
14 Improvement in 57% of patients 89
Combination of clindaycin and rifampicin in 
diff erent regimens and durations
Retrospective case 
series
34 Improvement in 84% of patients 91
Combination of clindaycin 300 mg BID and 
rifampicin 600 mg QD for 10 weeks
Retrospective case 
series
116 Signifi cant improvement in HS 
Sartorius severity score
90
Combination of rifampicin, moxifl oxacin and 
metronidacazol in diff erent regimens and 
durations
Retrospective case 
series
28 Complete remission in 57% of patients 92
Anti-TNF-alpha biologics
Infl iximab 5 mg/kg at week 0, 2 and 6 Prospective case 
series
10 54% reduction of HS severity by 
Sartorius score
95
Infl iximab 5 mg/kg at week 0, 2, 6, 14 and 22 RCT 38 Infl iximab was superior to placebo 96
Adalimumab 80 mg week 0, 40 mg EOW for 12 
weeks
RCT 22 Adalimumab induced a signifi cant 
reduction in HS sartorius severity score 
after 6 weeks
99
Adalimumab 160 mg week 0, 80 mg week 1, 40 
mg EOW for 12 weeks
Prospective case 
series
10 Statistically clinical improvement was 
not observed with adalimumab
100
Etanercept 50 mg weekly for 12 weeks Prospective case 
series
10 Etanercept is a safe and eff ective 
therapy for hidradenitis suppurativa
97
Etanercept 50 mg weekly for 12 weeks Prospective case 
series
15 Minimal evidence of clinically 
signifi cant effi  cacy of etanercept
98
Anti-androgens
Ee 50 mg/ca 50 mg VS. ee 50 mg/ng 500 mg for 
12 months
RCT 24 Both regimens produced similar 
improvement by physician global 
assessment
81
Antihormonal therapies, several antibiotics Retrospective case 
series
64 Antihormonal therapy was superior to 
antibiotics (55% versus 25%)
83
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diff erence between systemic tetracycline 1 g daily and topical clindamycin 1% twice daily. 
Both treatments resulted in improvement. Furthermore, the combination of clindamycin and 
rifampicin produced reasonable results89-91 as well as rifampicin combined with moxifl oxa-
cin and metronidazole92. The mechanism by which antibiotics ameliorate infl ammation in 
HS is unknown. Since bacterial cultures are often sterile, the anti-infl ammatory properties 
of antibiotics may be more important than anti-bacterial action. The use of antibiotics has 
drawbacks. The chronic and recurrent nature of the disease requires the use of antibiotic 
cycles which can lead to the development of bacterial resistance. Furthermore a frequent 
side eff ect is diarrhoea, which often leads to therapy discontinuation.
Anti-TNF-α biologics
The best studied drugs in HS are the anti-TNF biologics which include infl iximab, a chimeric 
monoclonal antibody, etanercept, a dimeric TNF-α decoy receptor, and adalimumab, a fully 
Table 4. (continued)
Trial type n Outcome Ref. #
Light and laser
Nd:Yag, 3 monthly sessions RCT 22 The Nd:Yag laser is eff ective for the 
treatment of HS, 63.3% improvement
102
PUVA twice weekly, median 25 treatments Retrospective case 
series
13 In 38% of patients complete remission 104
ALA PDT weekly for 4 weeks Prospective case 
series
12 Overall 29.9% reduction in lesion count 103
Retinoids
Isotretionoine mean dose 0.56 mg/kg/day for 
4-6 months
Retrospective case 
series
64 Disappointing results, efect 23.5% of 
mild cases
105
Isotretionoine mean dose 0.44 mg/kg/day for 
mean 7.8 months
Retrospective case 
series
88 Patients reported isotretinoine was not 
eff ective
106
Acitretin mean dose 0.59 mg/kg/day for mean 
10.8 months
Retrospective case 
series
12 All patients achieved remission 108
Other
15% resorcinol applied when necessary Prospective case 
series
12 In all patients pain and lesion duration 
decreased
113
Zinc 90 mg/day Prospective case 
series
22 All patients improved, complete 
remission in 8 patients
114
Antibiotics probably exert their function in HS primairily by immunomodulation and secondarily by 
bactericidal properties. Anti-TNF-α biologics exert their function by immunomodulation. How anti-
androgens exert their eff ect on HS is unknown. Light and laser therapies presumably exert their eff ect 
by destroying the hair follicle, and photo dynamic therapy additionally by bactericidal properties. The 
retinoid acitretin might exert its eff ect by normalizing infundibular keratosis and immunomodulation. 
Resorcinol unplugs the plugged hair follicles, and zinc acts by immunomodulation. QD:once a day, BID: 
twice a day, EOW:every other week, PUVA:psoralen+UVA, ALA-PDT:aminolevulinic acid photodynamic 
therapy, RCT:randomized controlled trial.
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human IgG1 monoclonal antibody. Anti-TNF biologics are generally applied only in severe 
cases of HS93. The rationale for anti-TNFα therapy in HS is based on the co-occurrence of 
Crohn’s disease and HS. Early reports showed that in these patients both diseases responded 
to infl iximab94. Infl iximab therapy for treatment of moderate to severe HS is well tolerated, 
reduces pain intensity as well as disease severity, and improves quality of life95,96. Etanercept 
showed more confl icting results97,98. The effi  cacy of adalimumab is modest and probably lies 
between that of infl iximab and etanercept99-101. This diff erence in effi  cacy might be explained 
by how these various biologics exert their eff ect. Etanercept binds only soluble TNF-α, in con-
trast to TNF-α antibodies (infl iximab and adalimumab), which additionally target membrane 
bound TNF-α, resulting in cytotoxicity. The effi  cacy of these three biologics is comparable in 
psoriasis, but analogous to HS the effi  cacy of etanercept in Crohn’s disease is less than of the 
other biologics.
Anti-androgens
As discussed above, hormones might play a role in the disease pathogenesis. A trial dem-
onstrated relative success for anti-androgens such as ethinylestradiol (ee) and cyproterone 
acetate (ca)81. In addition, a retrospective study suggested that some female HS patients 
respond better to anti-androgen therapy than to antibiotics83. Since the role of hormones in 
HS pathogenesis is unknown, the mechanism of how these drugs would exert their eff ect in 
HS is unclear.
Light and laser therapy
Tierney et al showed in a RCT that treatment with the Nd:Yag laser is eff ective for HS102. 
The effi  cacy can be explained by the destruction of hair follicles and vasculature by Nd:Yag 
laser emphasising the follicular nature of the disease102. Sweiger et al. demonstrated some 
improvement in HS with ALA PDT (aminolevulinic acid photodynamic therapy), although this 
treatment was quite painful103. The mechanism of action might be by destroying the hair 
follicle. Shareef reported in a retrospective case series that Bath PUVA (psoralen + UVA light) 
also caused some improvement. Its mechanism of action in HS is unknown104.
Retinoids
Based on the overlap of some disease features between HS and acne (e.g. open comedos 
and follicular occlusion), oral retinoids such as isotretinoin, etretinate and acitretin have 
been used in the treatment of HS. Despite its successful use in acne, isotretinoin has been 
found to be far less valuable in the treatment of HS105,106. This might be explained by the 
main mechanism of action of isotretionin in acne vulgaris, which is by inhibition of sebum 
secretion107. HS is not a disease in which the sebaceous glands play a signifi cant pathogenic 
role. Conversely, acitretin showed to be eff ective in a retrospective HS case series108. The exact 
mechanism of action of acitretin is still not fully clarifi ed. Acitretin has anti-proliferative and 
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immunomodulatory properties109. In keratinization disorders, acitretin has been reported to 
normalize epidermal cell proliferation, diff erentiation and cornifi cation110. In HS acitretin may 
target the process of infundibular keratinisation (plugging). Furthermore, acitretin inhibits 
the production of vascular endothelial growth factor (VEGF) by keratinocytes and has anti-
infl ammatory properties such as reduction of intra-epidermal migration of neutrophils111 and 
inhibition of IL-6-driven induction of Th17 cells112.
Other treatment modalities
Resorcinol is a topical peeling agent, which in a small open study reduced pain and shortened 
nodule duration in HS113. Resorcinol might exert its effi  cacy by skin peeling and promoting 
drainage of nodules and abscesses. Furthermore, it may prevent formation of new lesions by 
unplugging blocked hair follicles. In a pilot study, Brocard et al. showed good results by orally 
supplementing zinc salts114. The proposed eff ect of zinc in HS is by immunomodulation114. 
Zinc has been shown to inhibit chemotaxis of polymorphonuclear neutrophils, to inhibit 
expression of ICAM-1 on keratinocytes and production of TNF-α and IL-6 by keratinocytes 
and to activate natural killer (NK) cells and the phagocytic function of granulocytes114.
Surgery
In addition to drug therapies, surgery is frequently performed to control or cure HS. Surgery 
is generally regarded as one of the most eff ective treatments for HS115. The effi  cacy and recur-
rence rates of several types of surgical interventions have been reported in retrospective 
case series, but RCTs are lacking23. Surgical techniques are: incision and drainage or lancing, 
deroofi ng, local or wide excisions, and CO2 laser assisted surgery
23. Excisions can be local, 
with or without a healthy appearing perilesional tissue margin or removal of the complete 
terminal hair bearing area23. Reported recurrence rates between techniques vary enormously 
and cannot be compared since the reports employ diff erent follow up periods and defi ni-
tions of recurrence115. There is also no consensus on the best type of wound healing after 
surgery: options include healing by second intention, primary closure with suture, skin graft 
and skin fl aps23. The type of surgery strongly depends on the disease stage. For abscesses, 
simple incision and drainage provides quick pain relief but the reported recurrence rates 
are almost 100%23. Mild HS (Hurley I and II) can be treated with limited excision or deroof-
ing, the latter being a technique in which a nodule or abscess is probed for fi stulas and the 
roof lesion is removed followed by secondary healing116. When fi stulas are formed, or in case 
of severe disease, Hurley III surgery is accepted as the only method that can provide total 
disease clearance. There is no consensus of how far the excision margin should reach into 
healthy appearing tissue, but it should not be too limited as small margins are thought to 
be correlated with disease recurrence117. Furthermore, CO2 assisted surgery for HS has been 
described as an effi  cacious approach118,119. This method has the advantage, since it is virtually 
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bloodless, of providing a clear view of the diseased area during surgery, so that the extent of 
lesions can be followed in the tissue a vue.
Surgery also has disadvantages. In the acute stage, intervention by incision and drainage 
can be extremely painful, since abscesses are diffi  cult to anaesthetize. General anaesthesia 
brings along risk of complications. Furthermore, even wide radial excisions are not always 
curative since new lesions may develop next to the excised area115. Furthermore, in severe HS 
excision areas can be very extensive, increasing the risks of wound healing complications and 
mutilation and an extended recovery time.
AIMS AND OUTLINE OF THE THESIS
HS has been relatively neglected both clinically and scientifi cally; therefore it is almost 
‘virgin scientifi c territory’. This complicates reductionist approaches on immunopathogenic 
mechanisms and rational therapy development. The conceptual background of this thesis is 
therefore not limited to only one disease aspect. Instead, this thesis addresses selected major 
gaps in HS knowledge in terms of clinical aspects, pathomechanisms and treatment.
Clinical aspects of hidradenitis suppurativa
 Awareness about the disease severity and impact on quality of life is necessary to increase 
scientifi c interest. We hypothesized that depression is more common in HS patients than 
presently appreciated.
 There are striking clinical similarities between HS and Crohn’s disease. Demonstration 
of an association may imply that parallel or similar pathogenic mechanisms contribute 
to both diseases. We investigated whether HS occurs more frequently in Crohn’s disease 
patients than in the general population.
 Why HS prefers the inverse skin areas is unknown. We present a case that provides clues 
about the contribution of friction.
Pathomechanisms in hidradenitis suppurativa
 Characterization of the lesionalHS cytokine profi le can provide a basis for development 
of novel therapies and improves insight into immune mechanisms. We investigated 
whether secretion of prototypical pro-infl ammatory cytokines such as TNF-α and IL-1β is 
elevated in HS skin.
 Anti-TNF-α biologics show promising effi  cacy in HS, but the underlying mechanisms are 
largely unknown. We studied whether specifi c cytokines or infl ammatory mediators are 
signifi cantly aff ected by treatment with the anti-TNF-α biologic adalimumab.
 We showed that levels of TNF-α, IL-1β and IL-10 are increased in normal appearing 
perilesional HS skin. We therefore investigated the cellular source of these cytokines in 
non-lesional HS skin.
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Treatment of hidradenitis suppurativa
 Since antibiotic therapy is the most common treatment for HS, we addressed whether 
combination therapy with clindamycin and rifampicin is eff ective in HS.
 Deroofi ng is a surgical method for HS, but its effi  cacy has not been systematically inves-
tigated. We hypothesized that deroofi ng would be eff ective in recurrent single lesions of 
HS.
 Colchicine is a drug with anti-infl ammatory properties, and is successfully used in auto-
infl ammatory diseases. In a pilot study we studied the effi  cacy of colchicine in patients 
with HS.
Model for HS pathomechanisms
 In chapter 5 we present a model for HS pathomechanisms, incorporating the results of 
this thesis and literature. In this chapter we also do suggestions for future research on HS.
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ABSTRACT
Background: Hidradenitis suppurativa (HS) is a chronic recurrent infl ammatory skin disease 
with abscess formation and scarring, predominantly in the inverse areas. The disease is often 
diffi  cult to treat and patients experience a decreased quality of life (QoL). It is hypothesised 
that depression is more common in HS than in other dermatological conditions.
Objectives: To evaluate the prevalence of depression in patients with HS. 
Methods: 211 HS patients and 233 dermatological control patients were included in the 
study. Their QoL and depression scores were assessed using the Dermatology Life Quality 
Index (DLQI) and the (Major Depression Inventory) MDI questionnaires. HS severity was re-
corded with a questionnaire and Hurley stages were extracted from the case records.
Results: The DLQI was signifi cantly higher for HS patients than in control patients, 8.4 7.5 
versus 4.3 5.6 (p<0.0001) and correlated with Hurley stage severity. Mean MDI scores were 
signifi cantly higher for HS patients, 11.0 versus 7.2 (p<0.0001). However, clinically defi ned 
depression rates according to ICD-10 criteria were not signifi cantly higher in HS patients 
compared to controls (9% versus 6%).
Conclusions: HS has a major impact on quality of life relative to other dermatological condi-
tions. MDI depression scores in HS patients correlated with disease severity. This correlation 
could indicate that the MDI depression questionnaire, although not yet widely accepted, rep-
resents a valid measure of disease-related morbidity. Its usefulness as an outcome measure in 
future studies needs further validation. 
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INTRODUCTION
Hidradenitis suppurativa (HS), also called acne inversa, is a chronic recurrent infl ammatory 
follicular skin disease, which presents with painful suppurating lesions in the inverse skin 
areas1. It is a common disease, aff ecting up to 1% of the general population2,3. Treatment 
options include medical therapy, and laser as well as conventional surgery4. In spite of a 
growing number of therapeutic options the outcome is often unsatisfactory, and a consider-
able unmet need for therapy exists5,6.
Current information on the psychosocial consequences of the disease is limited. This may 
partly be due to the clear symptomatology and partly due to the lack of specifi c investiga-
tions. HS aff ects a range of psychosocial factors and it reduces the quality of life (QoL) sig-
nifi cantly7-11. The few studies addressing the QoL in HS found the disease to have a profound 
negative eff ect, often surpassing the negative QoL reported in other major dermatoses such 
as psoriasis and atopic dermatitis. Reduced QoL, reduced ”enjoyment of life”, and depressive 
mood has been linked to HS severity by Matusiak et al.9. In addition the self-reported health 
of HS patients is lower, and the average number of sick-days is higher than in controls10,12. We 
therefore speculated that depression is more frequent and pronounced among HS patients 
than among other dermatological patients, and thus a pertinent point of clinical interest and 
possible early intervention.
MATERIALS AND METHODS 
The study was conducted in the departments of dermatology at Deventer Hospital in the 
Netherlands and Roskilde Hospital in Denmark, from March to November 2009, as a survey 
among HS patients and a random sample of other dermatological outpatients as controls. HS 
patients were identifi ed from the records and they had the questionnaires mailed to them 
instead of handed out while attending physicians. Non-responders were accepted without 
further eff orts and no reasons were given for non-participation. Incorrectly completed 
questionnaires were handled in accordance to given guidelines for the instruments used. 
The disease defi nition was in agreement with the defi nition suggested at the HS-Foundation 
research meeting in 2009: a chronic infl ammatory, recurrent, debilitating skin disease that 
usually presents after puberty with painful, deep-seated, infl amed lesions in the apocrine 
gland-bearing areas of the body, most commonly the axillary, inguinal and anogenital re-
gions. No formal power calculations were carried out as the prerequisite epidemiological data 
were not available for the main outcome criteria of depression. The number of patients with 
HS was limited to those available in the records of each department. Cases and controls were 
matched for age and gender at a ratio of 1:1. The controls did not have HS, (20 – 60 years old) 
and were selected among patients attending the out-patient department as a convenience 
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sample on a running schedule depending on the availability of the investigators. The controls 
were contacted directly by an investigator (AO or SE) who handed them the questionnaires. 
Bias was avoided by handing the questionnaires without interfering in their understanding 
of the questions or their responses. For QoL assessment the Dermatology Life Quality Index 
(DLQI), range 0-30, was used, and for identifying depression the Major Depression Inventory 
(MDI) questionnaire, was used13,14. The MDI has a range of 0-50 and can be used in three 
ways: 1) As a diagnostic instrument according to ICD-10 criteria, 2) as a diagnostic instrument 
according to DSM-IV criteria or 3) as a depression rating scale. In the present study the MDI 
scores were used as an ICD-10 diagnostic instrument, and as a depression rating scale. The 
MDI questionnaire has 10 questions on a Likert scale with “All of the time”, “Most of the time”, 
“More than half of the time”, “Less than half of the time”, “Some of the time”, “At no time”. Three 
core questions have to be scored with either “All of the time” or “Most of the time” when 
diagnosing depression according to the ICD-10 criteria. If they scored lower, the patient was 
diagnosed with no depression. In contrast, when using the MDI as a depression rating scale 
no limits are given.
These validated questionnaires were supplemented by simple data gathering question-
naires to characterise the patients: duration of symptoms, location of lesions, days with 
symptoms during the past month, number of fl ares during the last month and days of 
absence from work. In addition patients were presented with two Numeric Rating Scales 
(NRS) to register severity of current pain and itch on a scale from 0-10, with the anchor points 
no pain/itching and most severe imaginable pain/itching at the two extremes. The Hurley 
stage of the patients was determined from the case records15. The Danish Ethical committee 
was consulted regarding the need for approval of the study, and informed the Authors that 
questionnaire studies were exempt from Ethical Committee approval. Statistical descriptive 
analysis was performed, and the signifi cance tested using the Wilcoxon Test. Spearman’s rank 
correlation coeffi  cient was used to assess the relationship between descriptive data, DLQI 
and MDI. 
RESULTS
A total of 539 patients were contacted and 444 patients (82%) accepted participation. The 
distribution of the participants was 211 HS patients and 233 controls, (77% women and 23% 
men). The mean age of HS cases was 43  11.8 years (range 16 - 70) and controls was 42 13.5 
years (range 9 – 77). There were no patients with a known primary psychological disorder. The 
diseases in the control group included skin tumors n=62 (27%), psoriasis n=29 (12%), eczema 
n=45 (19%), acne n=23 (10%) and 37 other diseases n=74 (32%).
The HS patients had HS for 16.8 11.6 (median 15, range 0-50) years, whereas controls had 
their skin disease for 12.7 12.6 years (median 7.5, range 0-48) years. Using Hurley stage as 
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disease severity measure, 30.1% of HS patients were stage I, 56.4% stage II and 13.5% stage III 
(total n=163). The self-reported distribution of HS lesions is shown in Table 1. During the four 
weeks prior to answering the questionnaires HS patients had had 13.5 11.8 days (median 
10) with fl ares, whereas the controls had had 18.1 13.7 days (median 30) with active disease 
(p=0.027).
At the time of answering the questionnaires the pain-score of HS patients was 3.6 3.2 
(median 3) and controls 1.9 2.6 (median 0) on a 0–10 NRS (p<0.001). Using a similar scale 
itching was scored at 3.3 3.1 (median 3) by HS patients and 3.3 3.4 (median 3) by controls 
(p=1, n.s.).
The range of sick days reported by the two groups was identical 0-90 days, median=0 for 
both groups for the last 3 months, but the mean number of days off  work was 3.1 13.6 for 
cases and 7.1 21.0 for controls (p=0.07, n.s.). 
The DLQI was signifi cantly higher for HS cases than for controls both in total with a mean 
value of 8.4 7.5 versus 4.3 5.6 (p<0.0001) as well as in sub-scores (Table 2). The DLQI corre-
lated positively and signifi cantly for both HS patients and controls with: MDI score, number of 
fl ares during the last month, pain, itch and sick-days during the last 3 months. For HS patients 
it further correlated with number of fl ares during the last month and Hurley severity score.
Table 2. DLQI scores
DLQI – Mean values (range 0-30) Cases (N=211) Controls (N=233)
Symptoms and feelings (Q1 + Q2) 2.42 (SD 1.87) Median 2 1.67 (SD 1.77) Median 1 (P=<0.001)
Daily activities (Q3 + Q4) 1.82 (SD 1.76) Median 2 0.88 (SD 1.37) Median 0 (P=<0.001)
Leisure (Q5+Q6) 1.47 (SD 1.89) Median 1 0.71 (SD 1.35) Median 0 (P=<0.001)
Work and school (Q7) 0.67 (SD 0.98) Median 0 0.29 (SD 0,67) Median 0 (P=<0.001)
Personal relationships (Q8+Q9) 1.62 (SD 1.94) Median 1 0.57 (SD 1.30) Median 0 (P=<0.001)
Treatment (Q10) 0.35 (SD 0.74) Median 0 0.22 (SD 0,59) Median 0 (P=0.044)
Total scores 8.35 (SD 7.49) Median 6 4.34 (SD 5.58) Median 2 (P=<0.001)
Similarly, mean MDI scores were signifi cantly higher for HS patients than controls 11.0 versus 
7.2 (p<0.0001), (Table 3), with 44 HS patients (21%) having scores indicating possible depres-
sion (≥20), compared with 26 controls (11%) (p=0.006). 
Table 1. Location of lesions
Number Percent
Under the arms 107 50.47
Under the breasts 27 12.74
In the crotch 165 77.83
On the buttocks 64 30.19
In the perineum/perianal 49 23.11
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Using the MDI as a diagnostic tool to assess the prevalence of depression among patients 
according to the ICD-10 criteria, 19 HS patients (9%) were found to suff er from depression, 
compared with 14 controls (6%) (n.s., p=0.34). 
For HS patients and controls the MDI scores as a rating scale correlated positively and sig-
nifi cantly with: days with lesions during the past month, pain, itch, sick-days due to the skin 
disease during the last 3 months, and for HS patients furthermore with the number of fl ares 
during the last month. Depression scores were not signifi cantly correlated to Hurley stage, 
although a near signifi cant value was seen when using the MDI as a diagnostic tool (Table 4).
Table 4. Depression score correlated to Hurley stageing (n=163) *p=0.06
Hurley stage I Hurley stage II Hurley stage III Total P
MDI score
(mean ±SD)
7.3 ± 8.9 11.0 ±11.3 5.0 ±0.0 5.0 ±10.0 n.s.
MDI used as a rating score suggesting 
depression (n, %)
5 (10.2%) 21 (22.8%) 7 (31.8%) 33 n.s.
MDI used a diagnostic guide for 
depression (n, %)
1 (0.5%) 7 (7.6%) 4 (18.2%) 12 n.s.*
Patients (n) 49 92 22 163 n.s.
DISCUSSION
It is easy to imagine the psychosocial impact of HS, and yet in order to deal with it in an 
evidence-based rational manner, objective facts are helpful. This survey is the fi rst large scale 
study reporting the impact of HS on quality of life. It confi rms that HS has a major negative 
eff ect on the QoL of patients, also when compared to other dermatological patients. The QoL 
as defi ned by the DLQI score was signifi cantly worse for HS than for a comparable group of 
dermatological patients. According to the interpretation guide proposed by Hongbo et al., a 
diff erence in mean scores of this magnitude (+4) can be interpreted as a signifi cant clinical 
diff erence17 suggesting that HS patients form a special high-need population of dermato-
logical patients. The diff erences in sub-scores refl ect diff erent aspects of QoL and all were 
statistically highly signifi cant in HS patients.
Table 3. MDI divided into rating scale scores and diagnostic scores
MDI (range 0-50)
(p>0.0001)
Cases (N=211)
Mean 11,0 (SD 10,99), Median 7
Controls (N=230)
Mean 7,2 (SD 9,55), Median 3
Rating scale Total score
Cases
ICD 10
Rating scale Total 
score
Controls
ICD 10
No depression 167 192 204 216
Mild depression 15 5 11 3
Moderate depression 11 5 1 7
Severe depression 18 9 14 4
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A comparison with other studies shows a discrepancy in DLQI results. Matusiak et al. 9 They 
found a mean DLQI score of 12.7 7.7 (n = 52, median 12) with a disease duration of 10.16 
7.64 years while von der Werth and Jemec8 and the present study found a mean on respec-
tively 8.9 8.3 and 8.4 7.5 with a disease duration of respectively 18.8 11.4 and 16.8 11.6 
years. We speculate that the duration of HS may have some infl uence on self-reported QoL, 
but other disease specifi c or demographic issues could also have an impact16. 
Although surveys are only suitable to describe correlations rather than causal associations, 
it has been suggested that the symptomatology and poor response to therapy induces clini-
cally signifi cant mood changes in patients. Depression scores of HS patients were signifi cantly 
higher than those of other dermatological patients, suggesting that the disease represents 
a signifi cantly heavier burden for patients than other skin diseases9. The proportion of 
depressed patients according to the ICD-10 criteria in this study was 9% while 21% were 
suspected of having depression using the MDI as a rating scale. Matusiak et al. used the Beck 
Depression Inventory-Short Form (BDI) to screen for depression in a smaller cohort (n=52). 
In their cohort 19.5% patients had a score of at least 10 on the BDI which might suggest the 
co-existence of depression9.
The MDI can also be used diagnostically to indicate the clinical level of depression, but 
although the mean scores were higher in HS patients and a larger proportion of HS patients 
scored high enough to warrant a diagnosis of depression, the prevalence of clinical depres-
sion was not signifi cantly greater in HS patients than in other dermatological patients. This 
discrepancy could be explained by the limitations of the MDI relative to ICD-10. Three core 
questions have to be scored with either “All of the time” or “Most of the time” in case of depres-
sion. If they score lower, the patient will not be diagnosed with depression. In contrast, when 
calculating scores on a rating scale no limits are given. In studies that focus on the general 
impact of a disease it may therefore be more relevant to use the MDI as a rating scale than as 
a diagnostic tool. This discrepancy may also suggest that HS patients have developed better 
coping skills due to the often long duration of their disease, or the chronic recurrent nature 
of their disease. It may be speculated that acquiring of HS provides patients with a coping 
mechanism that allows them to prevent higher depression scores, better than other patients. 
Such a coping mechanism is however unproductive in the long term, and may therefore add 
to the general psycho-social complications of HS18.
The MDI has not been used for other dermatological diseases so no direct comparison can 
be made between HS other dermatological diseases such as psoriasis. Although, depression 
rates established by diff erent questionnaires cannot be compared, studying depression in 50 
psoriasis patients showed that 58% of psoriasis patients scored high enough by Beck depres-
sion inventory (BDI) score to indicate depression19. Another study in 265 psoriasis patients 
the suspected depression rate was 32% measured by Center for Epidemiologic Study Depres-
sion Scale (CES-D)20. MDI scores of HS can however be compared to those of patients with the 
severe neurological disorder amyotrophic lateral sclerosis (ALS). HS demonstrated slightly 
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more frequent severe depression. In 51 ALS patients, 8% scored mild, 2% moderate, and 0% 
severe depression21, in HS these rates were 2%, 2%, and 4% respectively.
For HS patients as well as controls the DLQI and MDI scores were, signifi cantly correlated 
with frequency of fl ares, pain, itch, and sick-days. This also indicates that the depression scores 
represent a measure of disease related morbidity that may serve as out-come a measure in 
future studies.
There are several limitations to this study. One limitation is the selection bias by being 
a hospital-based sample, which restricts the generalization of the data. The use of other 
dermatological patients as a control group is a limitation and a strength. While limiting the 
generalization of the fi ndings to the general and healthy population, it refl ects the impact of 
this specifi c skin disease, underlining the burden of the disease. 
In conclusion, the results of this study indicate that HS has a major impact on quality of life 
compared to other dermatological diseases. Dermatologists should be aware of and actively 
look for signs of depression and in case of severe depression refer patient for treatment. The 
MDI depression scores correlate with HS disease severity. The MDI questionnaire may serve 
as an outcome measure in future studies.
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ABSTRACT
Background: The co-occurrence of hidradenitis suppurativa (HS) and Crohn’s disease (CD) 
published in a few case reports resulted in the wide acceptance of an association between 
these two diseases. However the combined prevalence of these diseases is currently un-
known, furthermore it is unknown whether this co-occurrence also applies for ulcerative 
colitis (UC). Objectives To estimate the prevalence of HS in patients with infl ammatory bowel 
disease (IBD) living in the South-West of The Netherlands.
Methods: During an IBD patient information meeting, randomly, 158 patients with IBD were 
interviewed about recurrent painful boils in the axillae and/or groin and were shown illustra-
tive clinical pictures of the appearance of HS.
Results: Of the 158 patients interviewed, 102 (64.6%) had CD and 56 (35.4%) had UC. Twenty 
fi ve people 25 (15.8%) responded that they had had or still experienced painful boils in axil-
lae and/or groin, of which 17 were CD (16.7%) and 8 UC patients (14.3%).
Conclusions: This pilot study shows for the fi rst time that HS occurs in patients suff ering from 
CD or UC. More prospective studies are warranted to establish the association between HS 
and IBD and its underlying pathogenesis.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic infl ammatory skin disease characterized by recur-
ring painful abscesses, nodules and draining sinus tracks, localized in the groin and axillae 
that often heal with scarring. HS usually develops during young adulthood and females are 
more frequently aff ected1. This painful disorder deeply aff ects the quality of life in these 
patients2,3. The pathogenesis of HS remains largely unknown and is probably multifactorial. 
The primary mechanism in the disease is thought to be hyperkeratinisation of the piloseba-
ceous infundibulum resulting in occlusion with subsequent infl ammation4. Other putative 
pathogenic factors include hormonal infl uences, biomechanical forces, obesity, smoking5,6, 
dysfunction of the immune system and an inappropriate response to commensal bacterial 
skin fl ora4. The latter is supported by a study that showed that the bacteria cultured from HS 
lesions are predominantly commensal skin fl ora7,8. Also genetic factors seem to be involved, 
since HS is a familiar disorder in 34% of cases9. Recently the prevalence of HS has been esti-
mated at 1% in the general French population10. In Denmark a point prevalence of 4.1% and 
a 1 year prevalence of 1% has been reported11. Current treatment options include topical or 
systemic antibiotics and immunosuppressive agents such as anti TNF-alpha1 in case of severe 
disease. Surgery forms the cornerstone of treatment, especially for advanced stages of the 
disease, consisting of unroofi ng of small lesions and total excision of large skin areas1. The 
occurrence of both Crohn’s disease and HS in the same individual has been reported in over 
37 cases12. These reports have led to generally mentioning this observed co-occurrence as an 
association in the literature, although the supporting evidence is weak.
Table 1. A comparison between Crohn disease, ulcerative colitis and hidradenitis suppurativa
Infl ammatory bowel disease Hidradenitis suppurativa
M. Crohn Ulcerative colitis
Localization Entire gastrointestinal tract Large bowel Inverse areas of the skin
Layer of infl ammation Transmural Surface epithelium Deep dermal
Confl uency of lesions Skip lesions with granuloma Continuous infl ammation with 
crypt abcesses
Tendency towards continuous 
lesions
Cicatrisation Yes, sometimes with 
subsequent obstruction
No yes
Formation of fi stulas Yes No yes
Infl uence of smoking Can aggravate Relapse after stopping Aggravates
Disease chronicity Yes Yes Yes
Epithelia inhabited by 
commensal fl ora
Yes Yes Yes
Genetic predisposition Yes Yes Yes
Response to anti TNF-alpha 
therapy
Yes Yes Yes
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Infl ammatory bowel diseases (IBD) consist of Crohn’s disease (CD) and ulcerative colitis 
(UC). The prevalence of adult CD and UC in the USA is 0.201% and 0.238% respectively13. 
The current concept is that a dysbalance in the immune response to the commensal bowel 
fl ora in combination with genetic predisposition and other environmental circumstances can 
trigger IBD14. There are several similarities between HS and CD (Table 1). Both are chronic 
diseases of epithelia which are inhabited by commensal fl ora. Smoking has been reported 
in 77 to 89% of HS cases1 and has been described as a risk factor for CD15, both diseases 
have a genetic predisposition and both show clincial response to anti TNF-alpha therapy. 
Furthermore HS and CD both are accompanied by fi stula formation. These striking parallels 
between HS and CD led us to address two questions: Can the proposed co-occurrence of HS 
and CD be further substantiated from a large group of IBD patients? Does HS co-occur with 
UC? To date HS is still a diffi  cult disease to treat with great unmet medical needs. Finding 
evidence for these associations would support the notion that parallel or similar pathogenic 
mechanisms contribute to HS and IBD, providing novel directions for future functional stud-
ies and therapy development.
Figure 1. Prototypical clinical photographs shown to patients
 
a b
a) Mild hidradenitis suppurativa in the axilla.
b) Severe hidradenitis suppurativa in the axilla.  (See also Color section, p. 196.)
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SUBJECTS AND METHODS
Patients attending the Crohn’s and ulcerative colitis patient information meeting in Rotter-
dam 2008, organised by the Dutch Society for Crohn’s and ulcerative colitis patients, were 
randomly interviewed. All patients were asked two questions: fi rst whether they had UC or 
CD and second if they ever experienced or still had recurrent painful boils in the axillae and/
or groin. This question on HS closely resembles the question used in a recent HS prevalence 
study in France10. In contrast to that study focusing only on the last year of the patient’s 
experience, we asked whether recurrent painful boils ever occurred in the patient’s life. To 
clarify the disease patients were questioned about, they were shown 2 prototypical clinical 
pictures of HS in diff erent stages in colour A4 format (Figure 1). For this type of investigation, 
no medical ethical committee approval is required under Dutch law.
RESULTS
We interviewed 158 patients randomly. The response rate was 100%. Of the 158 patients 
interviewed 102 (64.6%) had CD and 56 (35.4%) UC. Twenty fi ve patients (15.8%) reported 
to have or have had recurrent painful boils in the axillae or groin, which were 17 (16.7%) 
patients with CD and 8 (14.3%) patients with UC (Table 2).
Table 2. Interview results
Painful boils in groin or axillae
Number of patients yes no
Infammatory bowel disease 158 25 (15,6%) 133 (84,4%)
Crohn disease 102 (65%) 17 (16,7%) 85 (83,3%)
Ulcereative colitis 56 (35%) 8 (14,3%) 48 (85,7%)
DISCUSSION
The association between HS and CD has been reported in several case reports but has never 
been extensively investigated and hence cannot yet be accepted as a clinical fact. The results 
of this pilot study in a larger group appear to indicate that HS not only occurs more frequently 
than could be expected by chance in CD, but also in UC. However, this pilot study has some 
weaknesses. There are other causes of painful boils in the axillae and groin like furunculosis, 
lymphadenitis, ectopic Crohn’s disease or granuloma venereum. To reduce the chance for 
confusion with these conditions, we specifi cally asked about recurring boils. Perianal cutane-
ous CD lesions that can mimic HS were avoided by not to asking about painful boils in the 
perianal area. The interviewed patients suspected of having HS were not physically examined 
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in order to confi rm the diagnosis. Furthermore co-occurrence does not necessarily imply an 
association16. For these diseases to be associated, they must co-occur in a proportion greater 
than is expected by chance. To properly study an association between the diseases in both 
groups, one ideally should know the exact prevalence of both diseases within a population. 
Furthermore these two populations should both be taken from a homogeneous population 
because IBD has a variable prevalence among diff erent countries. For HS such a variance in 
prevalence is not known. We calculated that in order to show a twofold higher prevalence of 
both diseases in both groups, with a power of 80%, using 0.439 prevalence rate for IBD13 and 
1% for HS10, cohorts of 1.000 IBD and 2.000 HS patients are required. IBD patients should be 
biopsy-confi rmed and physically examined for HS. HS patients should be interviewed about 
endoscopically and biopsy-confi rmed IBD. If an association is present, pathogenic mecha-
nisms in IBD could contribute to HS. However a recent limited pilot study investigating a CD-
associated gene CARD15 in HS did not fi nd a relationship between CARD15 polymorphisms 
and HS17. Our results justify further investigation into the possible association between 
HS and IBD in an adequate and larger patient population. These investigations will clarify 
whether there is a true association between the diseases, which would open new perspec-
tives into the pathogenesis of HS and probably new treatment options.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic of recurrent, infl ammatory, follicular disease that 
usually presents after puberty with painful deep-seated, infl amed lesions in the inverse skin 
areas of the body. The development of fi stulas is an important hallmark of severe-stage HS. 
Estimated prevalence rates for HS range between 1% and 4%in the Western world1,2 and the 
disease is associated with a signifi cant reduction in quality of life3. Clinically HS resembles 
infection, but often no bacteria can be cultured from typical HS lesions4. Putative pathogenic 
factors include, genetic predisposition, smoking, obesity and alterations in host defence 
mechanisms5,6. Currently, the generally accepted primary mechanism in HS is hyperkeratini-
sation of the follicular infundibulum resulting in follicular occlusion5 followed by a foreign 
body-like infl ammatory reaction when the dilated follicles rupture and keratin fi bers and 
epithelial strands are spilled into the dermis5. Treatment of HS is challenging and includes 
topical and/or systemic antibiotics, and immunosuppressive drugs5. For defi nitive eradica-
tion of HS lesions in a specifi c area, surgical intervention often remains necessary. Predilec-
tion sites of HS are the inguino-femoral area which is aff ected in 90% of cases, axillary (69%), 
perineal/perianal (37%), buttocks (27%) and the breasts (18%)7. Because these predilection 
sites are rich in apocrine sweat glands, HS was initially considered an infl ammatory process 
originating from these glands5. However, histological examination of HS lesions demonstrated 
apocrinitis only in a minority of cases, suggesting that apocrinitis is a secondary event8. Why 
HS prefers the inverse skin areas is unknown. In this report, we describe a case of persistent 
HS-like lesions with fi stulas on a leg amputation stump, suggesting that mechanical friction 
and a favourable bacterial microclimate are important extrinsic pathogenic factors for HS 
development.
CASE
A 44-year old man presented at the outclinic dermatology department of the Erasmus MC, 
University Medical Center, Rotterdam, with recurrent, infl ammatory deep-seated nodules, 
abscesses and fi stulas on the amputation stump of his left leg. Five years earlier, he had 
been involved in a serious motorcycle accident, resulting in amputation of his left lower leg, 
and brain trauma, resulting in pituitary dysfunction. Since then he uses a lower leg pros-
thesis. Because of his pituitary dysfunction he used the following medications: metformine 
500 mg daily, somatoprine 0.2 mg daily, testosteron gel 50 mg daily, clobazam 10 mg BID, 
budesonide/formoterol 200 μg/6 μg. The recurrent infl ammatory lesions had previously 
been treated by several courses of oral antibiotics and several surgical incision-and-drainage 
interventions. Multiple adjustments were made to the prosthesis for an optimal fi t. Upon 
physical examination actively infl amed lesions such as several draining fi stulas, nodules and 
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abscesses were observed. In addition follicular keratotic papules and a few pustules were ob-
served (Figure1-3). The patient was overweight with a BMI of 31.3 and was a current smoker. 
The patient never had HS lesions in inverse skin areas and did not have a family history of HS. 
A routine culture of the purulent discharge showed growth of normal commensal skin fl ora.
We diagnosed him with HS-like lesions induced by prosthesis-related friction. Because of 
follicular keratosis with occlusion he was treated with 5% resorcinol cream. The fi stulas and 
abscesses were surgically removed using the deroofi ng technique under general anaesthesia 
(Figure 4).
Figure 1. Left lower leg stump with fi stulas and follicular keratotic papules  (See also Color section, p. 196.)
Figure 2. Detail of follicular keratotic papules on the medial side of the knee (See also Color section, p. 197.)
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Figure 3. Probed fi stula (See also Color section, p. 197.)
Figure 4. Extent of fi stulas after surgical deroofi ng and slight approximation by sutures (See also Color 
section, p. 197.)
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DISCUSSION
Lower limb amputees are frequently confronted with skin problems on their stump9. These 
stump skin problems comprise acroangiodermatitis, allergic contact dermatitis, bullous 
diseases, epidermal hyperplasia including epidermoid cysts and hyperkeratotic papules, 
hyperhidrosis, infections and ulcers10. Most of these stump skin problems can be traced back 
to the local, unnatural conditions such as shear forces and increased humidity when wearing 
a prosthesis10. The mechanical friction can lead to epidermal hyperplasia, epidermoid cysts 
and hyperkeratotic papules and acne mechanica in leg stumps10,11. However, abscessing 
infl ammation with fi stula formation has to our knowledge not been described earlier which 
indicates our case is distinctive. Several lesion characteristics in our patient strongly sug-
gested a HS-like disease rather than the previously described skin problems of lower limb 
amputees. First, the deep-seated infl ammatory abscesses, nodules and especially fi stulas 
clinically resembled HS rather than acne mechanica. Second, culture of the lesional exudate 
only yielded commensal skin fl ora unresponsive to antibiotic treatment as is often seen in HS. 
Third, the patient was a heavy cigarette smoker, which is a well-known risk factor for HS as it 
is associated with follicular occlusion12. Interestingly our patient never had recurrent HS-like 
lesions in the axilla or groin, nor a family history of HS, which is present in 40% of HS cases13.
The exact pathogenic mechanism by which mechanical friction contributes to HS develop-
ment is unknown. Circumstantial evidence that mechanical friction is important in HS derives 
from a mechanical friction-related skin disorder closely resembling HS, namely ‘jeep disease’. 
Jeep disease was characterized by abscesses, fi stulas, pilonidal sinuses and cysts at the but-
tocks of soldiers, caused by wobbly Jeep, truck or tank rides14. This disease caused consider-
able morbidity among the US army personnel during World War II. A second example is the 
case of an infant with a naevus comedonicus located in the groin, in which HS-like lesions 
developed only after the child started to move around15. The authors argued that friction 
caused dilated hair follicles to rupture leading to infl ammation15.
A leg prosthesis creates a warm humid climate, favourable for bacterial growth. It has been 
postulated that skin commensal microbiota trigger an immune response that may initiate 
HS. We hypothesize that a similar mechanism contributed to the HS-like lesions in our case 
presented here. The concept of the combination of friction and a favourable bacterial climate 
furthermore provide a rationale why HS is more common in the obese. In the obese, HS 
prefers the increased and extended abdominal skinfolds as well as the inner thighs, locations 
characterized by enhanced mechanical friction and by a warm and humid microclimate.
We treated the patient with the surgical deroofi ng technique which is often used in HS 
and is known to yield low recurrence rates16. Deroofi ng is a technique whereby the ‘roof’ of 
an abscess, cyst or sinus tract is electro-surgically removed16. A probe is used to explore for 
subcutaneous pockets and fi stulas originating from the HS nodule or abscess16.
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In summary, the patient demonstrated infl ammatory lesions, strikingly similar to HS, at an 
ectopic location free of apocrine sweat glands and induced by wearing of a leg prosthesis. 
We argue that the presence of apocrine sweat glands in HS-predisposed sites is based on 
coincidence. Overlapping characteristics between HS predisposed sites include mechanical 
friction and a warm humid, favourable bacterial microclimate. Mechanical stress may pro-
mote HS in a twofold manner. First, it may promote follicular keratosis and occlusion, similar 
to acne mechanica. Second, it may promote rupture of fragile dilated follicles. Furthermore, 
the warm and humid microclimate in HS predilection sites favours bacterial growth, which 
may trigger or worsen HS.
Hessel BW.indd   63 11-Oct-11   10:36:37 AM
Chapter 2.3
64
REFERENCES
 1 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its poten-
tial precursor lesions. J Am Acad Dermatol 1996; 35: 191-4.
 2 Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradeni-
tis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
 3 Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of 
life and professional activity. J Am Acad Dermatol 2010; 62: 706-8.
 4 Jemec GB, Faber M, Gutschik E et al. The bacteriology of hidradenitis suppurativa. Dermatology 
1996; 193: 203-6.
 5 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad 
Dermatol 2009; 60: 539-61.
 6 Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa--characteristics and conse-
quences. Clin Exp Dermatol 1996; 21: 419-23.
 7 Canoui-Poitrine F, Revuz JE, Wolkenstein P et al. Clinical characteristics of a series of 302 French 
patients with hidradenitis suppurativa, with an analysis of factors associated with disease sever-
ity. J Am Acad Dermatol 2009; 61: 51-7.
 8 Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996; 34: 994-9.
 9 Meulenbelt HE, Geertzen JH, Jonkman MF et al. Determinants of skin problems of the stump in 
lower-limb amputees. Arch Phys Med Rehabil 2009; 90: 74-81.
 10 Meulenbelt HE, Geertzen JH, Dijkstra PU et al. Skin problems in lower limb amputees: an overview 
by case reports. J Eur Acad Dermatol Venereol 2007; 21: 147-55.
 11 Ibbotson SH, Simpson NB, Fyfe NC et al. Follicular keratoses at amputation sites. Br J Dermatol 
1994; 130: 770-2.
 12 Hana A, Booken D, Henrich C et al. Functional signifi cance of non-neuronal acetylcholine in skin 
epithelia. Life Sci 2007; 80: 2214-20.
 13 von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Derma-
tol Venereol 2000; 14: 389-92.
 14 Classic articles in colonic and rectal surgery. Louis A. Buie, M.D. 1890-1975: Jeep disease (pilonidal 
disease of mechanized warfare). Dis Colon Rectum 1982; 25: 384-90.
 15 Dufour DN, Bryld LE, Jemec GB. Hidradenitis suppurativa complicating naevus comedonicus: 
the possible infl uence of mechanical stress on the development of hidradenitis suppurativa. 
Dermatology 2010; 220: 323-5.
 16 van der Zee HH, Prens EP, Boer J. Deroofi ng: a tissue-saving surgical technique for the treatment 
of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63: 475-80.
Hessel BW.indd   64 11-Oct-11   10:36:37 AM
3
P athomechanisms i n 
hidradenitis suppurativa
Hessel BW.indd   65 11-Oct-11   10:36:37 AM
Hessel BW.indd   66 11-Oct-11   10:36:37 AM
3.1
E levated levels of TNF-α, IL-
1β and IL-10 in hidradenitis 
suppurativa skin; a rationale for 
targeting TNF-α and IL-1β
HH van der Zee, L de Ruiter, DG van den Broecke, WA Dik, 
JD Laman and EP Prens
Br J Dermatol 2011; 164: 1292-8
Hessel BW.indd   67 11-Oct-11   10:36:38 AM
Chapter 3.1
68
ABSTRACT
Background: The pathogenesis of hidradenitis suppurativa (HS) is largely unknown and the 
disease is diffi  cult to treat. Patients are in high need of an eff ective treatment. Although it is 
not known whether the levels of TNF-α are aberrant in HS skin, anti-TNF-α biologics are used, 
with variable clinical effi  cacy.
Objectives: To determine the cytokine profi le in lesional and perilesional HS skin.
Methods: We cultured 20 lesional, 10 normal appearing perilesional HS skin samples, 7 
psoriasis and 6 healthy control skin samples in a transwell culture system. Two distinct cy-
tokine bead arrays were used to measure the spectrum of infl ammatory cytokines in the 
culture supernatant. Results from HS skin samples were compared with those of healthy and 
psoriasis skin.
Results: The pro infl ammatory cytokines IL-1β, TNF-α as well as the anti-infl ammatory cyto-
kine IL-10 were signifi cantly elevated in HS skin. Elevated levels of these cytokines were also 
found in perilesional HS skin. Fold increases relative to control skin of IL-1β, TNF-α and IL-10 in 
HS were 31, 5, and 34, compared to psoriasis 4, 1 and 2 respectively. Levels of all 3 cytokines 
showed a trend towards a positive correlation with disease severity. IL-2, IL-4, IL-5 and IFN-y 
were hardly detectable in HS or healthy control skin.
Conclusions: This study shows for the fi rst time that IL-1β, TNF-α and IL-10 levels are elevated 
in HS skin. These data provide a rationale for therapies with biologics targeting cytokines 
such as TNF-α and IL-1.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic, infl ammatory, recurrent, debilitating follicular 
disease that usually presents after puberty with painful deep-seated, infl amed lesions in the 
inverse skin areas of the body, most commonly, the axillary, inguinal and anogenital regions. 
Estimated prevalence rates range between 1% and 4%1,2. Because HS is a painful and dis-
tressing disorder and is associated with strong feelings of shame, it signifi cantly reduces the 
patients’ quality of life3-5. Since many treatments have been unsatisfactory, and as there are 
many recurrences, HS remains diffi  cult to treat. Treatment options include topical or systemic 
antibiotics, pain killers and immunosuppressive agents. In addition, surgical intervention is 
often necessary6.
The pathogenesis of HS is largely unknown and probably multifactorial. The most likely 
primary mechanism is hyperkeratinisation of the follicular infundibulum which results in 
follicular occlusion. The dilated follicle ruptures, spilling its content including keratin and 
bacteria into the dermis, subsequently causing infl ammation. Genetic predisposition, fric-
tion, obesity, smoking and hormonal infl uences are considered pathogenic factors6,7. Defects 
or alterations in host defence mechanisms may also contribute. It has been proposed that 
HS results from an inappropriate immune response to commensal bacterial skin fl ora. This 
concept is based on the co-occurrence and pathogenic similarities with Crohn’s disease, and 
is furthermore supported by frequent culture of only normal skin fl ora and not pathogens 
from HS aff ected skin8.
Immunosuppressive agents such as corticosteroids and anti-TNF-α biologics are used in 
the treatment of HS. The effi  cacy of anti-TNF-α biologics for HS was fi rst reported in patients 
with comorbid Crohn’s disease9. While these patients were treated with anti-TNF-α biologics 
for their Crohn’s disease, concomitantly their HS showed clear improvement. This unexpected 
observation resulted in a number of case reports followed by case series and more recent 
by a growing number of randomized controlled trials reporting predominantly positive on 
effi  cacy of anti-TNF-α biologics10-14.
Despite the concept of an altered immune response leading to HS and the promising addi-
tion of anti-TNF-α biologics to the HS treatment repertoire, basic immunological aspects such 
as cytokine profi ling, particularly TNF-α have yet to be demonstrated. Hence the aim of this 
study was to elucidate the spectrum of cytokines in HS skin infl ammation and to compare 
these levels to normal appearing perilesional HS skin, and the skin of healthy donors. In ad-
dition we compared the cytokine profi le of HS lesions to that of psoriasis. The results provide 
guidance for future functional studies and contribute to the rational development of new 
therapeutic strategies.
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MATERIALS AND METHODS
Lesional and perilesional HS skin
HS aff ected skin (LHS) was obtained from 20 HS patients (6 males, 14 females), undergoing 
radical excision surgery for their HS under general anaesthesia. Patient characteristics are 
shown in Table 1. HS skin was obtained from the groin 12/20, axillae 7/20 and gluteal regions 
1/20. Disease severity was based on staging according to Hurley. Stage I: Abscess formation, 
single or multiple without sinus tracts and cicatrisation. Stage II: Recurrent abscesses with 
tract formation and cicatrisation, single or multiple widely separated lesions. Stage III: Diff use 
or near diff use involvement or multiple interconnected tracts or abscesses across the entire 
area15. Five of twenty patients had Hurley stage III disease, 11/20 Hurley stage II disease and 
4/20 had Hurley stage I disease. Their mean age was 39.6 years, mean BMI 27.6 and 19/20 
were smokers. All patients had chronic, active disease and had not been using any medica-
tion for their HS at least 3 weeks prior to surgery. The group of HS patients in this study 
represented the HS population at large, although in the general HS population Hurley I is the 
most common stage of disease. In 10 of 20 patients, the HS-aff ected skin was excised with a 
healthy appearing skin margin of 2 cm. Biopsies from this adjacent perilesional HS skin (PHS) 
were also obtained and cultured.
Table 1. Patient characteristics
Lesional HS Perilesional HS
n=20 n=10
Gender 6 males;14 females 1 male; 9 females
Age mean (sd) 40 (15) 38 (15)
BMI mean (sd) 27.6 (4.1) 28.9 (4.5)
Smokers n=19 n=10
Location groin n=12 groin n=7
axillae n=7 axillae n=3
gluteal n=1
Disease severity Hurley 3 n=5 Hurley 3 n=1
Hurley 2 n=11 Hurley 2 n=7
Hurley 1 n=4 Hurley 1 n=2
Healthy control skin
Healthy control skin was obtained from submammary skin of 6 healthy females undergoing 
breastreduction surgery. We argue that skin from this region is especially suitable to function 
as healthy control for HS as submammary skin is an HS predilection site in female HS patients.
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Psoriasis skin
In order to interpret the levels of cytokines produced in HS skin into pathophysiological 
perspective, we compared them with another infl ammatory skin disease namely psoriasis. 
Hereto punch biopsies from lesional psoriatic plaques were obtained from 7 diff erent pa-
tients with plaque psoriasis. These patients were not on systemic drugs for their psoriasis and 
they did not use any topical treatment on the biopsied psoriatic plaque for at least 2 weeks.
Biopsy procedure
All study subjects gave their informed consent as required by the ethical review board. For 
HS aff ected, perilesional and control skin we obtained six, 3-mm diameter punch biopsies. 
The punch biopsies of HS aff ected skin were taken from indurated, erythematous areas as 
close as possible to the same palpable, infl amed, nodule or abscess. Abscesses themselves 
were not sampled because of the risks of only sampling the superfi cial roof of the abscess, 
and of potential bacterial contamination in culture. The punch biopsies of perilesional skin 
were obtained from clinically unaff ected skin 2 cm distanced from the erythematous border 
of an infl amed HS lesion. HS infl ammatory infi ltrates tend to be deep-seated, this is why all 
biopsies, including the ones from control skin, were taken as deep as possible (6-10 mm). 
For ethical reasons skin samples from the psoriatic plaques were single 4 mm diameter 
punch biopsies. To allow comparisons single 4 mm diameter punch biopsies were also taken 
Figure 1. Weight of the biopsies in each well before culture. Lesional HS skin was signifi cantly heavier 
than perilesional HS skin and healthy control skin. Means are shown.
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from the healthy control skin. We expected that the punch biopsies would vary in weight, 
in theory this diff erence in weight could introduce a confounder since the more tissue is 
put into culture the more cytokine could be released. Therefore we assessed the combined 
weight of the biopsies in each well prior to culture. The combined weight of biopsies per well 
cultured is shown in Figure 1. LHS skin had a mean (± sd) weight of 49 mg ± 16. PHS 15 mg ± 
8, and 27 mg ± 5 for healthy control. Psoriasis 25 mg ± 6 and 22 mg ± 7 healthy control skin 
for psoriasis. The LHS biopsies were signifi cantly heavier than control skin (p < 0.0001) and 
heavier than PHS skin (p < 0.0001). This potential confounder was settled by normalizing all 
cytokine levels for mg tissue weight that went into culture.
Skin culture
Three, 3 mm biopsies of HS aff ected skin, perilesional skin or control skin were placed tightly 
within punctured membrane of a transwell culture system (Netwell, Costar, Cambridge, MA) 
in duplicate as described previously16. Iscove’s Modifi ed Dulbecco’s Medium (IMDM, Gibco, 
Paisley, UK) containing 0.5% normal human serum, penicillin (100 units/ml), and streptomycin 
(100 ug/ml) was used as the culture medium. Since we assumed in vivo priming by DAMPS or 
PAMPS, no additional stimuli were added to refl ect the in vivo situation as much as possible. 
Psoriatic skin and the control skin were cultured with a single 4 mm biopsy per well. All skin 
biopsies were cultured for 24 h at 37 °C, in an atmosphere of 5% CO2 and 98% humidity. After 
incubation the culture medium was centrifuged for 3 min at 3300 G. The supernatants were 
stored at -80C° until further processing.
Cytokine measurements in culture medium
Cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-α and IFN-γ were measured using 
commercially available cytometric bead arrays (CBA Human Infl ammation Kit, BD Bioscien-
cesTM and CBA Human TH1/TH2 Cytokine Kit, BD BiosciencesTM) according to the protocol 
of the manufacturer. Measurements were performed on a FACS Calibur (BD Biosciences) and 
the analysis by FCAPTM Array Software (BD Biosciences). Assay sensitivity ranged from 5 pg/
ml to 5.000 pg/ml for all cytokines. In case a cytokine level was below or higher than the 
detection limit, the detection limit was used for further calculations. Hereafter all cytokine 
levels were normalized to the tissue weight and expressed as pg/ml/mg.
Statistical analysis
For parametrically distributed values mean and standard deviation are provided, these data 
were analyzed by t-test. In case of non-parametrically distributed values the median with 
inter quartile ranges are provided, these data were analyzed by Mann Whitney U test. Tests 
were done two- tailed. The criterion for statistical signifi cance was p < 0.05. For the statistical 
analysis the software GraphPad Prism 5 was used. In the fi gures p < 0.05 is presented as *, p 
< 0.01 as ** and p < 0.001 as ***.
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RESULTS
Pro infl ammatory cytokines IL-1β, TNF-α and IL-10 are signifi cantly elevated in 
lesional HS skin
Levels of IL-1β, TNF-α and IL-10 in LHS, PHS and healthy control skin are shown in Figure 2. 
The median secreted IL-1β in LHS skin was 5.85 pg/ml/mg, which was signifi cantly higher 
than 0.19 pg/ml/mg in the control skin (p= 0.0003). The LHS median value of secreted TNF-α 
of 0.99 pg/ml/mg was also signifi cantly higher than 0.19 pg/ml/mg in the control skin (p= 
0.0115). Not only the pro-infl ammatory cytokines IL-1β and TNF-α were signifi cantly elevated 
in LHS skin, IL-10 levels were even more strikingly elevated with a median of 14.6 pg/ml/mg 
compared to control skin 0.43 pg/ml/mg (p= 0.0006).
HS infl ammation extends beyond the visually infl amed border
Levels of IL-1β, TNF-α and IL-10 in LHS, PHS and healthy control skin are presented in Figure. 
2. Infl ammatory cytokines IL-1β, TNF-α but also the anti-infl ammatory IL-10 were signifi cantly 
elevated in LHS skin. In PHS skin IL-1β had a median of 1.38 pg/ml/mg, TNF-α of 0.57 and of 
IL-10 11.43. IL-1β in LHS skin was signifi cantly higher than in PHS skin (p= 0.0068) However, 
IL-1β in PHS was also signifi cantly higher than in control healthy skin (p= 0.0005). Levels of 
TNF-α and IL-10 in LHS skin were not signifi cantly higher than in PHS skin. Whereas both the 
Figure 2. Levels of IL-1β (A), TNF-α (B) and IL-10 (C) in lesional HS, perilesional and in healthy control skin. 
Medians are shown; cytokine levels are in pg/ml/mg tissue on a log scale.
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TNF-α and IL-10 levels in PHS skin were signifi cantly higher than the healthy control skin 
(p=0.0005 and p=0.0075 respectively). These results show that although IL-1β, TNF-α and 
IL-10 levels in PHS skin are lower than LHS skin, they are still signifi cantly elevated compared 
to healthy control skin.
IL-1β, TNF-α and IL-10 release in HS skin tends to correlate with disease severity
Since that IL-1β, TNF-α and IL-10 were elevated in HS skin, we investigated whether the levels 
of these cytokines were related to disease severity. To make this comparison we ranked LHS 
skin according to Hurley classifi cation. The secreted levels of IL-1β, TNF-α and IL-10 according 
to Hurley classifi cation are presented in Figure. 3. We conclude that IL-1β, TNF-α and IL-10 
levels tend to correlate with disease severity, but the groups became too small for statistical 
analysis.
IFN-γ, IL-12p70, IL-2, IL-4 and IL-5 are generally undetectable in HS skin
Levels of IFN-γ are shown in Figure. 4. IFN-γ was undetectable in 18 out of 40 LHS samples and 
in 13 out of 20 PHS samples, as well as in all healthy control samples. The median IFN-γ for 
LHS was 0.33 pg/ml/mg, for PHS 0.32 pg/ml/mg and for healthy controls 0.19 pg/ml/mg. The 
level of IFN-γ tended to be higher in LHS an PHS skin compared to healthy controls but there 
was no signifi cant diff erence between LHS and healthy controls, PHS and healthy controls 
and LHS and PHS. IL-12p70 was below the detection limit in all 40 LHS samples as well as in 
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all PHS and healthy controls. IL-2 was below detection limit in 35 out of 40 LHS samples, all 
PHS samples and in 11 out of 12 healthy controls. IL-4 was below detection limit in 34 out of 
Figure 3. Levels of IL-1β (A), TNF-α (B) and IL-10 (C) in LHS grouped by disease severity according to Hurley 
staging. Hurley I n=4, Hurley II n=11 Hurley III n=5 medians are shown; cytokine levels are in pg/ml/mg 
tissue on a log scale.
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40 LHS, in 18 out 20 PHS samples and in all 12 healthy control samples. IL-5 was beneath the 
detection limit in 37 out of 40 LHS samples and in all PHS and healthy control samples. These 
results suggest that IL-12p70, IL-2, IL-4, IL-5 and IFN-γ are not important in HS infl ammation. 
Interleukin-6 and IL-8 levels were above the detection limit of 5000 pg/ml in all samples 
including healthy controls.
IL-1β, TNF-α and IL-10 production in HS skin is higher than that of psoriatic skin
To make a quantitative comparison between HS and psoriasis, cytokine levels, IL-1β, TNF-α 
and IL-10 were expressed as fold inductions of the medians. The IL-1β median in psoriasis 
was 0.47 pg/ml/mg which was not signifi cantly diff erent from control skin levels of 0.12 pg/
ml/mg. Also TNF-α levels in psoriasis did not diff er from control skin and both had a median 
of 0.12 pg/ml/mg. The median IL-10 in psoriasis lesions was 0.39 pg/ml/mg versus 0.18 pg/
ml/mg in healthy control skin which was not signifi cantly diff erent. Calculations resulted in a 
signifi cantly diff erent IL-1β fold induction of 31 for HS compared to 4 for psoriasis (p=0.025), 
TNF-α showed a signifi cantly diff erent fold induction of 5 for HS compared to 1 for psoriasis 
(p=0.0309). The most striking diff erence was found for IL-10 which showed 34 fold induction 
of HS compared to 2 for psoriasis (p=0.0004)
Figure 4. Levels of IFN-γ in lesional HS, perilesional and in healthy control skin. Medians are shown; 
cytokine levels are in pg/ml/mg tissue log scale.
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DISCUSSION
Anti-TNF-α biologics are the most intensely studied drugs in HS. However, to our knowledge 
TNF-α levels have not been examined systematically in skin lesions of patients suff ering from 
HS. Matusiak et al. showed that TNF-α is signifi cantly elevated in the blood of HS patients17. 
This in contrast to another study which showed that in HS, after stimulation with LPS, pe-
ripheral blood-derived monocytes released less TNF-α and IL-6 than controls18. In this study 
we show that TNF-α is elevated in infl amed HS skin lesions, providing evidence for the use of 
anti-TNF-α biologics in HS. TNF-α is a pro-infl ammatory cytokine produced by many diff erent 
cell types, though mainly by macrophages and monocytes. It is expressed in the basal layer 
of the epidermis, sweat glands and hair follicles19.
We used a cytometric bead array containing a panel of diff erent cytokines in order to 
discriminate between a Th1, Th2 infl ammatory profi le in HS infl ammation. Most cytokines in 
the bead arrays like IL-12p70, IL-2, IL-4, IL-5 and to a lesser extent IFN-γ were frequently below 
detection limit in HS skin. On the basis of these results it is unlikely that HS is prototypical 
Th1 or Th2 driven infl ammatory disease. This predominantly innate infl ammatory response 
is supported by the absence of enlarged lymph nodes clinically and ultrasonographically20 
although a lymphocytic infi ltrate has been observed in early HS lesions21.
We here show that IL-1β, a potent pro-infl ammatory cytokine, is signifi cantly elevated in 
lesional well as in perilesional HS skin. IL-1β can be produced by many diff erent cell types 
but mainly monocytes and macrophages22. Biologically active IL-1β is generated in infl am-
masomes that cleave pro-IL-1 using caspase-1. Infl ammasomes function as cytosolic sensors 
which respond to diverse types of danger signals such as damage associated molecular pat-
tern molecules (DAMPS) and pathogen-associated molecular patterns (PAMPS). Examples of 
DAMPS and PAMPS which can trigger infl ammasomes to convert active IL-1β, are bacterial and 
viral sequences, a number of host-derived molecules indicative of injury such as extracellular 
ATP and hyaluron, uric acid in gout and signs of metabolic stress23. Furthermore a number of 
environmental irritants such as ultraviolet B and skin irritants also activate infl ammasomes23. 
We hypothesise that several of above mentioned DAMPS and PAMPS are present in HS and that 
they activate infl ammasomes via three pathways. First by DAMPS such as host-derived mol-
ecules indicative of tissue destruction and pyroptosis, a highly infl ammatory form of cell death. 
This concept is supported by the presence of pus and scarring in HS. Second by PAMPS, since HS 
lesions are frequently inhabited by commensal microbiotic fl ora. And third, we argue that free 
high molecular weight cornifi ed keratins in the dermis, spilled by ruptured follicular cysts, can 
activate infl ammasomes after phagocytosis, in analogy with uric acid crystals in gout. Because 
relatively high levels of IL-1β were found in HS skin, we argue that the infl ammasome is involved 
in HS skin infl ammation. This is a new pathogenic concept that warrants further investigations, 
also since the infl ammasomes and the IL-1β pathway can be targeted by drugs such as colchi-
cine, or biologics such as IL-1 receptor antagonist and IL-1β neutralizing monoclonal antibodies.
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In addition to the enhanced production of IL-1β and TNF-α, HS skin also produced an 
increased amount of IL-10. Interleukin-10 has a central, generally anti-infl ammatory role 
in infection and in limiting the immune response to pathogens and thereby preventing 
damage to the host. It furthermore has a crucial role in preventing infl ammatory and auto-
immune pathologies24. IL-10 is expressed by many cell subsets of adaptive immunity and is 
also expressed by innate immune cells. We speculate that macrophages in HS could be the 
prime producers of this vast amount of IL-10, since it was shown that bone marrow-derived 
macrophages stimulated by eff erocytosis (clearance of apoptotic neutrophils) are character-
ised by high IL-10 production and in addition produce TNF-α following re-stimulation with 
LPS25. This study suggested that such regulatory macrophages play a role in resolution of 
infl ammation25. There is a large overlap between this concept of IL-10 producing macro-
phages and what is known about HS. First macrophages and neutrophils can be found in 
high numbers in HS infi ltrates and abscesses. Second HS lesions are frequently inhabited by 
commensal microbiotic fl ora and therefore it is credible that HS macrophages are stimulated 
by LPS. Third we showed that TNF-α is present in HS just as it is present in the infl ammatory 
eff erocytosis model.
Our results also demonstrate that HS infl ammation extends beyond the visibly aff ected 
infl ammatory borders. Histologically, an infl ammation-driven process in the epidermis of 
HS skin is psoratiform hyperplasia26. It has been proposed that this psoratiform hyperplasia 
is a primary histological anomaly in HS26. Our data on the presence of infl ammatory cyto-
kines beyond the visibly aff ected infl ammatory borders is of clinical importance since high 
recurrence rates of HS lesions are reported after surgical excision27. We argue that the occult 
infl ammation in perilesional HS skin drives the psoratiform hyperplasia and can therefore be 
the cause of recurrence after surgery. This concept suggests that recurrence after excisions 
can be prevented by the administration of adjuvant medications which reduce infl ammation 
and infundibular epidermal hyperplasia.
The levels of especially IL-1β, IL-10 but also TNF-α in HS were relatively higher in HS than in 
psoriasis. These results suggest that infl ammation in HS skin is more intense than in psoriasis 
stressing the strong infl ammatory nature of the disease.
This study shows for the fi rst time that IL-1β, TNF-α and IL-10 production is elevated in HS 
skin. Our results provide a rationale for targeting these cytokines with specifi c biologics in 
HS patients.
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ABSTRACT
Background: Hidradenitis suppurativa (HS) is a diffi  cult to manage disease. Randomized 
controlled trials with anti-TNF-α biologics have been conducted and in most studies disease 
activity was reduced. However, the mechanism of action in HS skin is so far unknown.
Objectives: To assess whether anti-TNF-α treatment aff ects in situ cytokine production and 
frequency of infl ammatory cell populations in HS lesional skin.
Methods: Nine HS patients, participating in a larger placebo-controlled, double-blind phase 
IIb clinical trial on the effi  cacy and safety of adalimumab in patients with moderate to severe 
HS (M10-467), were randomized and treated for 16 weeks. In a mechanism of action sub-
study, biopsies were obtained at fi xed time points pre- and post-treatment. One part of the 
biopsy was cultured for 24 h for cytokine release in the culture medium, while another part 
was used for in situ analysis.
Results: Secretion of cytokines, including IL-1β, CXCL9 (MIG), IL-10, IL-11, BLC and IL-17A was 
signifi cantly elevated in HS. Adalimumab treatment was associated with decreased cytokine 
production in HS skin, especially IL-1β, CXCL9 (MIG) and BLC. Treatment signifi cantly reduced 
the number of CD11c+, CD14+ and CD68+ cells in HS lesional skin. The numbers of CD3+ and 
CD4+ T cells, CD20+ and CD138+ B cells were also reduced by adalimumab treatment.
Conclusions: Adalimumab treatment inhibits important cytokines and infl ammatory cell 
numbers in lesional HS skin especially infl ammatory CD11c+ dendritic cells and IL-1β levels.
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INTRODUCTION
Hidradenitis suppurativa (HS) is an infl ammatory debilitating skin disease characterized 
by recurrent, painful, deep-seated, infl amed boils with, in severe cases, odorous discharge 
from fi stulas and mutilating scarring. Predisposed skin areas are the axillary, inguinal and 
anogenital regions. The estimated prevalence rates of HS range between 1% and 4%1,2. The 
precise pathogenesis of HS is unknown, but the most widely accepted pathogenic concept is 
that of hyperkeratinisation of the follicular infundibulum and follicular occlusion followed by 
rupture of dilated follicles causing infl ammation. Besides genetic predisposition, exogenous 
factors such as cigarette smoking, obesity, shear forces, and hormonal infl uences contribute 
to the pathophysiology of HS3,4. Furthermore it has been speculated that an altered innate 
immune response to commensal skin microbiota contributes to or even is the primary cause 
of the disease5.
Levels of TNF-α are increased in the blood of patients with HS6, and we recently showed 
that both lesional HS skin and normal-appearing perilesional skin samples from HS patients 
released signifi cant amounts of cytokines, including TNF-α7. These data provide a rationale 
for the therapeutic use of anti-TNF-α biologics in HS. Small randomized, double-blind trials 
have assessed the clinical effi  cacy of TNF antagonists in HS with mixed results; etanercept 
was frequently ineff ective, but positive trends of effi  cacy were seen during infl iximab tri-
als and an adalimumab trial8-13. Despite the reported effi  cacy of anti-TNF-α biologics, the 
mechanism of action of these drugs in HS remains largely unknown. TNF-α is produced by 
many cell types including mast cells, macrophages, dendritic cells, T cells, granulocytes, fi bro-
blasts and keratinocytes14 all of which are present in HS lesions15. Because of its pleiotropic 
properties, TNF-α is able to direct infl ammation in several ways. With respect to its role in 
supporting chronic infl ammation in HS, the infl uence of TNF-α on monocyte activation and 
diff erentiation into infl ammatory type dendritic cells, granuloma formation, accumulation of 
neutrophils, activation of keratinocytes and the induction of several matrix metalloproteases 
(MMPs) are considered important mechanisms16.
Adalimumab is a fully human, IgG1, neutralizing monoclonal antibody specifi c for TNF-α. 
Here we report on alterations in cytokine production in lesional skin and the skin infi ltrate 
after adalimumab treatment for HS. The patients included in this study participated in a 
larger placebo-controlled, double-blind phase IIb clinical trial on the effi  cacy and safety of 
adalimumab in patients with moderate to severe hidradenitis suppurativa (M10-467, Clini-
calTrials.gov number: NTC00918255). The effi  cacy results of this RCT have been separately 
submitted for publication elsewhere.
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MATERIALS AND METHODS
Patients and treatment
Nine HS patients participated in this study after giving their signed informed consent as 
required by the ethical review board. All 9 HS patients (5 males, 4 females) had chronic, active 
disease, stable for at least 2 months. Patient characteristics are shown in Table 1. HS lesional 
skin samples were obtained from the groin in 6 out of 9 patients, axillae in 1 out of 9 and 
gluteal region in 2 out of 9 patients. Disease severity was based on staging according to 
Hurley17. Six out of nine patients had severe HS (Hurley stage III disease), 1 had Hurley stage II 
disease and 2 had Hurley stage I disease. According to the protocol of the above mentioned 
phase IIb double blinded RCT, patients were randomly assigned to three groups. Group 1 
received adalimumab 40 mg weekly (starting at week 4, after initial doses of 160 mg at week 
0 and 80 mg at week 2); group 2 received adalimumab 40 mg every other week (starting at 
week 1, after an initial dose of 80 mg at week 0). Group 3 received matching placebo. Local 
alteration in disease severity was evaluated using a four stage physician global assessment 
(PGA) score: worsening, no diff erence, slight improvement and improvement. Photographs 
at week 0 were taken to increase sensitivity of the PGA and to exactly pinpoint the prior 
biopsy location.
Table 1. Patient characteristics
Patient # Age (years) Gender BMI Smoking Biopsy site
Hurley 
stage PGA at 16 weeks
Group 1 1 47 ♀ 43.0 no inguinal 3 improvement
2 31 ♀ 18.3 yes inguinal 1 improvement
3 24 ♂ 27.1 yes axilla 3 worsening
Group 2 4 32 ♀ 29.4 yes pubis 3 improvement
5 58 ♀ 29.7 yes buttock 3 slight improvement
6 58 ♂ 26.2 yes pubis 2 improvement
Group 3 7 36 ♂ 38.5 yes inguinal 2 slight improvement
8 39 ♂ 22.8 yes inguinal 3 no diff erence
9 67 ♂ 22.6 yes buttock 3 no diff erence
Group 1 received adalimumab 40 mg weekly (starting at week 4, after initial doses of 160 mg at week 0 
and 80 mg at week 2); Group 2 received adalimumab 40 mg every other week (starting at week 1, after an 
initial dose of 80 mg at week 0). Group 3 received matching placebo.
Biopsy procedure
At time points 0 and 16 weeks, a 5 mm diameter punch biopsy was obtained. The punch 
biopsy at week 0 was taken from an indurated, erythematous, infl amed lesion as close as 
possible to a palpable nodule or abscess. Abscesses themselves were not sampled because of 
the risk of only sampling the superfi cial roof of the abscess. HS infl ammatory infi ltrates tend 
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Table 2. Cytokines in HS skin compared to healthy control skin
HS Healthy control skin
median IQR median IQR p fold induction
IL-1β 1.6 0.8 - 6.8 0.0 0.0 - 0.1 0.0028 ** 54.4
MIG (CXCL9) 219.8 180.0 - 320.1 13.8 9.7 - 17.1 0.0028 ** 16.0
IL-10 19.2 10.3 - 35.1 1.3 0.5 - 2.2 0.0028 ** 14.8
IL-11 78.6 38.6 - 152.6 7.2 2.4 - 10.8 0.0056 ** 11.0
BLC 8.1 4.6- 17.3 0.8 0.6 - 2.7 0.0056 ** 10.5
IL-17A 8.1 1.9 - 36.9 1.1 0.5 - 1.4 0.0056 ** 7.3
TNF RII 47.0 34.5 - 65.1 8.1 7.5 - 8.4 0.0028 ** 5.8
RANTES (CCL5) 7.6 3.1 - 23.7 1.4 1.0 - 2.0 0.0112 * 5.4
IL-16 22.3 21.2 - 50.3 4.2 1.7 - 5.6 0.0028 ** 5.3
IL-6sr 16.3 8.1 - 31.5 4.4 2.9 - 6.2 0.0028 ** 3.7
ICAM-1 98.7 70.4 - 187.4 31.9 27.2 - 41.0 0.0028 ** 3.1
MIP-1α (CCL3) 0.4 0.2 - 0.8 0.2 0.1 - 0.4 0.0196 * 2.0
TNF RI 78.0 56.3 - 90.2 40.2 30.8 - 46.3 0.0112 * 1.9
TNF-α 0.3 0.2- 0.9 0.2 0.1 - 0.2 0.0336 * 1.6
IL-1ra 44.0 37.3 - 65.6 29.6 24.1 - 32.7 0.0112 * 1.5
Eotaxin 0.1 0.1 - 0.2 0.1 0.1 - 0.2 ns
Eotaxin-2 3.9 0.5 - 9.2 2.5 1.7 - 9.3 ns
G-CSF 117.8 96.4 - 196.9 96.8 75.5 - 165.9 ns
GM-CSF 0.4 0.1 - 1.8 0.0 0.0 - 0.5 ns
I-309 0.4 0.3 - 2.2 0.3 0.3 -1.6 ns
IFN-γ 0.1 0.1 - 0.2 0.1 0.1 - 0.2 ns
IL-1α 0.2 0.1 - 0.4 0.1 0.1 - 0.1 ns
IL-2 0.8 0.4 - 1.0 0.4 0.3 - 0.6 ns
IL-4 0.0 0.0 - 0.1 0.1 0.0 - 0.1 ns
IL-5 0.2 0.1 - 0.2 0.2 0.2 - 0.2 ns
IL-6 124.4 72.2 - 159.8 101.9 79.2 - 121.1 ns
IL-7 0.4 0.3 - 0.5 0.4 0.3 - 0.5 ns
IL-8 14,1 9.5-18.7 12.0 10.2 - 14.4 ns
IL-12p40 0.5 0.4 - 0.6 0.4 0.3 - 0.4 ns
IL-12p70 0.0 0.0 - 0.1 0.0 0.0 - 0.0 ns
IL-13 0.0 0.0 - 0.1 0.1 0.0 - 0.2 ns
IL-15 1.9 1.6 - 2.8 2.9 2.6 - 3.9 ns
MCP-1 47.5 26.3 - 57.0 37.1 30.9 - 44.4 ns
MCSF 0.4 0.2 - 0.8 0.2 0.1 - 0.4 ns
MIP-1b 16.1 8.3 - 19.3 5.8 3.7 - 7.9 ns
MIP-1d 0.1 0.1 - 0.1 0.1 0.1 - 0.4 ns
PDGF-BB 0.5 0.3 - 1.3 0.2 0.1 - 0.3 ns
TIMP-1 260.1 183.4 - 370.0 166.2 160.2 - 195.0 ns
TIMP-2 989.2 680.8 - 2096.0 997.3 838.5 -1242.0 ns
TNF-β 0.4 0.3 - 0.5 0.4 0.3 - 0.5 ns
Signifi cantly altered cytokines are presented in descending order by their level of induction. Non-
signifi cantly altered cytokines are ordered alphabetically. Levels are in pg/ml/mg. Medians and interquartile 
ranges (IQR) are shown. p < 0.05 is presented as *, p < 0.01 as ** and p < 0.001 as ***. ns is not signifi cant.
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to be deep-seated, therefore all biopsies, including control skin, were taken as deep as pos-
sible (6-10 mm). The punch biopsy at week 16 was taken as close as possible to the previously 
biopsied site. The biopsies were split whereby 1/3 was processed for immunostaining and 
2/3 was cultured. Healthy mammary skin was obtained from 4 healthy females undergoing 
breast reduction surgery, and served as healthy control skin.
Skin culture
Two thirds of the 5 mm punch biopsy was cultured in a transwell system (Netwell, Costar, 
Cambridge, MA) as described previously18. In brief: biopsies were placed in holes made in 
the transwell fi lter in such a manner that the epidermis remained exposed to the air whereas 
the dermis was immersed in 1 ml Iscove’s Modifi ed Dulbecco’s Medium (IMDM, Gibco, Paisley, 
UK) containing 0.5% human AB serum, penicillin (100 units/ml), and streptomycin (100 ug/
ml). All skin biopsies were cultured for 24 h at 37°C, in an atmosphere of 5% CO2 and 98% 
humidity. After 24 h, the culture medium was collected, centrifuged for 3 min at 3300 G, and 
transferred to a polypropylene tube and stored at -80C° until further analysis.
Cytokine measurements in culture medium
A broad spectrum of 40 infl ammation-related cytokines was simultaneously measured in the 
supernatant using the commercially available Quantibody Human Infl ammation array 3 (Ray-
Biotech Inc, Norcross, GA). A list of the cytokines is presented in Table 2. In addition TNF-α was 
measured with the more sensitive CBA Human Infl ammation Kit, (BD BiosciencesTM, Franklin 
Lakes, NJ). All arrays were used according to the manufacturers’ protocol.
Immunostaining procedure
One third of the 5 mm diameter punch biopsy was fi xed in 4% formaldehyde and embedded 
in paraffi  n. Four micrometer thin sections were labeled with a panel of antibodies as listed in 
Table 3, to immunophenotype leukocyte subsets. A standard horseradish peroxidase DAB (di-
aminobenzidine) staining procedure was followed using a polymer detection system (K8005, 
Table 3. Antibodies used in immunostaining procedure
Marker Indicative for Clone Dilution Manufacturer
CD3 T cells polyclonal 1:150 Dako, Glostrup, Denmark
CD4 T helper cells 4B12 1:160 Monosan, Uden, The Netherlands
CD8 Cytotoxic T cells C9/144B 1:100 Dako, Glostrup, Denmark
CD20 B cells L26 1:400 Dako, Glostrup, Denmark
CD138 Plasma cells B-A38 1:25 IQ Products, Groningen, The Netherlands
CD14 Monocytes MY4 1:100 Novocastra, Newcastle, UK
CD68 Macrophages KP1 1:160 Dako, Glostrup, Denmark
CD11c Dendritic cells 5D11 1:60 Novocastra, Newcastle, UK
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DAKO, Glostrup, Denmark). All sections were counterstained with haematoxylin (4085-9005, 
Klinipath, Uden, The Netherlands) to visualize cell nuclei. Antigen retrieval for all antibodies 
was performed by heating sections (20 min at 97 °C) in DAKO PT modules (PT 101, DAKO, 
Glostrup, Denmark) in Envision Flex Target Retrieval Solution high pH (DAKO, K8004). Normal 
antibody diluent (Scytec ABB999 Scytec laboratories, Logan, UT) was used for blocking of 
sections and for dilution of the primary antibodies. Human tonsil was used as positive control 
tissue for all antibodies and was included on each glass slide in each staining run. Negative 
controls comprised omission of the primary antibody and replacement with normal antibody 
diluent.
NanoZoomer Digital Pathology Software (Hamamatsu, Herrsching am Ammersee, Ger-
many) was used to scan the stained sections. Leucocyte subsets within a HS infi ltrate were 
semi quantitatively scored by two independent observers in a blinded manner, using a scale 
from 0 to 4, whereas a score of 0 represented no stained cells, and a score of 4 meant staining 
of most cells. The average score was calculated from the score of both observers.
Statistical analysis
Diff erence in weight and volume of cultured skin samples, induced by manually cleaving 
the biopsies, could introduce a confounder. Therefore we assessed the weight of the tissue 
before culture. When detected cytokine levels were below or above the detection limit, the 
lower or upper detection limit was used for further calculations. All cytokine levels were 
normalized according to input weight and expressed in picograms per ml and per mg tissue 
weight (pg/ml/mg). The number of patients in the three treatment groups was too small 
for statistical analysis. To provide an impression of the eff ects of adalimumab treatment on 
HS lesions, patients treated with adalimumab were clustered and compared with placebo-
treated patients. Medians with interquartile ranges are provided for the non-parametrically 
distributed values that were analysed by two-tailed Mann Whitney U test. The criterion for 
statistical signifi cance was a p value less than 0.05.
RESULTS
We fi rst compared the cytokine levels released by lesional HS skin biopsies after 24 hours of 
culture with that of healthy skin from controls in order to determine HS infl ammation-related 
cytokines (Table 2). This comparison showed that the production of IL-1β was most signifi cantly 
increased in HS skin, a 54-fold increase compared to healthy control skin, followed by CXCL9 
(MIG; 16-fold) and IL-10 (15-fold). Other cytokines that were produced at signifi cantly higher 
levels in lesional HS skin were IL-11, B lymphocyte chemo attractant (BLC), IL-17A, soluble TNF-
receptor 2 (sTNF-R2), CCL5 (RANTES) IL-16, soluble IL-6 receptor (sIL-6R), soluble ICAM-1, CCL3 
(MIP-1α), soluble TNF-receptor 1 (sTNF-R1), TNF-α, and IL-1 receptor antagonist (IL-1ra).
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Figure 1. Alterations of cytokine levels in patients treated with adalimumab or placebo
IL-1E
placebo adalimumab
-400
-200
0
200
1)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
MIG (CXCL9)
placebo adalimumab
-20
0
20
40
2)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
IL-10
placebo adalimumab
-40
-20
0
20
40
3)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
IL-11
placebo adalimumab
-60
-40
-20
0
20
4)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
BLC (B-lymphocyte chemo attractant)
placebo adalimumab
-60
-40
-20
0
20
5)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
IL-17A
placebo adalimumab
-60
-40
-20
0
20
40
6)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
TNF-R2
placebo adalimumab
-15
-10
-5
0
5
7)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
RANTES (CCL5)
placebo adalimumab
-40
-30
-20
-10
0
10
8)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
Hessel BW.indd   88 11-Oct-11   10:36:39 AM
89
Adalimumab (anti-TNF-α) treatment of hidradenitis suppurativa ameliorates skin infl ammation
3
IL-16
placebo adalimumab
-10
-5
0
5
10
9)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
IL-6r
placebo adalimumab
-10
-5
0
5
10
10)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
ICAM-1
placebo adalimumab
-10
-5
0
5
10
11)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
MIP1D  (CCL3)
placebo adalimumab
-6
-4
-2
0
2
4
12)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
TNF-R1
placebo adalimumab
-1.5
-1.0
-0.5
0.0
0.5
1.0
13)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
TNF-D
placebo adalimumab
-10
-5
0
5
14)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
IL-1ra
placebo adalimumab
-3
-2
-1
0
1
2
15)
Fo
ld
 c
ha
ng
e 
w
k 
0-
16
Cytokines are ordered by their level of elevation in untreated, naïve HS skin. The median is presented. The 
star presents patient #3 in whom HS worsened despite treatment. The dotted line represents no change 
between week 0 and 16.
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Subsequently we checked whether adalimumab treatment aff ected the levels of cytokines 
released from HS skin lesions. Hereto, we compared the cytokine release in culture medium 
between week 0 and week 16 per individual patient. The data are presented in Figure 1. IL-1β, 
CXCL9 (MIG), BLC, IL-11 and CCL5 (RANTES) showed the most evident decrease after adalim-
umab treatment compared to placebo. The production of almost all other tested cytokines 
also decreased upon adalimumab treatment, although to a lesser extent. The production 
levels of TNF-α and IL-17A were not aff ected by adalimumab nor placebo treatment.
Figure 2. Alterations in semi-quantitative scores of leucocyte subsets in patients treated with 
adalimumab or placebo
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IL-1β activity is counter-regulated by its naturally occurring antagonist IL-1ra and therefore 
we calculated the mean IL-1ra/IL-1β ratio. In healthy control skin the median for this ratio 
was 1071 (IQR 336-1229) and in HS patients before adalimumab treatment the mean IL-1ra/
IL-1β ratio was 23 (IQR 7-84). Sixteen weeks after initiation of adalimumab treatment this ratio 
increased to 142 (IQR 11-526), while the IL-1/IL-1ra ratio remained stable in placebo treated 
patients at 30 (IQR 7-1373).
Adalimumab treatment altered the infl ammatory cell infi ltrate in HS skin considerably 
(Figure 2). The numbers of CD3+ and CD4+ T cells showed a signifi cant decrease, when com-
pared to placebo, while no change was observed in the number of CD8+ cytotoxic T cells. The 
number of CD20+ B cells and CD138+ plasma cells also decreased although to a lesser extent 
than that observed for T cells. Adalimumab therapy induced the most signifi cant reduction 
in the number of skin infi ltrating CD11c+ (Figure 3), CD14+, and CD68+ infl ammatory dendritic 
cells, monocytes and macrophages.
DISCUSSION
In this study, using a diff erent multiplex-based cytokine array, we confi rmed the recent 
fi nding that mRNA and protein levels of TNF-α, IL-1β and IL-10 are increased in HS7,19. More 
evidently elevated than TNF-α were its soluble receptors TNF-R1 and TNF-R2. In addition we 
identifi ed other cytokines that are produced in excess in HS skin that have not been linked to 
its pathophysiology before. Many of these cytokines are chemotactic for a variety of immune 
cells. BLC is a B-lymphocyte chemo attractant and the elevated levels of BLC correspond 
with the observed high number of B-cells in HS skin. CCL3 (MIP1α) is chemotactic for and an 
activator of granulocytes which are abundant in HS lesions. CCL5 (RANTES), IL-16 and CXCL9 
(MIG) are chemotactic for T cells and elevated levels of these cytokines correspond with the 
Figure 2. (continued)
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Scoring was performed in biopsies from week 0 and week 16 by two blinded independent investigators 
using a 4 point scale. Median values are shown. The star presents patient #3 in whom HS worsened 
despite treatment. The dotted line represents no change in the semi-quantitative score.
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increased number of T cells in HS. ICAM-1 (intercellular adhesion molecule-1, CD54) can be 
induced by IL-1 and TNF-α, both of which are increased in HS. Large numbers of CD4+ T helper 
cells were present in HS lesions. Interestingly, typical Th1 and Th2 cytokines such as IFN-γ, IL-
12p70, IL-4, IL-5 and IL-13 were not elevated. This sets the infl ammatory cytokine profi le in HS 
apart from psoriasis and atopic dermatitis. But high levels of IL-17A and IL-10 were measured 
indicating that they theoretically are derived from a subset of Th17 or T regulatory cells which 
provides a rational for the use of the Th17 modulating drug Ustekinumab20.
Figure 3. Immunohistochemical staining of CD11c+ dendritic cells in the clincally improved patient 6 in 
group 2: adalimumab EOW. (See also Color section, p. 198.)
a
b
a) Week 0 b) Week 16.
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After 16 weeks of adalimumab treatment the most evident decrease was seen in the levels 
of IL-1β, CXCL9 (MIG), BLC, IL-11 and CCL5 (RANTES) and to a lesser extent IL-6R IL-16, IL-
1ra, sTNF-R2, ICAM-1, IL-10, and CCL3 (MIP1α). TNF-α was only mildly increased in HS so no 
spectacular change after adalimumab treatment was to be expected, but the decrease in 
TNF-R1 and TNF-R2 was more evident. However, in this study we did not measure the levels 
of membrane-bound TNF-α.
The median ratio between IL-1β and IL-1 receptor antagonist showed a clearly reduced 
ratio of 32 for IL-1ra/IL-1β in HS, whereas 1071 was calculated for healthy skin. This aberrant 
ratio indicates a relative shortage of IL-1ra in HS with/or an overproduction of IL-1β. Adalim-
umab treatment induced a shift of the IL-1ra/IL-1β ratio to higher levels (142). The level of the 
anti-infl ammatory cytokine IL-10 did not follow the decrease of IL-1β or other infl ammatory 
cytokines.
The leucocyte subsets that were most clearly reduced in frequency by adalimumab 
treatment were dendritic cells, monocytes and macrophages followed by T helper cells and 
B-cells. Remarkably, the number of CD3+ and CD4+ T cells was clearly reduced compared 
to placebo, whereas no evident change was observed in the number of CD8+ T cells. The 
decrease in B-cells paralleled the decrease in BLC production. In analogy with our fi ndings in 
HS, in psoriasis adalimumab also induced a most marked decrease in the number of dendritic 
cells, macrophages and T cells21.
HS remains a diffi  cult to manage disease, which in this study is refl ected by the fact that not 
all patients were clinical responders despite the high dose of adalimumab used. According 
to the intention to treat principle all patients including the non-responders were included in 
the fi gures. Lack of clinical improvement highly correlated with the lack of alterations in the 
leucocyte subset scores and cytokine levels. Especially the absence of clinical improvement in 
patient #3, group 1, closely mirrored the in situ data. This particular patient is frequently the 
upper outlier in the fi gures and hereby infl uences the outcomes of adalimumab treated group.
This study has several limitations. For three arms a relatively small number of patients were 
studied whereby statistics could not be applied. Furthermore the absence of an assessment 
of changes early in treatment did not allow us to determine which the primary and secondary 
phenomena in disease improvement were.
Clinically the patients in the placebo group showed almost no change in disease severity, 
and the outcomes of the leucocyte subsets and cytokine release likely refl ect natural fl uc-
tuations in human biological processes. This variation is in accordance with an earlier study 
which showed a high variability in HS cytokine release confi rming the temporal and spatial 
heterogeneity of the disease7.
Although adalimumab is an anti-TNF-α biologic, TNF-α did not seem to be the cytokine 
most responsive to treatment. Further research is warranted to untangle the immunological 
processes operational in HS and how diff erent treatment modalities infl uence these pro-
cesses.
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appearing perilesional skin, 
early, and chronic hidradenitis 
suppurativa lesions
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ABSTRACT
Background: The current insight into the histopathological course of events during disease 
progression in hidradenitis suppurativa is fragmentary.
Objectives: To identify histological alterations and leucocyte subsets in normal appearing 
perilesional, early, and chronic HS skins.
Methods: In this observational study we examined skin samples from 8 perilesional, 6 early 
and 10 chronic prototypic HS lesions, as well as 4 healthy donors by using in situ immunos-
taining.
Results: Perilesional skin showed mild psoriasiform hyperplasia and follicular plugging 
as well as a low-grade infl ux of tryptase+ mast cells, CD3+ T cells, CD138+ plasma cells and 
FXIIIa+ dendritic cells. In early HS lesions, neutrophilic abscess formation and infl ux of mainly 
macrophages, monocytes and dendritic cells predominated. In chronic disease, the infi ltrate 
expands with noteworthy increased frequencies of CD20+, CD79a+ B cells and CD138+ plasma 
cells. As in early lesions, free keratin fi bers were detected in the dermis and within giant cells. 
Single detached keratinocytes and strands of follicular epithelium were observed in the 
dermis, the latter frequently expressing Ki67, indicative of active proliferation.
Conclusions: Psoriasiform hyperplasia, follicular plugging and low-grade leucocytic infi ltra-
tion are already present in normal appearing perilesional skin. Keratin fi bers in the dermis 
are associated with clinical disease. Early lesions are characterized by neutrophilic abscess 
formation and infl ux of mainly histiocytes, chronic lesions mainly by expansion of B and 
plasma cells in ‘pseudo’ follicles. Proliferating strands of follicular epithelium may initiate 
fi stula formation. Mast cells are increased in all HS stages including perilesional skin.
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INTRODUCTION
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic and recurrent infl am-
matory disease mainly aff ecting the inverse skin areas. HS is clinically characterized by 
recurrent, deep-seated, painful nodules and abscesses and, in severe cases fi stula formation, 
interconnecting sinus tracts and rope-like scarring. HS has an estimated prevalence between 
1% and 4%1,2 and has a signifi cant impact on patients’ quality of life3. Intrinsic and environ-
mental pathogenic factors include genetic predisposition, high body mass, smoking, shear 
forces and perhaps an altered immune response4.
The pathogenic concept of HS has substantially changed over time. In 1854, the French 
surgeon Verneuil associated the symptoms with infl ammation of the sweat glands and 
named the disease HS5. In 1990, by histological examination, this apocrinitis proved to be 
present in only 4/12 investigated HS specimens, and follicular occlusion was considered to 
be a far more constant histopathological feature6. Currently the generally accepted primary 
pathogenic mechanism is (hyper)keratinisation of the follicular infundibulum resulting in fol-
licular occlusion and apocrinitis as a sporadic secondary event4. A novel histological feature 
of the disease, which occurs in 43% of cases, is epidermal psoriasiform hyperplasia7. However, 
despite our advancing insight, many questions remain unanswered, such as the potential 
existence of subclinical histomorphological alterations prior to clinical onset of the disease. 
Von Laff ert et al. hypothesized that follicular hyperkeratosis and perifollicular infl ammation 
represent early events in HS pathogenesis8. In accordance with the concept of subclinical 
pathogenic alterations preceding overt clinical infl ammation, normal-appearing perilesional 
HS skin samples produce pro-infl ammatory cytokines ex vivo9. The subclinical infl ammation 
might lead to histomorphological changes in HS-prone skin.
Furthermore, a hallmark of moderate and severe HS is fi stula formation. How or why these 
fi stulas arise in HS and from where they primarily originate is unknown. Once fi stulas have 
developed, infl ammation often shifts from intermittent to chronic suppuration. Moreover, 
these fi stulas and sinus tracts constitute a major therapeutic challenge, since the only 
method of eradication is by surgical removal10.
The aims of this study were to assess histomorphological alterations, to phenotype infi l-
trating leucocyte subsets and to assess epithelial activation and/or proliferation in normal 
appearing perilesional HS skin, as well as in early and chronic HS lesions.
MATERIALS AND METHODS
Large, surgically resected specimens from chronic HS infl amed skin were obtained from 10 
patients undergoing radical excision of their HS under general anaesthesia. In our clinic HS 
lesions are excised with a healthy appearing skin margin of 2 cm. This normal appearing 
Hessel BW.indd   99 11-Oct-11   10:36:41 AM
Chapter 3.3
100
skin is denoted as perilesional skin. Six other HS patients visited the dermatology out-patient 
department (Deventer Hospital) with a newly emerging lesion, which the patient and an 
experienced dermatologist (JB) recognized as a new early HS lesion. All early HS lesions were 
biopsied within 4 days after onset. Healthy control skin consisted of submammary skin from 
4 healthy females undergoing breast reduction surgery at the department of Plastic Surgery.
Immunostaining procedure
The skin specimens were fi xed in 4% formaldehyde and embedded in paraffi  n. Four microm-
eter thin sections were stained with haematoxylin and eosin (H&E) or labeled with a panel of 
antibodies for immunophenotyping leukocyte subsets and for cellular proliferation. The anti-
bodies used are listed in Table 1. A standard horseradish peroxidase DAB (diaminobenzidine) 
staining procedure was followed using a polymer detection system (K8005, DAKO, Glostrup, 
Denmark). All sections were counterstained with haematoxylin (4085-9005, Klinipath, Uden, 
The Netherlands). Antigen retrieval for all antibodies, except anti- FXIIIa, was performed by 
heating sections (20 min at 97°C) in the DAKO PT modules (PT 101, DAKO, Glostrup, Denmark) 
in Envision Flex Target Retrieval Solution high pH (DAKO, K8004, Glostrup, Denmark). Normal 
antibody diluent (ABB999, Scytec laboratories, Logan, UT) was used for blocking all sections 
and for dilution of the primary antibodies. Positive tissue control, placenta for FXIIIa, skin for 
pankeratin, and tonsil for the other antibodies was included in each staining run. Negative 
staining controls comprised omission of the primary antibody and replacement with normal 
antibody diluent.
Table 1. Antibodies used for immunostaining
Marker Indicative for Clone Positive control Dilution Manufacturer
CD1a Langerhans cells O10 Skin 1:20 Immunotech, Prague, Czech Republic
CD3 T cells polyclonal Tonsil 1:150 Dako, Glostrup, Denmark
CD4 T helper cells 4B12 Tonsil 1:160 Monosan, Uden, The Netherlands
CD8 Cytotoxic T cells C9/144B Tonsil 1:100 Dako
CD11c Dendritic cells 5D11 Tonsil 1:60 Novocastra
CD14 Monocytes MY4 Tonsil 1:100 Novocastra
CD20 B cells L26 Tonsil 1:400 Dako
CD56 NK cells 123C3.D5 Tonsil 1:25 Thermo Fisher Scientifi c, Cheshire, UK
CD68 Macrophages KP1 Tonsil 1:160 Dako
CD79a B cells JCB117 Tonsil 1:100 Dako
CD138 Plasma cells B-A38 Tonsil 1:25 IQ Products, Groningen, The Netherlands
FXIIIa Dermal dendritic cells AC-1A1 Placenta 1:200 Thermo Fisher Scientifi c
Ki67 (MIB-1) Cell proliferation MIB1 Tonsil 1:100 Dako
Pan keratin Keratin AE1/AE3 Skin 1:200 Thermo Fisher Scientifi c
Tryptase Mast cells AA-1 Tonsil 1:800 Dako
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Histomorphology and quantifi cation of stained cells
NanoZoomer Digital Pathology software (Hamamatsu, Herrsching am Ammersee, Germany) 
was used to scan the stained sections. All H&E-stained sections were assessed for histological 
features by two independent observers (HZ, EP) blinded to disease stage. Histomorphological 
features systematically assessed included: epidermal psoriasiform hyperplasia, parakeratosis, 
follicular plugging / keratosis, dilated hair follicles, presence of cysts, hyperplasia of follicular 
epithelia, sinus tracts/fi stulas, neutrophilic abscess formation, multinucleated giant cells, 
keratin fi bers in the dermis, apocrinitis and eccrinitis. Apocrinitis and eccrinitis were defi ned 
as an infi ltration by infl ammatory cells with destruction of apocrine or eccrine glandular 
epithelial cells. In case of some discrepancy between observers, the section was re-assessed 
by the observers, including an experienced dermato-pathologist (JH), to reach consensus. 
Leucocyte subsets within HS infi ltrates tend to occur in a patchy, uneven distribution. There-
fore leucocyte subsets and the proliferation marker Ki67 were scored by two independent 
observers (HZ, EP) in a semi-quantitative manner, using a global assessment on a continuous 
scale from 0 to 4, where a score of 0 represents no stained cells, and a score of 4 means stain-
ing of most cells. The average score was calculated from the score of both observers and was 
used for statistics. Medians with interquartile ranges are provided for the non-parametrically 
distributed values that were analysed by two-tailed Mann Whitney U test. The criterion for 
statistical signifi cance was a p value below 0.05 (p< 0.05). Statistical analysis was performed 
using the Graphpad Prism 5 software.
RESULTS
Results of the histomorphological assessments are presented in Table 2. The semi quantita-
tive scores for the immunostained sections are presented in Figure 1.
Normal appearing perilesional skin
Normal appearing perilesional skin already showed mild psoriasiform hyperplasia of the 
interfollicular epidermis and follicular plugging in 5/8 and 5/7 samples respectively. The 
scores for CD3+ T cells, CD138+ plasma cells, FXIIIa+ dermal dendritic cells and tryptase+ mast 
cells were slightly but signifi cantly increased compared to healthy skin. These cell types were 
evenly distributed in the dermis.
Early HS lesions
In half of the early lesions, epidermal psoriasiform hyperplasia of the interfollicular epidermis 
occurred. In all samples, whenever a hair follicle was assessable, follicular plugging and 
dilated hair follicles were observed. In all biopsies we observed a variable degree of abscess 
formation with massive neutrophilic infi ltration. In the dermis, free ‘rod-like’ keratin fi bers 
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and keratinocyte remnants were detected in almost all samples. Multinucleated giant cells, 
regularly containing phagocytosed keratin fi bers (Figure 2), were seen in almost all samples. 
CD11c+ dendritic cells (DC) were especially abundant in abscesses. Numbers of CD14+ 
monocytes, CD68+ macrophages and FXIIIa+ dermal DC were also increased, whereas CD1a+ 
Langerhans cells showed a slight decrease. Apocrinitis was present in 2/6 and eccrinitis in 
3/6 of the lesions. CD8+ cytotoxic cells were regularly observed in the dermis and epidermis.
Table 2. Observed histological features n.a= not assessable
Perilesional Early HS Chronic HS
Psoriasiform no 3/8 3/6 0/10
hyperplasia mild 4/8 1/6 1/10
pronounced 1/8 2/6 9/10
Parakeratosis no 8/8 1/6 6/10
mild 0/8 5/6 4/10
Follicular n.a. 1/8 2/6 1/10
plugging no 2/7 0/4 0/9
mild 3/7 1/4 1/9
pronounced 2/7 3/4 8/9
Dilated n.a. 1/8 2/6 1/10
hair follicle no 2/7 0/4 0/9
mild 4/7 1/4 3/9
pronounced 1/7 3/4 6/9
Cyst yes 0/8 2/6 4/10
Hyperplasia n.a. 1/8 1/6 1/10
follicular no 7/7 5/5 0/9
epithelia mild 0/7 0/5 4/9
pronounced 0/7 0/5 5/9
Sinus tract yes 0/8 0/6 4/10
Abscessing no 8/8 0/6 1/10
neutrophilic mild 0/8 3/6 2/10
infl ammation pronounced 0/8 3/6 7/10
Giant cells no 8/8 1/6 2/10
mild 0/8 5/6 6/10
pronounced 0/8 0/6 2/10
Keratin no 8/8 1/6 2/10
remnants mild 0/8 4/6 3/10
pronounced 0/8 1/6 5/10
Apocrinitis n.a. 3/8 0/6 4/10
yes 0/5 2/6 3/6
Eccrinitis n.a. 1/8 0/6 1/10
yes 0/7 3/6 6/9
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Figure 1. Semi quantitative scores for immunophenotypic leucocyte subset markers
Note the diff erent scales in leukocyte subsets scores. p < 0.05 is presented as *, p < 0.01 as **
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FXIIIa+ dermal dendritic cells
he
alt
hy
 sk
in
pe
rile
sio
na
l
ea
rly
 le
sio
n
ch
ro
nic
 H
S
0
1
2
3 *
*
*
sc
or
e
CD11c+ dendritic cells
he
alt
hy
 sk
in
pe
rile
sio
na
l
ea
rly
 le
sio
n
ch
ro
nic
 H
S
0
1
2
3
4 **
*
sc
or
e
 
CD14+ monocytes
he
alt
hy
 sk
in
pe
rile
sio
na
l
ea
rly
 le
sio
n
ch
ro
nic
 H
S
0.0
0.5
1.0
1.5
2.0
2.5 **
*
sc
or
e
CD68+ macrophages
he
alt
hy
 sk
in
pe
rile
sio
na
l
ea
rly
 le
sio
n
ch
ro
nic
 H
S
0
1
2
3
4 **
*
sc
or
e
 
CD1a+ Langerhans cells
he
alt
hy
 sk
in
pe
rile
sio
na
l
ea
rly
 le
sio
n
ch
ro
nic
 H
S
0
1
2
3 *
sc
or
e
CD56+ NK cells
he
alt
hy
 sk
in
pe
rile
sio
na
l
ea
rly
 le
sio
n
ch
ro
nic
 H
S
0.0
0.2
0.4
0.6
0.8
sc
or
e
Hessel BW.indd   104 11-Oct-11   10:36:42 AM
105
Alterations in leucocyte subsets and histomorphology in normal appearing perilesional skin
3Chronic HS lesionsEpidermal psoriasiform hyperplasia was present in all chronic HS lesions and was more pro-
nounced compared to perilesional skin and early lesions. This psoriasiform hyperplasia was 
most pronounced in the interfollicular epidermis overlying infl ammatory infi ltrates (Figure 
3). Mild parakeratosis was observed in 3/10 lesions. Follicular plugging, dilated hair follicles 
and hyperplasia of follicular epithelia were observed in all chronic HS lesions when a hair fol-
licle was present in the sections. Four out of ten samples contained an epithelialized fi stula. 
Fistulas were exclusively seen in chronic lesions and only in Hurley grade 2 and 3 cases. One 
example of Ki67+ strand of keratinocytes in the deep dermis is shown in (Figure 4). Abscess 
formation with neutrophilic infl ammation was more extensive than in early lesions. Similar 
to early lesions, some multinucleated giants cells contained phagocytosed keratin fi bers and 
keratinocyte fragments (Figure 2). Using pankeratin staining several detached and dispersed 
single keratinocytes were seen in the dermis, densely surrounded by neutrophils (Figure 2). 
Apocrine glands were not present in all samples, yet apocrinitis was observed in 2/6 samples 
and eccrinitis in 5/9 samples. The numbers of CD3+, CD4+, CD8+ T cells, CD11c+ DCs, CD14+ 
monocytes, CD1a+ Langerhans cells, tryptase+ mast cells, and especially, CD20+, CD79a B cells 
and CD138+ plasma cells were all signifi cantly increased compared to early lesions. In con-
trast, the score for CD68+ macrophages and FXIIIa+ dermal DC remained stable. CD3+ T cells 
were diff usely located in the infi ltrate and in case of an abscess their location was more at the 
periphery of the abscess. CD4+ T cells were widely dispersed through the infi ltrate, although 
clustering and epidermal infi ltration was additionally observed. CD8+ T cells were scattered 
through the infi ltrate and were additionally present in the epidermis. CD20+ cells were ad-
ditionally diff usely located around abscesses. In addition, CD20+ cells showed a very patchy 
distribution in the infi ltrate (Figure 5). These clusters of CD20+ cells also expressed CD79a. In 
contrast, CD138+ plasma cells were quite homogeneously distributed. FXIIIa+ dermal DC were 
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located at the periphery of the infi ltrate but also along the basal membrane as well as deep 
in the dermis, but their numbers varied widely between samples. CD11c+ DC were especially 
abundant within abscesses. CD14+ monocytes were more diff usely spread throughout the 
infi ltrate. Likewise in perilesional skin and early lesions tryptase+ mast cells were abundantly 
and diff usely increased in the dermis (Figure 6). Numbers of keratinocytes, expressing Ki67 
were signifi cantly increased, especially in the epidermis overlying infi ltrates (Figure. 3). Epi-
dermal areas with increased Ki67 expression also exhibited psoriasiform hyperplasia. CD56+ 
NK cells were observed but their frequency was neither elevated nor decreased in any HS 
condition compared to healthy skin.
DISCUSSION
Although the current study was conducted in a limited number of patients, these were se-
lected as prototypic cases. Accordingly, we just as Jemec et al. observed little heterogeneity 
between samples, indicating the data is representative and can be extrapolated to the HS 
population at large11. Our results indicate that clinically unaff ected perilesional skin already 
displays epidermal psoriasiform hyperplasia, follicular plugging and dilated hair follicles. 
These histological alterations are accompanied by a mild and signifi cant infl ux of dermal CD3+ 
T cells, CD138+ plasma cells, FXIIIa+ dermal DCs and tryptase+ mast cells. Recently, we demon-
strated increased levels of secreted IL-1β, TNF-α and IL-10 in comparable clinically unaff ected 
perilesional skin9. On the basis of our data it is not possible to point out what comes fi rst, the 
epithelial alterations such as psoriasiform hyperplasia and follicular/infundibular keratosis or 
the infl ammation. We hypothesize that the mild infl ux of leucocytes, together with increased 
levels of cytokines in perilesional skin induce the epithelial alterations, possibly as a spill-over 
from adjacent infl ammation. The subclinical infl ammatory response may be initiated by an 
unknown trigger, possibly overgrowth of commensal bacteria. Nevertheless, we argue that 
these observations of subclinical infl ammation and histological alterations provide a ratio-
nale for the use of keratolytics and anti-infl ammatory agents in perilesional skin to prevent 
further disease progression. Likely candidates for such an intervention are topical resorcinol 
and oral acitretin, which have keratolytic as well as anti-infl ammatory properties, and have 
both been shown to be effi  cacious in HS12,13. The preventive eff ect of such agents should be 
investigated prospectively.
In newly emerged HS lesions, not older than 4 days, we observed marked psoriasiform 
hyperplasia, follicular plugging and dilation, cysts, free keratin fi bers in the dermis and 
intracellular fi bers in multinucleated giant cells. This suggests that upon disease progres-
sion dilated hair follicles or cysts rupture, spilling their keratin content into the dermis. In 
response to this foreign material, an abscessing neutrophilic infl ammation ensues at the site 
of rupture with an additional massive infl ux of CD68+ macrophages, CD14+ monocytes and 
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CD11c+ infl ammatory DC. The formation of multinucleated giant cells represents an attempt 
of the immune system to clear dermal keratin similar to a foreign body response, although 
prototypical granuloma formation was not observed. In this process large numbers of CD3+, 
T cells and B cells are attracted creating a mixed infi ltrate. Previous studies showed increased 
levels of IL-17, IL-10 and TNF-α, but not IFN-γ, IL-2, IL-12, in active HS lesions (own data sub-
mitted for publication)9,14. Therefore, the signature of T helper subsets in HS is a mixed one, 
and does not fi t into a classic Th1, Th2, Th17 or Th22 profi le and as such not comparable with 
Figure 2. Expression and distribution of keratin in HS lesions (See also Color section, p. 199.)
a
b
a) Keratin fi bers and isolated detached keratinocytes (brown staining) in an abscess in a chronic HS lesion.
b) Single detached keratinocytes in the dermis (arrows) in a chronic HS lesion.
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psoriasis nor atopic dermatitis. As described by von Laff ert8 we also observed modest CD8+ T 
cell epitheliotropism, for currently unknown reasons. Previously Boer and Weltevreden char-
acterized the infi ltrate in early lesions, using a limited set of immunohistological markers15. 
They demonstrated increased numbers of HLA-DR+, CD62L+ T cells and CD3+ T cells in early 
lesions15. Furthermore, the tendency of CD1a+ positive Langerhans cells in early lesions to 
decrease suggest emigration from the epidermis in response to an unknown trigger.
Figure 2. (continued)
1
2
c
d
c) Free keratin fi bers (arrow 1) and detached keratinocytes (arrow 2) in the dermis in an early lesion.
d) Phagocytosed keratin fi bers and remnants in multinucleated giant cells, in an early lesion (indicated 
with arrows).
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HS lesions can become chronic. This is characterized by dramatic expansion of the infi ltrate. 
The epidermal psoriasiform hyperplasia, follicular plugging, dilated hair follicles and cysts all 
become more pronounced and in contrast to Laff ert et al.7 we did observe mild parakeratosis 
in some samples. In addition, the follicular epithelia displayed hyperplasia. In the dermis, 
ectopic CD20+ and CD79a+ B cell ‘pseudo’ lymphoid follicles were observed, which might be 
bona fi de germinal centers. These ‘pseudo’ lymphoid follicles were previously not described 
Figure 3. Psoriasiform epidermal hyperplasia (See also Color section, p. 201.)
a
b
a) Psoriasiform epidermal hyperplasia with parakeratosis overlying an infi ltrate in a chronic HS lesion. 
Basal epidermal keratinocytes frequently express Ki67, indicating proliferation.
b) The same sample adjacent to the infi ltrate shows less pronounced psoriasiform epidermal hyperplasia 
and fewer Ki67 positive keratinocytes.
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in HS and may be explained as a reaction secondary to persistent infl ammation or bacterial 
colonization.
Figure 4. Strands of Ki67+ keratinocytes in the dermis in a chronic HS lesion (See also Color section, p. 202.)
a
b
a) Keratinocytes, in an epidermal strand in the dermis in a chronic lesion (H&E stained).
b) Overview of the same HS lesion, Ki67 stained, with an epidermal strand in the dermis indicated by the 
square.
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Using H&E staining keratin fi bers are easily overlooked. This might explain why these 
fi bers to our knowledge have not been described before in HS. The sustained presence of 
these keratin fi bers in chronic HS might be explained by impaired clearance of these fi bers 
or derived from new ruptured cysts. We argue that these rod-like keratin fi bers are diffi  cult 
to eradicate and the exaggerated immunologic response is comparable with that to uric 
Figure 4. (continued)
c
c) Higher magnifi cation of this epidermal strand showing multiple Ki67+ keratinocytes.
Figure 5. Scattered CD20 positive B cells, and a prototypical patch, creating ‘pseudo’ lymphoid follicles in a 
chronic HS lesion (See also Color section, p. 203.)
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acid crystals in gout activating the infl ammasome. Thus, these phagocytosed keratin fi bers 
activate the infl ammasome, resulting in activation of caspase 1, cleavage of pro-IL-1 into 
IL-1β, generating the high levels of bioactive IL-1β in HS lesions9. The infl ammasome may 
be further activated by other damage-associated molecular patterns (DAMP)16 from necrotic 
cellular debris that is abundantly present in abscessing HS lesions.
In chronic HS the formation of epithelialized fi stulas indicates a new phase in HS disease 
severity. It is currently unknown how and from where these epithelialized fi stulas originate. It is 
Figure 6. Increased number of tryptase positive mast cells in a chronic HS lesion (See also Color section, 
p. 204.)
b
a
a) Tryptase positive mast cells in a chronic HS lesion.
b) Tryptase positive mast cells in healthy control skin.
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has been postulated that fi stula formation originates from the leaf like dermal protrusions from 
the hyperplastic epidermis17 or from keratinocyte stem cells18. We here show a marked increase 
of Ki67+ proliferating keratinocytes in strands of epithelia, and single detached keratinocytes 
which are probably launched into the dermis from ruptured cysts. We propose that these 
epithelial strands are the forerunners of fi stulas, as they may form dermal epithelial tubes.
Initially HS was thought to be a disease of the apocrine sweat glands. However, in ac-
cordance with the recent literature, we observed apocrinitis and eccrinitis in 42% and 60% 
of cases, when assessable, and always as part of massive dermal infl ammation, never as an 
isolated or specifi c event. These percentages are slightly more than reported by Jemec and 
Hansen, who observed apocrinitis in 12% and eccrinitis in 25% of cases19. Because eccrinitis 
was more frequently observed than apocrinitis, it seems unlikely that the apocrine glands play 
an important role in the disease pathogenesis. We suspect that sweat glands are secondarily 
infl amed by chance, as bystanders. The still current term ‘apocrine-bearing skin’ to describe 
the predilection site for HS should therefore be considered a misnomer. Other characteristics 
of HS predilection sites such as mechanical friction forces, a ‘loose’ dermal composition and a 
warm, humid, bacteria-friendly microclimate seem more relevant.
HS patients frequently complain at a variable degree of concomitant itch20. To our knowl-
edge, we demonstrate for the fi rst time the presence of high numbers of tryptase positive 
mast cells in HS lesional skin. These excessive numbers of mast cells might be responsible 
for the patient reported itch. Furthermore, increased numbers of mast cells were not only 
present in chronic and early HS but were also abundant in perilesional skin. This suggests that 
mast cells are also important in the initial, subclinical phase of HS pathogenesis.
Our data indicate new potential therapeutic targets in HS and validate the use of current 
treatments for HS. The demonstration of ectopic ‘pseudo’ B cell follicles in chronic HS le-
sions opens the novel option of therapeutic interventions aimed at depletion or blocking 
of B cells. Neutrophils could be targeted by drugs that inhibit neutrophil chemotaxis such 
as anti-infl ammatory antibiotics and Dapsone. However, a recent retrospective case series 
demonstrated improvement only in 9 out of 24 patients treated with Dapsone21. Anti-TNF-α 
biologics also inhibit neutrophil chemotaxis and are already in use for the treatment of mod-
erate to severe HS. Furthermore mast cells might be a target for future intervention.
In conclusion, there are probably pathogenic mechanisms at work prior to clinical disease 
manifestation, indicated by follicular plugging and psoriasiform hyperplasia in the presence 
of low grade infl ux of a mixed infi ltrate in normal appearing perilesional skin. The appearance 
of painful nodules could be the result of an immunological response to breached dilated hair 
follicles or cysts. We stress that in almost all clinical lesions, early and chronic, multinucleated 
giant cells and keratin fi brils were observed indicating that, along with follicular plugging 
and psoriasiform hyperplasia, these are the most constant histological hallmarks of HS. Addi-
tional research is warranted to identify the cellular source of cytokines that promote follicular 
plugging, and whether this process can be ameliorated by therapeutic intervention.
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and oral rifampicin in patients 
with hidradenitis suppurativa
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ABSTRACT
Background: A previous limited study showed promising results of combined oral treatment 
with rifampicin 600 mg and clindamycin 600 mg for 10 weeks.
Objective: To expand and to validate the basis for this therapy we reviewed the response to 
diff erent treatment durations.
Method: A retrospective study in 34 patients.
Results: Twenty eight of 34 patients (82%) experienced at least partial improvement, and 16 
(47%) showed a total remission. The maximum eff ect of treatment appeared within 10 weeks. 
Following total remission, 8 of 13 (61.5%) of patients treated with above mentioned treat-
ment schedule experienced a relapse after a mean period of 5.0 months. Non-responders 
were predominantly patients with severe disease.
Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising 
treatment option for HS, despite the frequently occurrence of diarrhea as a side eff ect. The 
length and the dosage of treatment are not yet fi rmly established.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic infl ammatory skin disease characterized by recur-
ring painful abscesses and draining sinuses in the ano-genital-inguinal area and axillae, with a 
prevalence of 1%1. It has a signifi cant impact on the patients’ quality of life2,3. The exact cause 
of HS remains unclear4. Histopathologic studies have suggested occlusion of the follicular 
infundibulum as an important factor5,6. A large variety of microorganisms can be isolated 
from the lesions, but often lesions appear to be sterile7,8. Staphylococcus epidermidis species 
are the most frequently cultured bacteria and Staphylococcus aureus is found in a minority 
of lesions7,8. Other data however suggest that HS patients may suff er from low-grade bacte-
raemia, indicating that bacteria may play a role9. HS is currently thought of as being a sterile 
infl ammation but bacteria are suspected of playing a role in the disease process although not 
that of a simple infection. It is speculated that bacteria may play part through immune medi-
ated mechanisms of infl ammation in association with a dysregulated immune response in 
the hair follicles4. Antibiotic therapy is however widely used and mentioned in all textbooks 
of dermatology as a prominent form of treatment for HS. Curiously the literature reveals only 
a handful of studies on the use of antibiotics. Topical clindamycin was found to be superior 
to placebo in a randomized double blind clinical trial and in another randomized clinical trial 
there was no diff erence between systemic tetracycline 1 gr daily and topical clindamycin 1% 
twice daily10,11. A case report of two patients using systemic clindamycin in a high dosage 
of 1200 mg and 2400 mg respectively showed good improvement albeit with relapse on 
cessation of treatment12. The combination therapy with oral clindamycin and oral rifampicin 
has been suggested to be an eff ective treatment for other follicular occlusion disorders such 
as folliculitis decalvans13,14. Combined treatment with oral rifampicin 300 mg B.I.D. and oral 
clindamicin 300 mg B.I.D. for 10 weeks has been advocated for HS15,16. In order to assess the 
validity of these claims a review was made of the outcomes of combined oral clindamycin 
and oral rifampicin treatment of consecutive patients in two dermatology centers.
SUBJECTS AND METHODS
In total 47 patients diagnosed with HS were treated with the therapy of combined oral 
clindamycin and oral rifampicin at the dermatology departments of the Deventer Hospital, 
the Netherlands and Roskilde Hospital Denmark between 2006 and 2007. Information about 
age, sex, duration of HS, sites of infl ammation, previous treatment, the outcome of clinda-
mycin and rifampicin treatment, side eff ects and follow-up were extracted from the records. 
All included patients had active disease for many months or years and had failed several 
other HS treatments including topical clindamycin, other oral antibiotics and surgery prior to 
the clindamycin and rifampicin combination treatment (Table 1). The combination treatment 
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used in this study was not fi rst choice of disease management. The decision to use this treat-
ment was taken by JB (Deventer) or GJ (Roskilde). Thirteen patients were excluded because 
of concomitant oral or topical medication. Descriptive staging of disease severity based on 
the assessment of scarring and infl ammation according to Hurley was made17. Stage 1: Ab-
scess formation, single or multiple without sinus tracts and cicatrisation. Stage 2: Recurrent 
abscesses with tract formation and cicatrisation, single or multiple widely separated lesions. 
Stage 3: Diff use or near diff use involvement or multiple interconnected tracts or abscesses 
across the entire area. Patient characteristics are given in Table 1. Outcomes were presented 
as a physician global assessment and were classifi ed according to the eff ect of the treatment 
on infl ammation including suppuration, whereas the presence of non-infl amed lesions such 
Table 1. Patient characteristics. Figures in parentheses are percentages.
Number 34
Gender (F/M) 29/5
Age, years
 Mean 39.9
 Range 19-59
Duration of HS, years
 Mean 17.8
 Range 1-52
Disease severity
 Hurley 1 4 (11.8)
 Hurley 2 20 (58.8)
 Hurley 3 10 (29.4)
Aff ected areas
 Groin 26 (77.5)
 Axillae 12 (35.3)
 Gentitalia 8 (23.5)
 Buttocks 8 (23.5)
 Perianal 4 (11.8)
 Other 2 (5.9)
Previous medication
 Oral antbiotics 23 (67.6)
 Surgery 22 (64.7)
 Isotretinoin 12 (35.3)
 Resorcinol 10 (29.5)
 Topical antibiotics 9 (26.5)
 Acitretin 3 (8.8)
 Infl iximab 1 (2.9)
 Prednisone 1 (2.9)
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as sinus tracts or scars was not considered. Partial improvement was defi ned as less than 75% 
clinical improvement from baseline, whereas total remission was defi ned as total clearance 
or at least improvement by more than 75%.
RESULTS
Five diff erent dosage regimens were used. Four dosage regimens contained only 7 or fewer 
patients. Outcomes are presented according to intention to treat principle. In the group as a 
total, 28 of 34 patients (82.4%) responded to treatment, 12 (35.3%) showed partial improve-
ment and 16 (47.1%) total remission. Six (17.6%) patients showed no improvement (Table 2). 
No cases of worsening of the disease were observed during the treatment period. There was 
not much diff erence in outcomes between patients treated for 10 weeks or longer compared 
to patients that were treated shorter than 10 weeks. Outcomes according to the Hurley 
classifi cation at onset are shown in Table 3. Patients with no response were predominantly 
patients with severe disease. Adverse side-eff ects occurred in 13 of 34 patients (38.2%), of 
which diarrhea was the most common, 9 patients (26%). In addition 2 patients experienced 
a Candida vaginitis, 2 nausea, 2 dizziness, and 1 glossodynia. Nine patients (26%) stopped 
treatment due to the side-eff ects. Six of these 9 patients discontinued due to diarrhea. The 
largest subgroup of patients studied was treated according to the scheme of Mendonça 
and Griffi  ths15 (n=23). This group was therefore further analyzed. Thirteen (56.5%) patients 
experienced total remission, 7 (30.4%) partial improvement and 3 (13%) no improvement. All 
non-responders in this group were Hurley stage 3. Following total remission in this group, 8 
of 13 patients (61.5%) experienced a relapse of the disease after a mean of 5.0 months (range 
Table 2. Outcomes according to diff erent treatment durations. Figures in parentheses are percentages.
Any dosage of clindamycin + rifampicin combination Clindamycin 2x300 mg rifampicin 2x300 mg
weeks <10 
(n=13)
weeks 10≥ 
(n=21)
any weeks 
(n=34)
weeks <10 
(n=7)
weeks 10 
(n=16)
any weeks 
(n=23)
No improvement 1 (7.7) 5 (23.8) 6 (17.6) 0 3 (16.8) 3 (13)
Partial improvement 6 (46.2) 6 (28.6) 12 (35.3) 3 (42.9) 4 (25) 7 (30.4)
Total remission 6 (46.2) 10 (47.6) 16 (47.1) 4 (57.1) 9 (56) 13 (56.5)
Table 3. Outcomes according to Hurley score at onset. Figures in parentheses are percentages.
Any dosage of clindamycin rifampicin combination Clindamycin 2x300 mg rifampicin 2x300 mg
Hurley 1 (n= 4) Hurley 2 (n=20) Hurley 3 (n=10) Hurley 1 (n=1) Hurley 2 (n=15) Hurley 3 (n=7)
No improvement 1 (25) 1 (5) 4 (40) 0 0 3 (43)
Partial improvement 1 (25) 9 (45) 2 (20) 0 6 (40) 1 (14)
Total remission 2 (50) 10 (50) 4 (40%) 1 (100) 9 (60) 2 (29)
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0.3-18 months). Three patients (23.1%) were still in remission at the end of study after a mean 
follow-up of 7.3 months (range 1-12 months). Two (15.4%) patients with total remission were 
lost to follow up.
DISCUSSION
This study shows that treatment of HS with combined oral clindamycin and oral rifampicin 
results in clinical improvement in 28 of 34 patients (82.4%). Our results are in agreement with 
those of Mendonça and Griffi  ths15 as well as Gener et al.16. Mendonça and Griffi  ths15 showed 
that the combined treatment with oral clindamycin 300 mg BID and oral rifampicin 300 mg 
BID for 10 weeks was eff ective in 10 of 14 (71.4%) treated patients. Gener et al.16, showed in a 
in large series of 116 consecutive patients complete remission in 8 of the fi nally analysed 70 
patients (11%), improvement in 60 of 70 patients and worsening in 2 of 70 patients after 10 
weeks of the combined treatment. Our study has some limitations because it was a retrospec-
tive study and further there was heterogeneity in the group of HS patients included, it does 
however refl ect clinical practice and variation. Although a 10 week treatment period seems 
rather short for a chronic fl uctuating disease like HS, we did not observe big diff erences in 
outcomes between patients treated 10 weeks and longer and patients treated for a shorter 
period. Actually, a higher percentage of non-responders were observed in the group treated 
10 weeks or longer, indicating that shorter treatment duration may be eff ective. Furthermore 
the response to treatment tends to correlate with the disease severity as all non-responders 
in the 10 week course15 were Stage 3, i.e. those with signifi cant scarring of a larger aff ected 
area. However, not many Hurley 1 patients were treated making a more precise estimate of 
the infl uence of disease severity on outcome more diffi  cult. Most patients who achieved total 
remission at the end of treatment in the 10 week course15 also experienced a relapse after a 
mean of 5.0 months (range 0.3-18 months). This may indicate that the used antibiotics do not 
cure the disease but relieve the symptoms. A 5 month disease free period does not look long 
but for these chronic HS patients it was quite a relief. The number of patients experiencing side 
eff ects in this study was quite high, 13 of 34 patients (38.2%) making 9 of 34 patients (26%) 
to discontinue this regimen. This side eff ect rate was higher than Gener et al.16 who showed 
that 10 of 70 patients (14%) experienced side eff ects, making 8 of 70 (11%) to discontinue 
this regimen. This high incidence of side eff ects forms the major drawback of this combina-
tion treatment schedule and hampers the usefulness in daily practice. Clindamycin usage is 
associated with the development of Clostridium diffi  cile colitis. None of the patients with diar-
rhoea in this study experienced a Clostridium diffi  cile colitis. The mechanism of action of these 
two drugs in HS needs further elucidation. A signifi cant proportion of HS lesions appear to 
be sterile7,8 and anti-infl ammatory therapy with e.g. cyclosporine18, dapson19, methotrexate20, 
prednisone21 or biologicals22 has been described as an alternative therapy to antibiotics in HS. 
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Moreover, besides their bactericidal eff ects the antibiotics used in the treatment of HS also 
have immunomodulatory properties23, suggesting that the latter property is also responsible 
for their benefi cial eff ect in HS. Rifampicin is a derivative of Streptomyces mediterranei. It is a 
lipid-soluble, broad spectrum antibacterial agent which acts by binding to and inactivating 
bacterial deoxyribonucleic acid-dependant ribonucleic acid polymerase24. It can sterilize 
staphylococcal abscesses25 and maintains its bacteriolytic eff ect even when the targets are 
engulfed in phagocytic cells26. It inhibits the growth of the majority of gram positive bacteria 
as well as many gram negative microorganisms27. Rifampicin is highly active against both S. 
aureus and coagulase negative staphylococci. Furthermore, bacterial resistance can occur 
rapidly when rifampicin is used as monotherapy. In addition to its antimicrobial eff ects it 
also modifi es cell mediated hypersensitivity by suppressing antigen-induced transformation 
of sensitized lymphocytes, and T-cell function23. Clindamycin is the chlorine substituted 
successor to lincomycin. It binds to the 50s subunit of the bacterial ribosome and inhibits 
the early stages of protein synthesis. The antimicrobial eff ect is primarily bacteriostatic. It is 
active against gram-positive cocci except enterococci and most anaerobic bacteria28. Like 
rifampicin, clindamycin has the potential to modify or suppress infl ammation. It suppresses 
the complement-derived chemotaxis of polymorphonuclear leukocytes in vitro, reducing in-
fl ammation29. In addition rifampicin and clindamycin have eff ective bactericidal action when 
given together30. HS is a notoriously diffi  cult to treat disease, and the encouraging results 
of this retrospective case series and that of Gener et al.16 emphasize the need for a large 
prospective, dose fi nding, randomized controlled clinical trial.
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ABSTRACT
Background: Hidradenitis suppurativa (HS) is a chronic infl ammatory skin disease, often 
refractory to treatment. HS patients as well as dermatologists are in need of an eff ective, fast 
surgical intervention technique. Deroofi ng is a tissue saving technique, whereby the “roof” of 
an abscess, cyst or sinus tract is electro-surgically removed. The use of a probe is mandatory 
in order to explore the full extent of a lesion.
Objective: To evaluate the effi  cacy and patient satisfaction of the deroofi ng technique for 
recurrent Hurley 1 (mild) or Hurley 2 (moderate) graded HS lesions at fi xed locations.
Methods: An open study consisting of 88 deroofed lesions in 44 consecutive HS patients, 
treated by a single clinician with a follow-up time of up to 5 years.
Results: Fifteen out of 88 (17%) treated lesions showed a recurrence after a median of 4.6 
months. Seventy three treated lesions (83%) did not show a recurrence after a median follow-
up of 34 months. The median patient satisfaction with the procedure rated 8 on a scale from 
0 to 10. Ninety percent of the treated patients would recommend the deroofi ng technique to 
other HS patients. One side eff ect occurred in the form of post-operative bleeding.
Limitations: Some patients were lost to follow up.
Conclusions: The deroofi ng technique is an eff ective, simple, minimally invasive, tissue-
saving surgical intervention for the treatment of mild to moderate HS lesions at fi xed loca-
tions and it is suitable as an offi  ce procedure.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic, infl ammatory, recurrent, debilitating follicular 
skin disease that usually presents after puberty with painful deep-seated, infl amed lesions 
in the apocrine gland-bearing areas of the body, most commonly, the axillary, inguinal and 
anogenital regions1. Prevalence rates of up to 4% have been estimated2. This painful disorder 
deeply aff ects the quality of life of aff ected patients3. The exact pathogenesis of HS remains 
largely unknown and is probably multifactorial4. The primary mechanism in the disease is 
thought to be hyperkeratinisation of the pilosebaceous infundibulum resulting in occlusion 
of the follicle followed by its rupture with subsequent infl ammation5. To date, HS remains 
diffi  cult to treat, with often unsatisfactory clinical results. Current pharmaceutical options 
include topical or oral antibiotics, hormonal therapies, anti TNF-alpha biologics1 and topical 
resorcinol5. Retinoids in the form of oral isotretinoin have limited clinical effi  cacy1. In addi-
tion to pharmaceutical drugs, surgical interventions are often used. Surgical interventions 
include incision with drainage, limited excision using cold steel6 or electro surgery and CO2 
laser evaporation7,8. Sometimes large skin areas are excised en bloc. Defects may be sutured, 
closed with grafts, local or distant fl aps or left open for healing by secondary intention. Rigor-
ous surgery is considered to be more eff ective than treatments with drugs and conserva-
tive surgery. The treatment of choice depends on severity, disease course and the wishes 
or preferences of the patient. In chronic, severe cases, surgery is considered mandatory1. In 
mild and moderate HS, patients may benefi t from topical or systemic treatment, surgery, or 
not uncommon, a combination of both. Treating the disease at an early stage is considered 
essential as delay in treatment could lead to a situation whereby disease activity has got out 
of control making wide surgical excision necessary. There is need for an eff ective and fast 
surgical technique, other than simple incision and drainage, which is suitable as an offi  ce 
procedure. We therefore propose the deroofi ng technique. This technique converts, with 
limited surgery and maximal preservation of the surrounding healthy tissue, painful recur-
rent lesions into cosmetically acceptable scars. The deroofi ng technique was fi rst described 
by Mullins9 as early as 1959. Ever since, deroofi ng has been mentioned in many reviews and 
dermatology textbooks but its effi  cacy has never been properly investigated. Nevertheless 
dermatologists in The Netherlands adopted this technique and it is now widely used and 
yielding positive results, which were mostly published as case reports10-12. Therefore, the aim 
of this study was to evaluate the effi  cacy and patient satisfaction of the deroofi ng technique 
in a larger population of patients with HS. Here, we report the results of an open study on 
the deroofi ng intervention in 44 patients with Hurley grade I and II, with a follow-up of up to 
5 years.
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PATIENTS AND METHODS
Forty-four consecutive HS patients were treated in an open trial with the deroofi ng technique 
in the outpatient department of Dermatology, Deventer Hospital in the period 2003-2007. 
The criteria used to establish the diagnosis of HS were: Presence of typical lesions, i.e. deep-
seated painful nodules, abscesses, draining sinuses, bridged scars and ‘tombstone’ open 
comedones in secondary lesions. Typical topography, i.e. axillae, groin, perineal and perianal 
region, buttocks, infra and inter mammary folds and a history of chronicity and recurrences1. 
The physical examination, the decision to perform deroofi ng intervention and follow-up were 
all done by the same investigator (JB). Descriptive staging of the disease severity according 
to Hurley was made in all patients13. Stage 1: Abscess formation, single or multiple, without 
sinus tracts and cicatrization. Stage 2: Recurrent abscesses with tracts and scar formation 
single or multiple, widely separated lesions. Stage 3: Diff use or near diff use involvement or 
multiple interconnected tracts or abscesses across the entire area. The following questions 
were always asked: Are recurrences of the HS lesions located at exactly the same “fi xed” 
locations? at various locations? or a combination of both. Lesions at fi xed locations and 
that were assessed as Hurley 1 or 2 were considered suitable for deroofi ng. All patients gave 
their informed consent. Age, age at onset of the disease, sex, BMI, treated area, length of 
the created defect, patient-reported healing time, complications and recurrences at follow-
up were recorded and monitored. All patients were initially seen 6 weeks after deroofi ng, 
patients were asked the number of days required for complete closure of the surgical defect. 
Recurrence of a deroofed lesion was clinically assessed and asked at each follow-up visit. A 
recurrence was defi ned as an infl ammatory boil in, or less than 0.5 cm adjacent to the scar. 
The patients were interviewed by telephone in 2008 or 2009 for their views on the long term 
outcomes of the deroofi ng treatment. The questionnaire consisted of the following ques-
tions: “On a scale of 1-10 how satisfi ed are you with the treatment (0, very dissatisfi ed; 10, very 
satisfi ed)”? Would you recommend this treatment to other patients with HS? The telephone 
interview was conducted by one of the authors (HZ).
The deroofi ng technique
Pre-operatively HS lesions to be deroofed were identifi ed by visual inspection and palpation, 
and were marked with ink (Figure 1). The skin was disinfected with 0.05 mg/ml chlorohexidine 
solution. Local anaesthesia was performed in two steps: First, anaesthesia solution, lidocaine 
1% (10 mg/ml) plus adrenaline 1:2000.000 (5 μg/ml) (AstraZeneca, Södertälje, Sweden) was 
injected to infi ltrate the surrounding area. Secondly, the nodule and/or sinus tract was also 
injected with the same local anaesthetic. The latter procedure provides good demarcation 
of the extent of the lesion. Because the anaesthesia injections were experienced as painful, 
in some cases lidocaine prilocaine cream (EMLA, AstraZeneca, Södertälje, Sweden) was ap-
plied one hour before the injections. For electrosurgical cutting, the Erbotom ICC50 (Erbe 
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Surgical systems, Marietta, GA,) operating at 35 W, with a manually controlled hand-piece 
fi tted with a loop was used. A hyfrecator with a sharp tip and used in the fulguration mode 
would probably give a comparable eff ect. A blunt probe was inserted in sinus openings that 
were discharging purulent exudate. In case openings were not detectable a small incision 
was made to introduce the probe. The lesion was then explored with the probe in all di-
rections in order to fi nd and explore all communicating tracts (Figure 2). It was common 
to fi nd considerable areas of undermined skin with tracks sometimes running at diff erent 
depths (Figure 3). Care was taken not to create false passages with the probe. In case a blunt 
probe is not available the blunt tip of a closed, fi ne forceps or 'mosquito' could be used as a 
probe. Then the roof of the lesion was surgically removed using the probe as a guide, leaving 
the fl oor of the lesion exposed (Figure 4). The walls were carefully probed again for other 
Figure 1. Draining HS nodule, located in groin (Patient 1) (See also Color section, p. 205.)
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remaining communicating sinus tracts, in order not to miss those tracts. The gelatinous and 
sanguinolent material on the fl oor of the exposed and infl amed lesions was carefully scraped 
away with a disposable curette. The created defects were left open for healing by secondary 
intention. Postoperative wound care consisted of once daily application of mupirocine oint-
ment in the defect, together with a non-adhering (Mepitel®) dressing that served as a wedge 
to keep the wound open, for fi ve days. Thereafter the patient switched to application of daily 
dressings consisting of iodine ointment containing gauzes (Betadine®) until the defect was 
closed. Patients were instructed to rinse the defect twice daily using the shower. Generally 
the defects healed into cosmetically acceptable scars. (Figure 5)
Figure 2. Blunt probe is inserted to explore extent of lesion (Patient 1) (See also Color section, p. 205.)g
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Figure 3. Sinus tracts can be unexpectedly long (Patient 2) (See also Color section, p. 205.)
Figure 4. The roof of the lesion is removed and left for healing by second intention, after removal of 
debris by curette (Patient 2) (See also Color section, p. 206.)
Hessel BW.indd   133 11-Oct-11   10:36:48 AM
Chapter 4.2
134
RESULTS
Forty-four HS patients, 3 males and 41 females, with in total 88 lesions were deroofed during 
the investigated period. No deroofed patients were excluded from the study. Patient charac-
teristics are given in Table 1. All patients had a history of active long-standing HS. The median 
age of disease onset was 28 years. The median age at time of deroofi ng was 35 years with a 
median BMI of 26.8.
Lesion characteristics are given in Table 2. Most of the deroofed lesions, 41 (47%), were lo-
cated in the groin followed by the axillae, 39 lesions (44%). Eight treated lesions were located 
on the buttocks. The mean length of the created defect was 3.0 cm. The mean healing time 
was 14 days. Fifteen out of 88 (17%) deroofed lesions showed a recurrence, after a median 
Figure 5. Lesion healed into a cosmetically acceptable scar. Result after 1 year (patient 1)  (See also Color 
section, p. 206.)
 
Table 1. Patient characteristics
Patients, n = 44 (41 female, 3 male) Median (interquartile range)
Age of disease onset, y 28 (20-37)
Age, y 35 (28-43)
Body mass index 26.8 (22.3-30.9)
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of 4.6 months (interquartile range 1.2- 6.2). Seventy three deroofed lesions (83%) did not 
show a recurrence after a median follow-up of 34 months (interquartile range 24-44). One 
complication occurred in the form of a post-operative bleeding. No infections were observed, 
also no impairment of movement occurred due to post-operative scarring. Thirty-seven out 
of 44 patients (84%) were contacted and interviewed by telephone, 7 patients could not be 
traced by any means and were considered lost to follow up. The median satisfaction rate for 
deroofi ng was 8.0. Patients without a recurrence evaluated the technique higher than pa-
tients with a recurrence, 8.0 versus 7.0 respectively. Ninety percent of treated patients would 
recommend the deroofi ng technique to other HS patients (Table 3). Interestingly, patients 
with a recurrence recommended the procedure almost as frequent as patients without a 
recurrence: 92% vs. 82%.
Table 3. Patient satisfaction with deroofi ng procedure. *Median and interquartile range
All patients n=44 No recurrence n=29 Recurrence n=15
Satisfaction score ( 0 to10) 8 (7-9)* 8 (7-9)* 7 (4-8)*
Score 6 16% 8% 36%
Recommending deroofi ng to other patients 90% 92% 82%
DISCUSSION
The treatment repertoire for HS consists of medical (topical, systemic) and surgical interven-
tions. Early intervention is considered mandatory in order to prevent disease activity getting 
out of control with consequences such as fi brosis, scarring and sinus tract formation causing 
therapy resistance and major quality of life impairment. Several surgical interventions have 
been described for HS often with considerable recurrence rates. The reported recurrence 
rates after incision with drainage are up to almost 100%, for limited excision using cold steel 
43% and for wide excisions 27%14. Here we show that after a median follow up of 34 months 
from 88 deroofed lesions 83% did not recur. Systematic comparison of studies is hampered 
by variable defi nitions of recurrence. The deroofi ng technique, as used in this study, was fi rst 
described in 1959 by Mullins et al.9 In 1983 Culp et al.15 reported on deroofi ng in a group of 
Table 2. Characteristics of treated lesions. *Mean with SD
Treated lesions n = 88
Location of treated lesion Axillae 44.3%
Groin 46.6%
Buttocks 9.1%
Size of defect directly post-operatively, cm 3.0 ± 1.7* (range 1-10)
Healing time, d 14.1± 7.8* (range 2-35)
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30 patients with HS of the anal region. Unfortunately recurrences and follow-up were not 
studied and the diagnosis of HS was questionable. However, a novelty was that in contrast 
to Mullins9, Culp15 left the fl oor of the exposed lesions untouched. The authors stated that 
preservation of the exposed lesion fl oor was essential for its epithelial regenerative elements. 
In 1986 Brown et al.16 presented three HS cases treated with deroofi ng. In their opinion, like 
Culp15, epithelial cells from sweat glands and hair follicles remnants were present in the de-
bris and at the fl oor of the exposed lesion which could rapidly re-epithelialize the defect. We 
agree with Mullins et al.9 that the debris on the fl oor should be removed, because keratinous 
debris or viable epithelial remnants could get entrapped deep within the dermis when not 
removed and may cause recurrence8. It is known that other sites for recurrences are irradically 
excised lesions, which appear to be the major cause for recurrence after conventional sur-
gery17. Excision of HS lesions should be done “en bloc” with all its communicating sinus tracts. 
Therefore we argue that the use of a probe is mandatory. Ninety percent of our deroofed 
patients would recommend deroofi ng to other HS patients. This was the same percentage as 
Madan et al.7 who treated 9 HS patients with the CO2 laser. They achieved a total clearance 
in 7 out of 9 patients (78%) after a 12 months of follow-up, and a patient satisfaction rate of 
8.5 in contrast to 8.0 with deroofi ng. In comparison with our method, Madan et al.7 treated 
all HS lesions in one session under general anaesthesia. In contrast to deroofi ng, CO2 laser 
treatment is more time consuming, rather expensive and must be performed by experienced 
hands. Recently Aksakal and Adişen18 reported on the use of electro surgery for HS areas 
assessed as Hurley 1 and 2. Thirty lesions in 12 patients were treated. The effi  cacy of the 
technique was measured by post-operative wound infection, recurrence rate was however 
not reported. In comparison to the deroofi ng technique, Aksakal and Adişen18 did not use a 
probe. This approach resembles normal excision with cold steel and is therefore less tissue-
saving. Due to the pathophysiology of HS, new lesions can always occur in the predisposed 
HS areas. Some HS lesions spontaneously resolve, never to come back at the exact location. 
Another type of HS lesion stays at exactly the same location, is a non-tender nodule when 
in remission, but can fl ame up periodically. This last type of lesion is especially suited for 
deroofi ng. Deroofi ng of such lesions can be applied both when it is infl amed or in remis-
sion. Lesions in Hurley 3 areas are not deroofed in this way in our clinic, since we argue that 
deroofi ng does not add any advantages in these cases. In our opinion these areas can only be 
treated with radical wide excision, mostly under general anaesthesia. Because the deroofi ng 
technique does not take much time, our HS patients are generally deroofed during the same 
consultation in which they present with their lesions. We argue that early intervention with 
deroofi ng can prevent disease aggravation, and so prevent radical surgery. The deroofi ng 
technique generally makes small defects so no general anaesthesia is needed. In addition, 
single-lesion surgical treatment off ers low morbidity and moreover the chance of creating 
unacceptable cosmetically results is clearly diminished and scar contractures are prevented. 
This is supported by the high patient satisfaction rate and recommending rate. Due to the 
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use of the electro surgical loop good haemostasis is achieved, allowing good visualisation 
of the operative area. In conclusion the deroofi ng method is easy to conduct and cheap. 
We provide evidence that it is safe to conduct with prolonged eff ectiveness for recurrent 
HS lesions at fi xed locations in Hurley 1 or 2 areas. We argue that the deroofi ng technique is 
superior over incision with drainage and simple excisions with cold steel.
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ABSTRACT
Background: Hidradenitis suppurativa (HS) is a chronic, infl ammatory skin disease. Because 
current treatments are unsatisfactory for many patients, there is a high need for eff ective 
drugs for this debilitating disease. Recent pathogenic insights suggest infl ammasome acti-
vation and IL-1β production are important in HS. Colchicine is effi  cacious in the IL-1β- and 
infl ammasome-mediated diseases gout, familial Mediterranean fever and Behçet’s disease, 
and therefore a potentially eff ective drug in HS.
Objective: To investigate the effi  cacy of colchicine in HS.
Methods: In an open prospective pilot study, 8 HS patients were treated with the accepted 
gout maintenance regimen of 0.5 mg colchicine b.i.d. orally up to 4 months. Effi  cacy was 
assessed by a physician global assessment.
Results: Colchicine treatment did not result in a clinical relevant improvement of disease 
severity. Three patients experienced nausea and diarrhea as known side eff ects.
Conclusion: Colchicine in the used dose regimen does not ameliorate HS severity.
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INTRODUCTION
Hidradenitis suppurativa (HS) is an infl ammatory, debilitating follicular skin disease that 
usually presents after puberty with painful deep-seated, infl amed lesions in the axillary, in-
guinal and anogenital areas of the body. HS is not uncommon with prevalence rates ranging 
between 1% and 4% in European countries1,2. It signifi cantly compromises quality of life in 
aff ected patients, even more than alopecia, chronic urticaria, psoriasis or atopic dermatitis3,4. 
Evidence-based therapies for HS are scarce, making HS diffi  cult to treat. Moreover, the chronic 
and often refractory nature makes HS treatment even more challenging.
Randomized controlled trials in HS are scarce. Topical clindamycin was superior to pla-
cebo5. Oral tetracycline was equally eff ective as topical clindamycin6. Oral contraconceptives 
were shown to improve HS to some degree in women7, Infl iximab and adalimumab both 
demonstrated signifi cant improvement8,9 and also 3 monthly sessions with the Nd:Yag laser 
improved HS10.
Other relative successful treatment options include combination therapy of clindamycin 
and rifampicin11, in milder cases topical resorcinol12 and the surgical deroofi ng method13. Oral 
isotretinoin showed very limited effi  cacy in HS14 but acitretin demonstrated improvement by 
physician global assessment in 12/12 patients15.
Our knowledge of the pathomechanisms underlying HS is still in its infancy. It has been 
suggested that HS is an auto-infl ammatory disease16 with comparable pathologic mecha-
nisms as diseases such as gout, familial Mediterranean fever (FMF) and Behçet’s disease. 
HS is probably the result of a mixture of intrinsic and environmental factors in a genetically 
predisposed individual. It is thought that the disease starts with occult skin infl ammation 
causing follicular infundibular keratosis17. The hair follicles become blocked, and cyst forma-
tion ensues. Abscesses and infl ammatory nodules acutely manifest when these occluded 
and dilated hair follicles or cysts rupture. This event subsequently causes an infl ammatory 
abscessing response in an attempt to clear the foreign material such as keratin fi bers and 
commensal bacteria. Recently we demonstrated that IL-1β secretion is signifi cantly increased 
in HS lesions which strongly suggests the involvement of the IL-1β/infl ammasome pathway17. 
IL-1β and the infl ammasome play a crucial role in gout, FMF, Behçet’s disease and other auto-
infl ammatory diseases18,19.
We argue that the spilled keratin fi bers in HS trigger an infl ammasome-mediated infl am-
matory response similar to the activation of the infl ammasome by uric acid crystals in gout18. 
Colchicine is a well-recognized valid therapy for gouty arthritis, FMF and Behçet’s disease20,21. 
Thus we hypothesized that colchicine could improve HS infl ammation by reduction of in-
fl ammasome activity.
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MATERIALS AND METHODS
In an open prospective pilot study the effi  cacy of 0.5 mg colchicine b.i.d. (twice a day) was 
investigated in 8 patients with moderate to severe HS. Informed consent was obtained. All 
included patients had previously been refractory to several other HS treatments including oral 
antibiotics, oral anti-conceptives, isotretinoin, resorcinol and even surgical deroofi ng or wide 
excisions. Thus colchicine was used as a last resort. All included patients had active disease for 
at least a year. After 1 month, in case of insuffi  cient improvement, patients were off ered a dose 
escalation to 0.5 mg t.i.d. (three times a day). Baseline characteristics including, age, previous 
treatments, BMI, smoking habit and disease staging according to Hurley are presented in Table 
1. Blood samples for monitoring of routine lab parameters such as liver and kidney function as 
well as hematological markers, were collected prior to initiation of treatment and at each visit. 
At each visit, patients were asked about side eff ects and clinical photographs were taken. The 
outcome was assessed by the same investigator (HZ) using a physician global assessment (PGA) 
compared to baseline -2 corresponded with clear worsening, -1 slight worsening, 0 no change, 
1 slight improvement, 2 clear improvement en 3 total clearance of infl ammatory lesions.
Table 1. Patient characteristics and outcomes by PGA score
Patient # Gender Age BMI Hurley 
stage
Current 
smoker
Previous treatments 1 month 
PGA
2 month 
PGA
4 month 
PGA
1 ♀ 24 31.2 2 no AB, resor, OC 0 1* 1*
2 ♀ 27 29.1 1 yes AB, deroof, resor, OC 0 0 -
3 ♀ 37 26.2 1 yes AB, deroof, resor, roac, OC 0 - -
4 ♂ 54 27.4 2 no AB, deroof, resor, roac 0 0 -
5 ♂ 34 25.7 3 yes AB, surg, resor 0 -1* -
6 ♀ 19 24.2 3 yes AB, surg, resor, OC 1 - -
7 ♀ 58 20.0 3 yes AB, surg, resor 1 1 -
8 ♀ 46 29.8 3 yes AB, surg, resor 0 1 -1
AB: oral antibiotics, deroof: deroofi ng, OC: oral contraceptive, resor: topical resorcinol, surg: wide 
excisions, roac: isotretinine, * 0.5 mg colchicine t.i.d.
RESULTS
Outcomes by PGA assessment are presented in Table 1. After 1 month, 2/8 patients expe-
rienced slight improvement of their symptoms whereas 6/8 experienced no change. Six 
patients completed 2 months of treatment. Three of six patients experienced slight improve-
ment; one patient deteriorated and two patients showed no change. Two patients were able 
to tolerate the increased dosage of 0.5 mg t.i.d. Only two patients were treated for 4 months; 
one patient slightly improved the other one deteriorated compared to baseline (Figure 1). 
Three patients experienced some level of nausea and diarrhea as a side eff ect, for patient #3 
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4this was the argument to stop colchicine treatment after one month. Other patients drop-ping out of the study reported lack of effi  cacy as the argument for cessation. No patient 
experienced clinically signifi cant changes in blood parameters during treatment.
DISCUSSION
Colchicine has been used in medicine for a long time and is a natural product that can 
be extracted from plants of the lily family20. Colchicine is lipophilic and is absorbed in the 
jejunum and ileum, and it is excreted via the bile tract and kidneys20,22. The bioavailability 
ranges between 24% and 88% and steady state plasma levels are reached within 8 days20. 
Colchicine has a narrow therapeutic to toxicity window. The therapeutic plasma levels are 
achieved by intake of 0.015 to 0.03 mg/kg which generally corresponds with 1-2 mg colchi-
cine per day20. The narrow therapeutic-toxicity window and the interindividual bioavailability 
variation make colchicine clinically diffi  cult to titrate. The therapeutic mechanism of action of 
colchicine is not fully understood. Colchicine inhibits microtubule polymerization inhibiting 
several cytokine signalling pathways22. In gout, colchicine suppresses infl ammasome-driven 
caspase-1 activation, IL-1β processing and release18. Colchicine also accumulates in neutro-
phils23, inhibiting neutrophil expression of cell adhesion molecules and decreasing neutrophil 
Figure 1 Right groin of patient #1 with a PGA score of 1 (slight improvement) (See also Color section, p. 207.)
a b
a) at baseline; b) at 4 months
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degranulation, chemotaxis and phagocytosis20. Its effi  cacy in neutrophilic auto-infl ammatory 
diseases is attributed to its eff ect on neutrophils in addition to the inhibition of the infl am-
masome20. Since colchicine is metabolised through the CYP3A4 and P glycoprotein system, 
avoidance of drug interactions is essential. For example macrolides used for treating HS such 
as clarithromycin inhibit P-glycoprotein and CYP3A4 and therefore likely impair colchicine 
elimination20. Although antibiotics are frequently used to manage HS, the patients in this 
study did not use any concomitant antibiotics.
In gout, colchicine is used as an intervention therapy and as a maintenance therapy. The 
treatment of gout fl ares recommended by the FDA is 1.2 mg at onset followed by 0.6 mg in 
1 h24. The maintenance therapy of gout is between 0.5 and 1.0 mg daily24. For treatment of 
FMF and Behçet’s disease only a maintenance therapy is used of an oral dosage of 1-2 mg per 
day20. The therapeutic effi  cacy of colchicine is normally seen within one week of treatment.
We administered 1 mg of colchicine daily and patients #1 and #5 received 1.5 mg daily after 
the fi rst month. The lack of effi  cacy in HS might be explained by initial underdosing. Perhaps 
a higher intervention/start dose as in gout for the fi rst day followed by the maintenance dos-
age of 1 mg daily would improve effi  cacy. However, data from auto-infl ammatory diseases 
have shown that fi ve percent of patients with either FMF or Behçet’s disease do not respond 
to a daily dose of 2 mg of colchicine20. We argue that the observed variation of HS disease 
activity in time is due to the natural course of the disease rather than induced by colchicine.
Common side eff ects of colchicine are of gastro-intestinal nature; such as nausea and diar-
rhea. In this study 3 patients reported some level of nausea and diarrhea. Even higher side 
eff ect rates are to be expected when a higher dose will be used.
The plasma level of colchicine was not measured, so it is unknown if the patients reached 
therapeutic colchicine levels. However the occurrence of side eff ects indicates that suffi  cient 
levels had been reached.
A limitation of this pilot study is the small sample size of only 8 patients and the fact that 
selection of patients was restricted to patients refractory to other regular therapies.
The effi  cacy of an intervention dose of colchicine should be studied in a larger patient 
cohort. We suggest that colchicine treatment should start with 1 mg followed by 0.5 mg 
every 2 hours with a maximum of 5 mg cumulative, followed by 1 mg daily. The plasma levels 
of colchicine should be monitored and the dose should be adjusted accordingly. In Behçet’s 
disease the addition of pimecrolius cream increases the effi  cacy of colchicine, although not 
signifi cantly21. It would be worthwhile to also investigate the addition of pimecrolius cream 
to colchicine in HS in a randomized controlled trial. Furthermore since IL-1β secretion is sig-
nifi cantly increased in HS lesions17 other drugs modulating the IL-1 pathway such as Anakinra 
(an IL-1 receptor antagonist) and Canakinumab (a human monoclonal antibody targeting 
IL-β) are potential treatment modalities for HS as well.
In conclusion, this prospective pilot study suggests that treatment with colchicine 0.5 mg 
b.i.d. does not result in a signifi cant clinical improvement in HS disease activity.
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Hidradenitis suppurativa (HS) was, until recently, a scientifi cally underestimated and clinically 
poorly recognized disease, despite its prevalence, severity and its high unmet medical need. 
The aim of this thesis was not restricted to a single aspect of the disease, but instead took a 
broad approach on the aetiology, pathomechanisms and treatment.
In this chapter we fi rst recapitulate the specifi c aims of this thesis. Second, we summarize 
the key results and present the main conclusions in Box 1. Third, the lack of an animal model 
for HS is discussed. Fourth we systematically discuss the topics addressed in this thesis and 
present a comprehensive view on HS pathogenesis. This chapter fi nishes with future perspec-
tives on HS research.
The specifi c aims and research questions of this thesis were the following:
Clinical aspects of hidradenitis suppurativa
Awareness about the disease severity and impact on quality of life is necessary to increase 
scientifi c interest. We hypothesized that depression is more common in HS patients than 
presently appreciated.
There are striking clinical similarities between HS and Crohn’s disease. Demonstration of 
an association may imply that parallel or similar pathogenic mechanisms contribute to both 
Box 1. Main conclusions of this thesis
Clinical aspects of hidradenitis suppurativa
  HS has a major impact on quality of life compared to other dermatological diseases. Depression 
scores in patients with HS correlate with disease severity scores.
  HS is probably associated with IBD and vice versa. HS occurs in about 15% of patients suff ering 
from Crohn’s disease or ulcerative colitis.
  We argue that the presence of apocrine sweat glands in HS-predisposed sites is based on 
coincidence. Overlapping characteristics between HS predisposed sites include mechanical friction 
and a warm humid microclimate, permissive to bacterial growth.
Pathomechanisms in hidradenitis suppurativa
  Secreted levels of IL-1β, TNF-α and IL-10 protein are highly elevated in lesional HS skin as well as in 
normal appearing perilesional skin.
  Psoriasiform hyperplasia, follicular plugging and low-grade leucocyte infi ltration are present in 
normal appearing perilesional skin and may precede clinical disease. Detached keratinocytes and 
strands of follicular epithelium may represent the fi rst steps in fi stula formation.
  Adalimumab treatment inhibits important cytokines and infl ammatory cell numbers in lesional HS 
skin, especially CD11c+ dendritic cells and IL-1β levels.
Treatment of hidradenitis suppurativa
  Combination treatment with oral rifampicin and clindamycin is an eff ective treatment option for 
HS, despite the frequent occurrence of diarrhoea as a side eff ect.
  The surgical deroofi ng technique is an eff ective, simple, minimally invasive, tissue-saving 
intervention for the treatment of single or isolated mild to moderate HS lesions at fi xed locations.
  Colchicine in the 0.5 mg b.i.d. dose regimen does not ameliorate HS severity.
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diseases. We investigated whether HS occurs more frequently in Crohn’s disease patients 
than in the general population.
Why HS preferable aff ects the inverse skin areas is unknown. We present a case that pro-
vides clues about the contribution of friction.
Pathomechanisms in hidradenitis suppurativa
Characterization of the HS cytokine profi le can provide a basis for development of novel 
therapies. We investigated whether secretion of prototypical pro-infl ammatory cytokines 
such as TNF-α and IL-1β is elevated in HS skin.
Anti-TNF-α biologics show promising effi  cacy in HS, but the underlying mechanisms are 
largely unknown. We investigated whether specifi c cytokines or infl ammatory mediators 
were signifi cantly aff ected by treatment with the anti-TNF-α biologic adalimumab.
We showed that levels of TNF-α, IL-1β and IL-10 are increased in HS lesions and normal ap-
pearing perilesional HS skin. We therefore investigated the possible cellular source of these 
cytokines.
Treatment of hidradenitis suppurativa
Since antibiotic therapy is the most common treatment for HS, we addressed whether com-
bination therapy with clindamycin and rifampicin is eff ective in HS.
Deroofi ng is a surgical method for HS, but its effi  cacy has not been systematically investi-
gated. We hypothesized that deroofi ng would be eff ective in recurrent single lesions of HS.
Colchicine is a drug with anti-infl ammatory properties, and is successfully used in auto-
infl ammatory diseases. In a pilot study we investigated the effi  cacy of colchicine in patients 
with HS.
MAIN RESULTS
The quality of life of HS patients, as assessed by the Dermatology Life Quality Index (DLQI), 
was signifi cantly reduced compared to control patients p<0.0001 (8.4 ± 7.5 versus 4.3 ± 5.6). 
Depression scores, as assessed by the Major Depression Inventory (MDI), were signifi cantly 
higher for HS patients, 11.0 versus 7.2 (p<0.0001). However, actual depression rates as de-
fi ned by the International Classifi cation of Diseases-10 (ICD-10) criteria were not signifi cantly 
higher in HS patients compared to controls (9% versus 6%).
In a group of 158 patients with infl ammatory bowel disease (64.6% Crohn’s and 35.4% 
ulcerative colitis patients), 25 patients (15.8%) (7 with Crohn’s and 8 patients with ulcerative 
colitis) reported the occurrence of painful boils in the axillae and/or groin suggestive for HS.
We described a patient with infl ammatory lesions, strikingly similar to HS, at an ectopic 
location free of apocrine sweat glands and induced by wearing of a leg prosthesis.
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Secretion of the cytokines IL-1β, TNF-α, CXCL9 (MIG), IL-10, IL-11, BLC (B-lymphocyte che-
moattractant) and IL-17A as well as the anti-infl ammatory cytokine IL-10 were signifi cantly 
elevated in HS skin. Elevated levels of IL-1β (31-fold), TNF-α (5-fold) and IL-10 (34-fold) were 
also found in perilesional HS skin. Levels of the latter three cytokines showed a weak positive 
correlation with disease severity according to the Hurley stage. Remarkably, IL-2, IL-4, IL-5 and 
IFN-γ were almost undetectable in HS skin.
Treatment with adalimumab resulted in decreased cytokine production in HS skin, espe-
cially IL-1β, CXCL9 (MIG), BLC, and a signifi cantly reduced number of infl ammatory CD11c+ 
dendritic cells (DC), CD14+ monocytes and CD68+ macrophages in HS lesional skin.
Histologically, in early HS lesions, neutrophilic abscess formation and infl ux of mainly 
macrophages, monocytes and DC predominate. In chronic disease, additionally increased 
numbers of CD20+, CD79a+ B cells and CD138+ plasma cells are seen. Free keratin fi bers were 
detected in the dermis and within giant cells in all phases of HS infl ammation. Single de-
tached keratinocytes and strands of actively proliferating follicular epithelium were observed 
in the dermis. Perilesional skin showed mild psoriasiform hyperplasia and follicular plugging 
as well as a low-grade infl ux of tryptase+ mast cells, CD3+ T cells, CD138+ plasma cells and 
FXIIIa+ dendritic cells.
Combination therapy with clindamycin and rifampicin resulted in improvement in 82% of 
patients including a temporary complete remission in 47%. The maximum eff ect was seen 
within 10 weeks. Following complete remission, 62% of patients treated with a 10-week 
schedule experienced a relapse after a mean of 5.0 months. Non-responders were predomi-
nantly patients with severe disease.
The surgical deroofi ng technique yielded a recurrence rate of 17% that appeared after a 
mean of 5 months after surgery. Eighty three percent of deroofed lesions did not show a 
recurrence after a median follow-up period of 34 months.
Treatment with the TNF-α antagonist adalimumab showed a better clinical response at 
week 16 in patients receiving weekly injections versus injections every other week (17.6% vs. 
9.6%). A decline in the response rate was seen following the switch from weekly dosing to 
every other week.
Colchicine treatment, in a dose of 0.5 mg b.i.d. orally for up to 4 months, did not result in a 
clinical relevant improvement of disease severity in 8 patients with HS.
Can HS-like disease in animals serve as a model?
An animal model mimicking HS would greatly facilitate the study of pathogenic mechanisms 
and rational design of therapeutics. Ideally, such an animal model would exhibit the cardinal 
clinical as well as immunopathological characteristics of HS. However, no such animal model 
is currently available. To our knowledge 5 cases of spontaneous canine HS have been re-
ported1,2. However, these reports were published in 1969 and 1973 when human HS was still 
considered apocrinitis rather than follicular occlusion. The main criterion for the diagnosis of 
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canine HS was therefore apocrinitis. Canine HS looked clinically distinct from human HS and 
was characterized as recurrent suppurative, sharply marginated, erythematous, non-tender 
warm plaques at the inner thighs, groin scrotum, vulva or axilla. There were no deep-seated 
nodules or fi stulas as in human HS. Histological examination showed polymorphic neutrophil 
invasion of the apocrine glands. Staphylococcus aureus was cultured in all cases. Hence, we 
argue that this canine disease is probably not comparable to human HS.
Another naturally occurring canine skin disease, closely resembling human HS, is deep 
pyoderma in German shepherd dogs also known as German shepherd dog pyoderma (GSP) 
(Figure 1). GSP is rare and closely mimics the clinical aspects of human HS. GSP is character-
ized by deep seated chronic and infl ammatory lesions in the dermis and subcutis resulting in 
ulceration, fi stulisation, necrosis with hemopurulent exudate and oedema3. Main histopatho-
logical fi ndings include acanthosis, ulcerations and an infl ammatory infi ltrate consisting of 
mainly neutrophils and mononuclear cells3. Frequently this infi ltrate is present around the 
adnexa with frequent destruction of the hair follicles and sweat glands3. GSP commonly 
starts in the lumbar region. Opportunistic pathogenic coagulase-positive Staphylococci are 
frequently cultured from the lesions, although these bacteria can also be found on normal ca-
nine skin. Like in human HS, particular genetic traits and immunological dysfunctions are the 
suspected pathogenic factors4,5. Like HS, the effi  cacy of antibiotics and/or glucocorticoids is 
poor or temporary3. Although these similarities are striking, there are also some discrepancies. 
Figure 1. The back of a German shepherd dog with GSP (source Dr. M.A. Wisselink) (See also Color section, 
p. 207.)
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The most notable dissonance is the histological lack of follicular plugging with cyst formation 
and rupture. Furthermore, the skin areas most liable to mechanical stress do not seem to be 
predisposed areas. Recently, mutations in γ-secretase genes were discovered in familial HS6,7. 
In that study and the corresponding editorial, mouse models of gamma-secretase signalling 
were proposed as animal models for HS6,7. These mouse models would mimic HS and show 
follicular and epidermal abnormalities. However, these transgenic mice formed follicular cysts 
but none of these models showed other distinct clinical HS characteristics such as infl am-
mation, abscesses, fi stulas and scarring. Moreover, the mice in the model of Pan et al. shed 
hair, something which is not seen in HS, and they lacked the psoriasiform hyperplasia of the 
epidermis8. The mouse models of Xia et al. and Li et al. spontaneously developed squamous 
cell carcinomas9,10. Squamous cell carcinoma is rare in HS and is considered as a sequela of 
longstanding infl ammation and scarring. The mouse model of Nicolas et al. developed basal 
cell carcinomas11, something which is not seen in HS. Hence we argue that there are too many 
discrepancies between these mouse models and human HS. In conclusion, a valid animal 
model for HS is currently not available and the many discrepancies between human HS and 
the possible models are daunting. Therefore the prospects of developing a valid animal 
model at the short term seem poor.
Does HS lead to depression?
Information on the psychosocial consequences of HS is limited. Compared to other derma-
toses such as severe psoriasis and hand eczema, HS causes a greater impairment of quality 
of life (QoL)12-16. Relative depression rates for HS are unknown. In case depression would be a 
frequent event in HS patients, dermatologists should be attentive and, when needed, consult 
or refer to a psychiatrist for appropriate help.
In chapter 2.1 we studied depression in HS. We show that the QoL as defi ned by the DLQI 
score is signifi cantly worse in patients with HS than in a comparable group of general derma-
tological patients.
We also show that the depression scores of HS patients are signifi cantly higher than those 
of other dermatological patients. This suggests that HS represents a heavier burden than 
other skin diseases. The high depression scores in HS were in agreement with those described 
by Matusiak et al. who used the Beck Depression Inventory-SF16.
A limitation of our study was a selection bias. We investigated a hospital-based patient 
population which restricts generalization of the data.
We used the major depression inventory score (MDI) to study depression. The MDI can 
be used to diagnose depression using the ICD-10 criteria, but also as a rating scale to mea-
sure depression severity17,18. The mean MDI scores used as a rating scale were higher in HS 
patients than the group of general dermatological patients. However, when the MDI was 
used as a diagnostic tool, the prevalence of clinical depression was not signifi cantly higher 
in HS patients than in other dermatological patients. This discrepancy might indicate that 
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the MDI score is a better severity rating tool than a diagnostic tool for depression. It may also 
indicate that HS patients have developed eff ective coping skills. The MDI score has not been 
used before for other dermatological diseases, but comparing HS to the severe neurological 
disorder amyotrophic lateral sclerosis (ALS), HS demonstrated comparable severe depres-
sion19. In conclusion, the results of our study indicate that HS has a major impact on quality 
of life compared to general dermatological patients. Depression scores in patients with HS 
correlate with disease severity scores. Depression scores may serve as outcome measures in 
future studies and dermatologists should be aware of and actively search for signs of depres-
sion in patients with HS.
Is HS associated with infl ammatory bowel disease?
Infl ammatory bowel disease (IBD) comprises Crohn’s disease (CD) and ulcerative colitis (UC)20.
The occurrence of both Crohn’s disease and HS in the same individual has previously been 
reported in over 37 individual cases21. Based on these sporadic case reports an association 
was assumed in the literature. Yet, in attempts to fi nd a common genetic basis, two limited 
studies investigating the CD-associated gene CARD15, also known as NOD2, did not demon-
strate CARD15 polymorphisms in HS22,23. The current pathogenic concept of IBD is that a dis-
balance in the immune response to commensal bowel fl ora together with a specifi c genetic 
predisposition and other environmental factors trigger IBD24. An association between HS and 
CD may imply that parallel or similar pathogenic mechanisms are operative in both diseases.
In chapter 2.2 we investigated the co-occurrence of HS in IBD patients. The results of this 
pilot study indicate that HS not only occurs frequently in CD (16.7%), but also in UC (14.3%).
However, the study had some limitations. First, other diseases may also cause painful boils 
such as furunculosis, lymphadenitis, ectopic Crohn’s disease, or granuloma venereum. We 
reduced the chance of confusion with these conditions by specifi cally asking for recurrent 
lesions and showing clinical photographs of prototypical HS lesions. Because perianal cuta-
neous Crohn’s lesions can mimic HS, we did not ask for painful boils in the perianal area in 
order to avoid confusion. Second, the interviewed patients suspected of having HS were not 
physically examined to confi rm the diagnosis. Third, co-occurrence in a small sample does 
not necessarily imply an association.
In conclusion, this study suggests that HS occurs not only in Crohn’s disease but also in 
patients suff ering from ulcerative colitis.
Is the presence of apocrine sweat glands necessary to develop HS lesions?
In chapter 2.3 we presented a patient who developed HS-like lesions on a leg stump wearing 
a leg prosthesis. We argue that the lesions on the leg stump in this patient were not compat-
ible with acne mechanica or other known skin problems in leg amputees25. Especially the 
presence of fi stulas strongly suggested a HS-like disease. Furthermore, other characteristics 
conform HS included a lesional culture demonstrating a commensal skin fl ora rather than 
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pathogens. In addition the patient was a heavy cigarette smoker, which is a well-known risk 
factor for HS as it stimulates follicular occlusion26. On the other hand, the patient never had 
recurrent HS lesions in the axilla or groin, nor a family history of HS, which is present in 40% 
of HS cases27.
The skin of a leg stump is exposed to mechanical friction and a warm humid climate of 
the prosthesis. We argue that the presence of apocrine sweat glands in HS-predisposed sites 
is based on coincidence. Overlapping characteristics between HS predisposed sites include 
mechanical friction and a warm humid, microclimate promoting bacterial growth. Mechani-
cal stress may promote follicular keratosis/occlusion and rupture of fragile dilated follicles. 
Furthermore, the microclimate in HS predilection sites favours bacterial growth, which may 
trigger or worsen HS.
Which cytokines are important in HS skin infl ammation?
Little is known about the spectrum and the quantity of cytokines that are produced in HS 
lesions. Until recently the use of anti-TNF-α biologics in HS was therefore solely based on 
empirical grounds.
In chapter 3.1 and chapter 3.2 we assessed the ex vivo cytokine production by lesional 
HS biopsies in a transwell culture system. The cytokine signature of HS might provide clues 
about activated infl ammatory pathways and thereby support development of potential 
therapeutic targets.
In chapter 3.1 we show that the pro-infl ammatory cytokines IL-1β, TNF-α as well as the anti-
infl ammatory cytokine IL-10 were signifi cantly elevated in HS lesions. Compared to psoriasis, 
the levels of especially IL-1β, IL-10 but also TNF-α were higher in HS lesions. Fold increases 
relative to control skin for IL-1β, TNF-α and IL-10 were for HS 31, 5, and 34, and for psoriasis 4, 
1 and 2, respectively. IL-1β is a potent pro-infl ammatory cytokine, that is produced by many 
diff erent cell types, but monocytes and macrophages in particular28. Biologically active IL-1β 
is generated in the infl ammasome by cleavage of pro-IL-1 by caspase-1 which was formerly 
known as ICE, an acronym for interleukin-1 converting enzyme29. The relatively high level of 
IL-1β in HS skin is suggestive for involvement of the infl ammasome in HS skin infl ammation. 
The infl ammasome functions as a cytosolic sensors that respond to diverse types of danger 
signals such as damage associated molecular pattern molecules (DAMP) and pathogen-
associated molecular patterns (PAMP)30. Some examples of PAMP and DAMP are bacterial and 
viral DNA and RNA sequences, host-derived molecules indicative of injury such as extracel-
lular ATP, hyaluronic acid, uric acid crystals and metabolic stress31. We argue that several such 
DAMP and PAMP are abundantly present in HS and that they may activate the infl ammasome 
in three ways. First, by DAMP such as host-derived molecules indicative of tissue destruction 
and pyroptosis (a highly infl ammatory form of cell death), which is supported by the occur-
rence of pus and scarring in HS. Second, by PAMP, since HS lesions are frequently inhabited 
by commensal microbiota32. And third, by free high molecular weight cornifi ed keratins in 
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the dermis, spilled by ruptured cysts. We propose these can activate the infl ammasome 
after phagocytosis, in analogy with uric acid crystals in gout33,34. Remarkably, HS skin also 
produces an increased level of IL-1035. IL-10 generally has an anti-infl ammatory role, limiting 
the immune response to pathogens and thereby preventing excess damage to the tissue36. It 
furthermore has a crucial role in preventing infl ammatory and auto-immune pathologies35. 
IL-10 is expressed by many cell subsets of adaptive immunity and is also expressed by innate 
immune cells. We speculate that macrophages in HS could be the prime producers of this vast 
amount of IL-10. It has been shown that bone marrow-derived macrophages stimulated by 
eff erocytosis (clearance of apoptotic neutrophils) are characterised by high IL-10 production 
and in addition produce TNF-α following re-stimulation with LPS37. This corresponds with 
the infl ammatory reaction observed in HS. First, macrophages and neutrophils are present in 
high numbers in HS infi ltrates and abscesses. Second, HS lesions are frequently inhabited by 
commensal microbiota, therefore it is conceivable that HS macrophages are exposed to LPS 
and other microbial PAMP. Third, we showed that TNF-α is elevated in HS lesions.
In chapter 2.2 we complement the list of cytokines increased in HS with CXCL9 (MIG), 
IL-11, BLC, IL-17A, TNF-R2, CCL5 (RANTES), IL-16, IL-6sR, ICAM-1, CCL3 (MIP-1α), TNF-R1 and 
IL-1ra. Many of these cytokines are chemotactic for a broad spectrum of immune cells. The 
arrays used contained a panel of cytokines in order to discriminate between a Th1 or Th2 
infl ammatory profi le. Typical Th1 and Th2 cytokines such as IL-2, IL-4, IL-5 and IFN-γ were 
hardly detectable in HS. Another array that was described in chapter 3.1 again did not detect 
signifi cant levels of Th1 nor Th2 cytokines. On the basis of these results we conclude that 
HS is not a prototypically Th1 or Th2 driven infl ammatory disease. The high levels of IL-17A 
and IL-10 indicate that theoretically Th17 and Treg cells play a role in HS pathogenesis. In a 
highly recent paper increased levels of IL-17 in HS lesions was confi rmed by semiquantitative 
real-time polymerase chain reaction, furthermore a cellular source of this cytokine were CD4+ 
T helper cells demonstrated by double immunofl uorescence38.
Elevated levels of IL-1β, TNF-α and IL-10 were also detected in perilesional HS skin. This 
indicates that HS infl ammation extends beyond the visible borders of aff ected lesions. The 
presence of infl ammatory cytokines in perilesional areas can be of clinical importance since 
high recurrence rates of HS lesions have been reported after surgical excision39. We argue that 
the occult perilesional infl ammation drives follicular keratinisation and plugging and may 
therefore contribute to perilesional recurrences after surgery. This concept further suggests 
that recurrence after surgery may be prevented by the administration of adjuvant medica-
tions which reduce infl ammation and infundibular epidermal hyperplasia and keratosis.
In conclusion, we show that among other cytokines especially TNF-α, IL-1β, IL-10 are 
elevated in infl amed HS skin lesions. The elevated levels of TNF-α provide evidence for the 
rational use of anti-TNF-α biologics in HS. In addition we show that HS infl ammation extends 
beyond the visibly aff ected infl ammatory borders.
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Are histological and leucocyte subset alterations present in clinically normal 
appearing skin?
In chapter 3.2 we demonstrated that levels of IL-1β, TNF-α and IL-10 are elevated perilesion-
ally. In chapter 3.3 we investigated histological characteristics in the clinically normal skin 
in the periphery of active HS lesions. We show that clinically unaff ected perilesional skin 
already displays epidermal psoriasiform hyperplasia, follicular plugging and dilatation of 
hair follicles. These histological alterations are accompanied by a mild infl ux of CD3+ T cells, 
CD138+ plasma cells, FXIIIa+ dermal DC and tryptase+ mast cells. The mild infl ux of leucocytes, 
together with increased levels of cytokines in perilesional skin, represents a subclinical 
infl ammatory response, possibly due to diff usion of chemokines from the actively infl amed 
lesion that paves the wayfor expansion of a pre-existing HS lesion. This subclinical infl am-
mation may induce psoriasiform hyperplasia and infundibular keratosis. In newly emerged 
HS lesions, we observed cysts, free keratin fi bers in the dermis, and intracellular fi bers in 
multinucleated giant cells. This indicates that during progression of the disease, dilated hair 
follicles or cysts rupture and spill their keratin contents into the dermis. This foreign material 
induces an abscessing neutrophilic infl ammation at the site of rupture with an additional 
massive infl ux of CD14+ monocytes and CD11c+ DC. Also multinucleated giant cells develop, 
which may indicate that these cells attempt to clear and sequester foreign keratin material. 
In this process large numbers of CD3+ T cells and B cells are attracted.
When HS becomes chronic, a dramatic expansion of the infi ltrate is observed. In addition, 
the follicular epithelium displays focal hyperplasia. We also demonstrated ectopic CD20+ 
and CD79a+ B cell ‘pseudo’ lymphoid follicles in the dermis of chronic lesions. These ‘pseudo’ 
lymphoid follicles were previously not described in HS. We argue that these lymphoid fol-
licles appear as a reaction secondary to persistent bacterial colonization or to chronic infl am-
mation. It is known that in chronic infl ammation e.g. in rheumatoid arthritis and multiple 
sclerosis, lymphoid follicles can be formed in the infl amed tissue40,41.
In chapter 3.1 we hypothesize that the high levels of IL-1β are the result from infl amma-
some activation by free keratin fi bers comparable with that of uric acid crystals in gout33,34. In 
this study we demonstrate these keratin fi bers deep in the dermis of clinical HS, supporting 
our hypothesis.
A characteristic of moderate or severe HS is fi stula formation. How or why fi stulas arise 
in HS and from where they primarily originate is unknown. It is has been postulated that 
fi stula formation originates from downward expansion of the leafl ike dermal protrusions 
from the hyperplastic epidermis42 or from keratinocyte stem cells43. We have demonstrated 
ectopic strands of Ki67+ proliferating epithelia, and single detached keratinocytes deep in 
the dermis, that were probably derived from ruptured cysts. We propose that these strands 
of epithelial lining and single keratinocytes are the initiators of epithelialized fi stulas, similar 
to the artifi cially induced fi stulas in acne, induced by puncturing a comedo with a needle44.
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In the past, HS was thought to be primarily an apocrinitis. In our study we observed 
apocrinitis as often eccrinitis (50% and 67%) and always as part of massive dermal infl am-
mation, never as an isolated event. Therefore the term ‘apocrine-bearing skin’ to describe 
the predilection site for HS should be considered a misnomer and should be abandoned. 
Other characteristics of HS predilection sites such as mechanical friction, the ‘loose’ dermal 
structure and a favorable bacterial microclimate are likely more relevant.
Clinically we noted that many HS patients complain about itch. We demonstrated for the 
fi rst time the presence of high numbers of tryptase positive mast cells in HS early and estab-
lished lesions, and also in perilesional skin. Hence it is tempting to speculate these mast cells 
are the cause of the itch.
These observations of subclinical infl ammation and histological alterations in perilesional 
skin provide a rationale for the use of keratolytics and anti-infl ammatory agents to prevent 
further disease progression even though the disease is not visibly active at that time. Likely 
candidates for such an intervention would be topical resorcinol and oral acitretin, which 
have keratolytic as well as anti-infl ammatory properties, both already shown to be of benefi t 
in HS45,46. The increased numbers of mast cells might also be a future target for therapeutic 
intervention via modulation of IL-9. Recently a humanized anti-IL-9 biologic demonstrated 
promising results in asthma patients47.
A possible limitation of this study is the limited number of patient samples analysed. 
But since big excised lesions were serially sectioned and little heterogeneity was observed 
between samples, we argue that the results are likely representative for the HS population 
at large.
In conclusion we demonstrate that diff erent pathogenic mechanisms are operational in 
perilesional skin. In chronic clinical disease we demonstrate ‘pseudo’ lymphoid follicles as 
well as increased numbers of mast cells. The appearance of painful nodules is likely the result 
of an immunological response to breached dilated hair follicles or cysts. The free keratin fi -
bers in active lesions might activate the infl ammasome to produce bioactive IL-1β. We argue 
that fi stulas might originate from observed detached keratinocytes and strands of follicle 
epithelium.
How eff ective is combination therapy with clindamycin and rifampicin?
Currently, antibiotic therapy is still the most common form of treatment for HS. The combined 
treatment with oral rifampicin 300 mg and oral clindamycin 300 mg, both twice daily, has 
previously been advocated for HS based on a small case series48.
In chapter 4.1 we studied the effi  cacy of this antibiotic regime in a larger HS population and 
showed that this combination therapy resulted in clinical improvement in 82% of patients. 
The results are in agreement with previously published case series and also with those of 
Gener et al., whose study was published back to back with our study48,49. However, 61.5% of 
patients treated for 10 weeks experienced a relapse after a mean period of 5.0 months. This 
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indicates that this antibiotic combination does not cure the disease but relieves symptoms 
and reduces infl ammation.
A limitation of our study is the retrospective approach. We did not observe major diff er-
ences in outcomes between patients treated 10 weeks and longer and patients treated for 
a shorter period, indicating that treatment shorter than 10 weeks may also be eff ective. We 
argue that the mechanism of action of these antibiotics in HS is probably more immuno-
modulatory than bactericidal or bacteriostatic, since bacterial cultures from HS lesions are 
frequently negative32. A drawback of this combination treatment was the occurrence of side 
eff ects in 38% of patients, most frequently diarrhoea.
In conclusion, the combination treatment with oral rifampicin and clindamycin induces 
an improvement of symptoms in 84% of cases and is therefore an eff ective treatment for HS, 
despite the frequent occurrence of diarrhoea as a side eff ect.
Is surgical deroofi ng eff ective?
The treatment repertoire for HS consists not only of pharmaceutical but also of surgical 
interventions. Several surgical interventions have been described for HS, often with con-
siderable recurrence rates. The reported recurrence rates after incision with drainage are 
up to almost 100%, for limited excision 43% and for wide excisions 27%39. Two methods of 
deroofi ng have been described in the literature. One method leaves the fl oor of the exposed 
lesions untouched assuming that preservation of the exposed lesion fl oor is essential for its 
epithelial regenerative elements50,51. The other method argues that the debris on the fl oor of 
lesions should be removed, because viable epithelial strands could get entrapped and cause 
recurrence52.
In chapter 4.2 we studied the effi  cacy of the latter deroofi ng method in HS. We showed 
that deroofi ng results in an 83% cure rate after a median follow up of 34 months. The median 
patient satisfaction with the procedure rated a 8 on a scale from 0 to 10 and 90% of treated 
patients would recommend the deroofi ng technique to other HS patients. The deroofi ng 
procedure may be performed by using electrosurgery, cold steel or with the CO2 laser
53,54. 
Compared to electrosurgical deroofi ng, CO2 laser-assisted surgery is more time consuming 
and rather expensive. The use of a probe during the procedure is necessary in order to detect 
subcutaneous fi stulas.
Among the diff erent types of HS lesions, a type is the chronic lesion that recurs at exactly 
the same location. We argue that this type of lesion is especially suited for deroofi ng. In our 
opinion Hurley 3 lesion areas are not suitable for deroofi ng, since it would require deroofi ng 
of the entire aff ected area and would be almost similar to radical excision. We argue that early 
intervention by deroofi ng can prevent disease aggravation. Advantages of the deroofi ng 
technique include: small defects avoiding the need for general anaesthesia, limited chance 
of creating extensive scarring, single-lesion surgical treatment gives low morbidity and the 
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use of electrosurgery provides good haemostasis which is highly needed because HS lesions 
are well vascularized.
In conclusion the deroofi ng method is cheap, simple, safe, and has a prolonged effi  cacy for 
recurrent HS lesions at fi xed locations in Hurley 1 or 2 areas. The deroofi ng technique yields 
superior outcomes, and hence is preferable over incision with drainage and simple excisions 
with cold steel.
Does the anti-TNF-α biologic adalimumab reduce HS infl ammation?
HS is often refractory to treatment. The effi  cacy of anti-tumor necrosis factor alpha (TNF-α) 
infl iximab was fi rst shown in single cases, later in case series and in small RCTs55.
Mechanisms of action of TNF-α antagonists were unknown. In chapter 3.3 we investigated 
whether adalimumab aff ects the in situ cytokine production and the frequency of diff erent 
infl ammatory cell populations in HS lesions. We showed that after 16 weeks of adalimumab 
treatment the most evident decrease was seen in the levels of IL-1β, CXCL9 (MIG), BLC, IL-11 
and CCL5 (RANTES) and to a lesser extent for IL-6R IL-16, IL-1ra, sTNF-R2, ICAM-1, IL-10, and 
CCL3 (MIP1α). Adalimumab treatment induced a shift most pronounced in the numbers of 
dendritic cells, monocytes and macrophages, followed by T helper and B-cells. These in situ 
results generally correlated with the clinical response of individual patients. By which mecha-
nisms adalimumab ameliorates infl ammation in HS is unknown. In psoriasis adalimumab is 
thought to exert its function by inhibiting the p38 mitogen-activated protein kinase (MAPK) 
pathway56,57. P38 MAPK is a kinase that regulates the expression of infl ammatory cytokines 
such as IL-1β, IL-8, and TNF-α, IL-12/IL-23(p40), IL-23(p19) and IL-2057. Adalimumab might 
ameliorate infl ammation in HS in a similar fashion.
This in situ study had several limitations. From each of three dosing arms, a relatively 
small number of patients were included so that statistics could not be applied. Furthermore, 
sequential biopsies were not taken during treatment. So it was not possible to link in situ 
infl ammatory changes to the clinical response.
In conclusion, Adalimumab treatment inhibits cytokine production and reduces infl amma-
tory cell numbers in lesional HS skin. The most pronounced reduction was observed in IL-1β 
levels and in the number of infl ammatory DC.
Is the anti-infl ammatory drug colchicine eff ective?
In chapter 4.3 we demonstrated that IL-1β secretion is signifi cantly increased in HS lesions 
suggesting activation of the IL-1β/infl ammasome pathway58. IL-1β and the infl ammasome 
play a crucial role in gout, familial Mediterranean fever (FMF) and Behçet’s disease34,59. Col-
chicine is a well-recognized therapy for gouty arthritis, FMF and Behçet’s disease60. Therefor 
we hypothesized that colchicine could improve HS infl ammation by reducing infl ammasome 
activity. In a prospective pilot study we investigated the effi  cacy of 0.5 mg colchicine b.i.d. in 
8 patients for up to 4 months. This daily dose is frequently used as a maintenance therapy in 
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patients with gout61. Two patients received 1.5 mg daily after the fi rst month. A limitation of 
this study was the small sample size and the fact that selection of patients was restricted to 
patients refractory to other regular therapies. No patient experienced a clinically signifi cant 
change in HS severity, while three patients experienced some level of nausea and diarrhea as 
a side eff ect. The effi  cacy of an intervention dose of colchicine should be studied in a larger 
patient cohort. We suggest that colchicine treatment should start with 1 mg followed by 0.5 
mg every 2 hours with a maximum of 5 mg cumulative, followed by 1 mg daily. The plasma 
levels of colchicine should be monitored and the dose should be adjusted accordingly.
Figure 2. Comprehensive hypothetical model of factors infl uencing HS development, activity and 
chronicity
In a genetically predisposed individual, commensal skin microbiota triggers a subclinical infl ammatory 
response. This promotes plugging and occlusion of the hair follicles, leading to formation of cysts, which 
can be amplifi ed by mechanical friction and smoking. These cysts rupture by mechanical friction or 
pressure spilling their content of highly cross-linked keratins and epithelial strands into the dermis. These 
subsequently fuel an abscessing infl ammation which promotes follicular plugging in the surrounding 
skin. Epithelial strands are incited to proliferate by cytokines from the infl ammatory reaction leading to 
epithelialized fi stulas. These fi stulas form an easy passage for bacteria and allow colonization of ectopic 
areas aggravating infl ammation.
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Figure 3. Key histological and immunological alterations in early and chronic HS skin  (See also Color 
section, p. 208.)
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VIEW ON HS PATHOGENESIS
Based on the results of studies in this thesis and existing literature we postulate the following 
model and sequence of events in HS pathogenesis Figure 2 and 3.
HS results from a combination of intrinsic and environmental factors in a genetically 
predisposed individual. The pathogenic process starts prior to the fi rst visible clinical mani-
festation in response to unknown triggers, which might be the commensal skin microbiota. 
Pre-clinically a mild infl ux of mainly T cells but also mast cells occurs which secrete a mixture 
of chemokines and cytokines including TNF-α, IL-1β and IL-10. This subclinical infl ammation 
results in epidermal psoriasiform hyperplasia and follicular infundibular keratosis. Smoking 
and mechanical friction contributes in this phase by amplifying the follicular keratosis. The 
hair follicles become plugged, followed by swelling of the hair follicle, forming cysts. Clinical 
HS, with abscesses and infl ammatory nodules, acutely manifests when the fragile epithelial 
lining of the dilated hair follicle or cyst ruptures. The characteristic loose structure of the sub-
cutaneous tissue of the axilla and groin skin facilitates vertical and horizontal inward spread-
ing of the spilled keratin content into the dermis. In response to these keratin fi bers together 
with commensal fl ora, an abscessing neutrophilic infl ammatory reaction forms at the site 
of rupture with an additional massive infl ux of macrophages, monocytes, T cells, B cells and 
dendritic cells and the formation of multinucleated giant cells. The latter likely are involved 
in the clearing of keratin fi bres and keratinocyte remnants by phagocytosis. We argue that 
A Early HS
Commensal bacteria might elicit an infl ammatory response with subsequent occlusion of the hair follicle’s 
infundibulum by keratin plugging or epidermal hyperplasia. Or conversely, friction of pressure forces 
induce occlusion of the hair follicle’s infundibulum followed by overgrowth of commensal bacteria, 
leading to an infl ammatory response. The interfollicular epidermis shows mild psoriasiform hyperplasia. 
HS clinically manifests acutely when a occluded and dilated hair follicle / cyst ruptures, spilling its 
keratin-rich content into the dermis. Subsequently ‘rod-like’ keratin fi bers are present freely in the dermis 
and are phagocytosed by multinucleated giant cells, while single keratinocytes derived from the follicle 
epithelium are launched into the dermis. Increased numbers of mast cells are diff usely spread in the 
dermis. There is abscess formation with massive neutrophilic infi ltration with in addition dendritic cells, 
macrophages, T cells, some B cells and plasma cells, and CD8+ T cells show modest epidermotropism.
B Chronic severe HS
In chronic severe HS plugging of the follicular infundibulum increases resulting in cyst formation. After 
rupture, these cysts may be interconnected by epithelialized sinus tracts, draining onto the skin surface 
through multiple orifi ces. The epidermal psoriasiform hyperplasia is pronounced and involves the 
interfollicular epidermis as well as cyst and sinus tract walls. As in early lesions also free keratin fi bers 
are present in the dermis and within multinucleated giant cells. Single detached keratinocytes but also 
strands of follicular epithelium are ectopically present in the dermis, which may form epithelialized 
fi stulas. The abscessing infi ltrate expands, with increasing numbers of T cells, dendritic cells, macrophages, 
B cells and plasma cells. B cells are diff usely located around abscesses, and in addition demonstrate a 
patchy distribution in the infi ltrate forming pseudo-follicles. The number of mast cells increases and CD8+ 
cells show modest epitheliotropism.
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the infl ammasome plays a key role in HS pathogenesis and is activated by phagocytosing 
these free keratin fi bers. This infl ammatory response is boosted by host-derived molecules, 
indicative of tissue destruction, such as self DNA and RNA, together with AMP, pyroptosis and 
bacteria. The activated infl ammasome generates the bioactive and highly pro-infl ammatory 
IL-1β by cleaving intracellular pro-IL-1 by means of caspase 1.
After this acute phase, HS lesions may become chronic. Secondary bacterial colonisation 
nourishes infl ammation. Furthermore, the multinucleated giant cells fail to phagocytose all 
keratin fi brils. Strands of epithelial lining and single keratinocytes in the dermis launched 
from follicular epithelia after rupture proliferate from which epithelialized fi stulas are formed. 
These fi stulas form a direct route for bacteria to invade the deep dermis. A vicious circle of 
infl ammation leading to follicular plugging, rupture, and then again an infl ammatory reac-
tion occurs. This infl ammation may spread the disease into the surrounding healthy tissue 
causing plugging of hair follicles.
FUTURE PERSPECTIVES
HS is scientifi cally still an orphan disease, although the number of publications is rising. Our 
advancing insight gives rise to new questions while still many basic questions remain to be 
answered. Important questions to be addressed in future studies are discussed below and 
are presented in Box 2.
Box 2. Outstanding questions
Genetics Immunology
Concordance of HS in monozygotic twins The role of the infl ammasome in HS
Identifi cation of SNP in HS The role of mast cells in HS pathology
Smoking Functional studies on infl ammatory cell subsets
Eff ect of smoking cessation on disease severity Treatment
Obesity Preventive eff ects of current HS drugs
The eff ect on HS severity after weight loss in the obese Effi  cacy of infl ammation modulating drugs
Bacteria Clinical
Bacterial characterisation of HS lesions by 16S ribosomal RNA Creation of an accepted validated severity score
Mode of action of smoking in HS pathogenesis Identifi cation of clinical HS subgroups
Diagnosis
The diagnosis of HS is made on the basis of the clinical signs; no additional tests are necessary62. 
But despite its frequent occurrence and straight forward clinical presentation, the reported 
time until diagnosis is 7 years63. This puzzling fact refl ects the limited awareness about the 
disease of many clinicians. Intensifi cation of HS research and the thereby generated publicity 
might raise the degree of awareness about the disease and the available treatment options 
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among clinicians. In The Netherlands the medical curriculum does not specifi cally elaborate 
on HS. Medical students are likely to encounter HS only once or twice during their internships, 
most likely during the ER surgery internship. Frequently they are wrongfully educated that 
HS is an apocrinitis which is treatable with oral antibiotics and incision and drainage. A single 
lecture incorporated in the future curriculum would be suffi  cient to teach medical students 
the basics of HS pathogenesis and treatment. Furthermore, since general practitioners are 
frequently the fi rst and only medical doctor a HS patient visit, education about HS should be 
incorporated in the GP traineeship and post-graduate courses as well. Visibility of HS would 
also be greatly promoted if and when a well–known public fi gure would manifest as an HS 
patient in popular media.
Prognosis and pathomechanisms
Data on disease progression and the natural course are limited27. Thus it is unpredictable 
which patients and how rapidly patients will progress to the more severe stages of the dis-
ease. It is therefore important to identify predictive parameters. This would ideally be done 
prospectively in a patient cohort from the fi rst disease manifestation and onward followed 
without interventions. However, since such a study would not be ethical. The clinical predic-
tive parameters might also be determined in a retrospective study in a large cohort, focusing 
on a comprehensive set of patient characteristics and detailed data on disease progression.
Genetics
Genetic predisposition evidently contributes to HS development64, but ill-defi ned HS popula-
tions hamper current genetic research. Whether nature or nurture is more important in HS 
pathogenesis has yet to be established. The concordance of HS in monozygotic twins might 
answer this question. To our knowledge, HS in monozygotic twins has yet to be reported. 
Furthermore, genome wide association studies (GWA) might discover single nucleotide 
polymorphisms (SNP) that provide guidance into pathogenic mechanisms and HS variants. 
GWA studies require large cohorts of well-documented HS patients65. For such a GWA study 
specialized HS centres in diff erent countries should combine forces to reach appropriate 
power in terms of numbers of patients and matched controls.
Smoking
Cigarette smoking is undoubtedly associated with HS66. It is, however, unclear which patho-
genic mechanisms of smoking contribute to HS disease development and/or its mainte-
nance. Cigarette smoke contains many components which may potentially contribute to HS 
pathogenesis (reviewed by Smith67). Furthermore, it is unknown whether smoking cessation 
infl uences disease severity, and whether the quantity of smoking correlates with disease 
severity. Smoking cessation is a low cost intervention and it would be highly worthwhile 
studying its eff ects in patients with HS in a prospective case control study.
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Bacteria
The results from bacterial studies in HS are hitherto inconclusive, but an important factor 
has not been addressed thus far. Before one can speak of an aberrant microbiome in HS, the 
microbiome of healthy skin should be characterized. Currently, the US National Institutes 
of Health human microbiome project is characterizing the human skin microbiota using 
advanced, molecular, deep sequencing techniques with interesting results relevant for HS 
pathogenesis68. First, it is now evident that only a small minority of skin bacterial species 
are able to thrive in culture68. Particularly anaerobic microorganisms in the hair follicles are 
diffi  cult to isolate using routine culture68. It has been estimated that less than 1% of bacterial 
species can be cultured68. This suggests that the culture-based approach used in the past to 
study HS lesions is unreliable and that no hard conclusions can be drawn from these data. 
New molecular sequencing techniques can not only identify but also quantify skin microbiota. 
Genomic characterization of bacteria relies on sequence analysis of the 16S ribosomal RNA. 
This genomic approach already revealed a much greater diversity of microorganisms on and 
in the skin than obtained by culture-based methods68. Hence, the HS microbiome should be 
reinvestigated using these new molecular deep sequencing techniques. Such a study might 
reveal non culturable bacteria causing HS or a microbiome shift to more pathogenic species.
Immunological pathways
We demonstrated that the dense cellular infi ltrate in HS contains many leucocyte subsets, 
but the functional roles and balance between infl ammatory cell subsets in HS infi ltrates is 
currently unknown. Further functional and in situ investigations into the infl ammatory cell 
subsets and their cytokine production are highly needed. In this thesis we demonstrated 
that mast cells are present in vast quantities, not only in clinical HS skin, but also in normal 
appearing perilesional skin. The role of mast cells in HS pathogenesis is currently unknown. 
They might play an important role in HS pathogenesis and form a target for further inves-
tigations. In this thesis we demonstrate high levels of IL-1β in HS lesions together with the 
presence of free keratin fi bers in the dermis. We therefore proposed that the infl ammasome 
is activated in HS. This pathogenic mechanism could explain the intense infl ammatory re-
sponse characterizing HS. The contribution of individual infl ammasome components such 
as Nlrp3, Nlrp1, Nlrc4, and AIM2 need to be explored in more detail. The Nlrp3 is the most 
widely studied infl ammasome and can be activated by a large number of stimuli. It can be 
activated by muramyl dipeptide (MDP), bacterial RNA, double stranded RNA and DAMP such 
as uric acid crystals, all components that are present in HS lesions, but also by amyloid-β and 
an exogenous compound such as asbestos30. Nlrp1 can be activated by MDP and anthrax 
toxin, Nlrc4 by fl agelin and AIM2 by dsDNA30. Since infl ammasomes not only generates IL-1β 
but also IL-18, levels of IL-18 should also be investigated additionally in future studies and its 
natural antagonist IL-18 binding protein.
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Therapy and monitoring
HS is notoriously diffi  cult and challenging to treat. The effi  cacy for many HS treatment mo-
dalities is based on case series or trial and error rather than on randomized controlled trials. 
The lack of evidence-based therapies in patient care is illustrated by the example that failure 
of immunosuppressive therapy such as systemic corticosteroids is required before anti-TNF-α 
biologics are reimbursed by health insurers in The Netherlands. However, there is no scien-
tifi c evidence that systemic corticosteroids improve HS. The presumed effi  cacy of systemic 
corticosteroids is solely based on a single report from 197069. Another example is the use of 
intralaesional corticosteroid injections. Intralaesional corticosteroid injections are used on 
a regular basis, whereas there is no evidence on the effi  cacy of this treatment what so ever.
HS patients will benefi t from improved clinical care based on evidence-based medicine. But 
clinical trials in HS have to deal with several challenges. First, there is no accepted uniform HS 
severity score. The currently used severity scores according to Hurley70 and Sartorius71 both 
have clear limitations. In order to be able to compare the effi  cacy of diff erent studies, a sensi-
tive and specifi c validated severity score is warranted. Such a new severity score is currently 
under development by a European consortium on HS scoring. Second, the heterogeneous 
results of most drugs in HS may indicate the existence of clinical variants of HS. Attempts 
should be made at identifying clinical variants of HS, because patients with a specifi c clinical 
HS variant may show a positive response to certain therapy even when the HS population as 
a whole remains unresponsive. Such personalized treatment would greatly improve clinical 
care. In this thesis we demonstrate subclinical disease activity in perilesional skin. This ob-
servation provides a rationale for the use of treatments aimed at disease prevention such as 
topical or systemic keratolytic and immunomodulating agents, which should preferably be 
investigated prospectively.
It has been suggested that HS is classifi able as an auto infl ammatory disease72 defi ned 
as a disease caused by a dysregulation of the innate immune system72, and as such many 
anti-infl ammatory and/or immunomodulating drugs available on the market qualify for the 
treatment of HS. Some of these drugs have already been anecdotally described for the treat-
ment of HS, but most have not. Below we briefl y discuss several immunomodulating drugs 
and summarize them in Table 1.
By demonstrating high levels of IL-1β in HS lesions, we identifi ed the infl ammasome 
pathway as a potential new target for therapy. Anakinra is an IL-1 receptor antagonist and 
canakinumab is a human monoclonal antibody targeting IL-β. Both these biologics show 
a marked effi  cacy in infl ammasome-mediated auto infl ammatory diseases73. It would be 
worthwhile investigating the effi  cacy of these IL-1β modulating biologics in randomized 
controlled clinical trials in HS.
Ustekunimab is a fully human monoclonal antibody directed against interleukin 12 and 
interleukin 23 (anti-p40). IL-12 is considered a Th1-promoting cytokine and IL-23 a Th17-
promoting cytokine. The effi  cacy of ustekunimab has been demonstrated in psoriasis74. Since 
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we showed that IL-17 is elevated in HS and a recent paper demonstrated elevated levels of 
p19 IL-23 mRNA38 (Th17 cytokines), ustekunimab is a potential new biologic for the treatment 
of HS. Gulliver et al. reported that in a pilot study ustekunimab improved HS in 2/3 patients75, 
but this should obviously be investigated in a larger HS patient population.
Azathioprine is an immune-modulating drug that was originally developed for the con-
trol of graft rejection in transplant surgery, but nowadays it is also in use for treatment of a 
wide range of auto-immune and immune-mediated diseases such as Crohn’s disease (CD) 
and rheumatoid arthritis (RA). Azathioprine is an imidazole derivative of 6-mercaptopurine 
(6-MP) that interferes with DNA and RNA synthesis, resulting in a signifi cant inhibition of 
lymphocyte proliferation and a decreased immune response76. Since azathioprine is a highly 
eff ective drug for Crohn’s disease, it constitutes a potential therapeutic for HS which has yet 
to be tested in clinical trials.
Methotrexate (MTX), a folate antagonist with anti-infl ammatory and immunomodulatory 
properties, is used for treating infl ammatory diseases such as psoriasis, RA and CD. MTX 
inhibits DNA synthesis, the production of the pro-infl ammatory cytokines TNF-α, IL-6 and 
IL-8 and impairs neutrophil chemotaxis. Furthermore secretion of sIL-2 receptor and the IL-1 
receptor are inhibited, while production of IL-10 is promoted77. The effi  cacy of MTX has been 
investigated in 3 patients with HS, but showed minimal therapeutic eff ects78.
Cyclosporine is a calcineurin inhibitor that acts selectively on T cells by preventing the 
phosphorylation of nuclear factor of activated T cells and, therefore the transcription of IL-279. 
Table 1. Immunomodulating drugs with potential use in HS
Immunomodulating 
drug
Main infl ammatory disease 
indications
Main mechanism of action Effi  cacy in HS
Anakinra RA, cryopyrin-associated 
periodic syndromes
IL-1 receptor antagonist ?
Canakinumab RA, cryopyrin-associated 
periodic syndromes
IL-1β neutralising monoclonal antibody ?
Ustekunimab Psoriasis Anti-p40 (IL-12 and IL-23) monoclonal antibody Improvement in 
2/3 patients
Azathioprine CD, RA Inhibits lymphocyte proliferation, and decreases 
immune response
?
Methotrexate (MTX) Psoriasis, RA, CD Inhibits TNF-α, IL-6, IL-8, , sIL-2 receptor, blocks IL-1r, 
promotes IL-10
Limited in 3/3 
patients
Cyclosporine Graft vs host, psoriasis, 
AD, RA
Inhibits T cells Improvement in 
4/4 patients
Tacrolimus AD, CD Inhibits calcineurin ?
Thaladomide / 
lenalidomide
CD, RA Inhibits TNF-α, IL-6, IL-1β, IL-12, GM-CSF, ICAM-1, COX-2 ?
Rituximab RA Depletion of CD20+ B cells ?
HuMab 10F8 Palmoplantar pustulosis IL-8 neutralizing monoclonal antibody ?
AD: Atopic dermatitis, CD: Crohn’s disease, RA: Rheumatoid arthritis
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Cyclosporine is used to prevent graft vs. host disease, psoriasis, atopic dermatitis (AD) and 
other infl ammatory diseases. Since we demonstrated increased numbers of T cells in HS le-
sions, cyclosporine could be a treatment option for HS. Cyclosporine has thus far anecdotally 
been used in 4 HS patients and showed favorable results80-82.
Tacrolimus is a macrolide antibiotic with potent immunomodulating properties. It is in 
use for the prevention of organ-transplant rejection and it is clinically eff ective in diff erent 
autoimmune diseases83. Tacrolimus can be applied topically as an ointment or systemically. 
The mechanism of action of tacrolimus in general is comparable with that of cyclosporin, 
since most eff ects of tacrolimus are thought to be mediated by the inhibition of calcineurin83. 
However, it has secondary eff ects on other infl ammatory cells that are normally activated by 
T cell-derived factors. Tacrolimus inhibits expression of IL-2, ICAM-1, NF-κβ, INF-γ and TNF-α84. 
The use of tacrolimus in HS has not yet been reported. Both topical and systemic applications 
could potentially be eff ective.
Thalidomide is glutamic acid derivate; lenalomide is an amino substitute of thalidomide 
and 2000 times more potent in TNF-α inhibition85. Thalidomide acts as an immunomodulator, 
by inhibiting critical infl ammatory cytokines/mediators as TNF-α, IL -6, IL-1β, IL-12, GM-CSF, 
ICAM-1 and COX-285. It has been used with promising effi  cacy in infl ammatory diseases such 
as for RA, ankylosing spondylarthritis and systemic sclerosis86. Thalidomide is highly terato-
genic and neurotoxic. One patient with pyoderma gangrenosum with comorbid HS has been 
described using thalidomide, but the clinical eff ect on HS severity was not described87.
With our demonstration of ectopic ‘pseudo’ B cell follicles in chronic HS lesions, a new fi eld 
of research in HS pathogenesis has potentially opened. Till to date the function of B cells in HS 
infl ammation remains largely unclear. Therapeutic intervention aimed at depletion of B cells, 
via treatment with rituximab, a chimeric monoclonal antibody against the protein CD20, re-
quires further in depth investigations into the function of these B cells in HS. Demonstration 
of their pathogenicity in HS would provide a rationale for rituximab treatment of patients 
with HS.
Since high numbers of neutrophils are present in abscessing HS lesions, IL-8, as a potent 
neutrophil chemoattractant, forms a potential therapeutic target. Interleukin-8 is a chemo-
kine that has been implicated in a number of infl ammatory diseases involving neutrophil 
activation. HuMab 10F8 is a novel fully human mAb against IL-8, which eff ectively neutralizes 
IL-8-dependent human neutrophil activation and migration88. Treatment with HuMab 10F8 
for palmoplantar pustulosis showed promising results and could be eff ective in HS88.
CONCLUDING REMARKS
HS remains a diffi  cult to treat disease, which is frustrating for patients as well as clinicians. 
In the past few years our understanding of the pathomechanisms involved has increased 
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and we gained more insight into the effi  cacy of multiple treatment options. HS research is 
still in its infancy and much research as indicated in this chapter remains to be done. Our 
investigations confi rmed the severe burden of the disease, provided support for existing 
treatments and generated novel insights into disease pathomechanisms with a perspective 
of new therapies.
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Hoofdstuk 1 geeft een algemene inleiding tot dit proefschrift. Hidradenitis suppurativa (HS) 
is een recidiverende of chronische, infl ammatoire huidziekte uitgaande van de haarzakjes/
follikel. HS komt voornamelijk voor in de huidplooien zoals oksels, liezen en billen, terwijl 
bij vrouwen ook de borsten aangedaan kunnen zijn. De huidafwijkingen (lesies) bestaan uit 
pijnlijke abcessen en acuut gevormde ontstekingen. Deze ontstekingen kunnen verbindin-
gen met elkaar vormen en op deze manier een netwerk van gangen vormen met uitgangen 
naar buiten, zogenaamde fi stels. Bij langdurige ontsteking kan er ook ernstige verlittekening 
optreden. De klachten bestaan voornamelijk uit pijn en riekende pus uitvloed die vaak 
schaamtegevoelens oproept. De prevalentie is recent geschat tussen de 1% en 4%. Ondanks 
het feit dat HS dus zeker geen zeldzame ziekte is, duurt het gemiddeld 7 jaar tot de diagnose 
gesteld wordt. Waarschijnlijk komt dit door onbekendheid van artsen met de aandoening. 
De ziekte ontstaat meestal na de puberteit, tussen het 20ste en 30ste levensjaar, en komt vaker 
voor bij vrouwen dan bij mannen met een ratio van 3:1. Op het eerste gezicht lijkt HS een 
besmettelijke (infectieuze) ziekte, maar vaak worden geen of alleen normale huidbacteriën 
gekweekt. Anders dan de naam doet vermoeden, hidradenitis=zweetklierontsteking, is HS 
een aandoening van verstopte haarzakjes. Factoren die een rol in het ziekte proces lijken 
te spelen, zijn genetische aanleg, roken, wrijvingskrachten, zwaarlijvigheid, kolonisatie door 
bacteriën, een disbalans van het immuunsysteem en hormonen. HS is erg moeilijk te be-
handelen, de meeste behandelingen geven slechts een gedeeltelijke verbetering of slechts 
een verbetering van korte duur. Behandelingen voor HS bestaan uit antibiotica kuren, im-
muunsysteem modulerende middelen zoals anti-TNF-α biologics, anti-hormonale middelen, 
licht- of lasertherapie, retinoïden en chirurgische ingrepen. Chirurgische behandelingen 
kunnen weer onderverdeeld worden in kleine, lokale ingrepen en grote waarbij de gehele 
haardragende huid van een gebied verwijderd wordt. Er is wetenschappelijk gezien relatief 
weinig bekend over HS. Zowel over de ontstaanswijze als de daaraan ten grondslag liggende 
mechanismen, als de eff ectiviteit van behandelingen, bestaat veel onduidelijkheid. Daarom 
is het onderwerp van dit proefschrift niet beperkt tot één enkele factor van de aandoening, 
maar worden zowel kwaliteit van leven en pathogenese als de therapeutische mogelijkhe-
den bestudeerd.
In hoofdstuk 2.1 beschrijven wij de resultaten van ons onderzoek naar het voorkomen (pre-
valentie) van depressie en de kwaliteit van leven. In totaal onderzochten wij 211 HS patiënten 
en vergeleken deze met 233 patiënten met een andere dermatologische aandoening. Voor 
het onderzoek naar depressie gebruikten wij de MDI vragenlijst en voor kwaliteit van leven 
de DLQI vragenlijst. De DLQI score was signifi cant hoger voor HS patiënten dan de controle 
patiënten en stond in verband met de ziekte ernst. De MDI score was ook signifi cant hoger 
voor HS patiënten. Klinisch gedefi nieerde depressie (volgens het ICD-10 model) was met 9% 
bij HS patiënten niet duidelijk hoger dan bij de controle patiënten (6%). Wij concluderen 
dat HS een grote impact heeft op de kwaliteit van leven en dat de ernst van HS hiermee 
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gecorreleerd is. De depressie vragenlijst kan ook gebruikt worden om de kwaliteit van leven 
te bepalen, en om de eff ectiviteit van behandelingen te meten. Verder vinden wij dat artsen 
bij HS patiënten alert moeten zijn op symptomen van depressie en, indien nodig, patiënten 
moeten doorverwijzen voor gespecialiseerde hulp.
In hoofdstuk 2.2 onderzoeken wij of HS vaak voorkomt bij patiënten met chronisch infl am-
matoire darmziekten (IBD). IBD bestaat uit de ziekte van Crohn en colitis ulcerosa (UC). Onze 
hypothese was dat als IBD en HS vaker samen voorkomen, dit zou wijzen op gelijksoortige 
ontstaans- en werkingsmechanismen in het ziekte proces. Tijdens een IBD patiënten informa-
tiedag vroegen wij 158 IBD patiënten (65% Crohn en 35% UC) naar klachten die op HS wijzen 
en lieten voorbeeldfoto’s zien van HS lesies. Op grond van deze enquête concludeerden wij 
dat 16% van de IBD patiënten zeer waarschijnlijk HS hebben (17% Crohn, 14% UC). Hiermee 
lieten wij voor het eerst zien dat HS relatief frequent voorkomt bij patiënten met Crohn of 
UC. Mogelijk kunnen geneesmiddelen voor IBD ook gebruikt worden voor de behandeling 
van HS.
In hoofdstuk 2.3 beschrijven wij een patiënt met een onderbeenprothese die HS-achtige 
huidafwijkingen ontwikkelde enkel op zijn beenstomp. Deze casus suggereert dat HS kan 
ontstaan op locaties met toegenomen wrijving en een warm vochtig milieu, en niet alleen op 
plaatsen die apocriene zweetklieren bevatten, zoals algemeen wordt verondersteld.
In hoofdstuk 3.1 wordt onderzocht welke ontstekingsfactoren (cytokinen) verhoogd zijn 
in chronisch aangedane HS lesies en in normaal ogende huid naast een HS ontsteking 
(perilesionaal). Deze waarden werden vergeleken met die verkregen zijn uit psoriasis lesies. 
Deze huidbiopten werden kortdurend gekweekt en de uitgescheiden ontstekingsfactoren 
in het kweekmedium bepaald. De ontstekingscytokinen IL-1β en TNF-α, maar ook het anti-
infl ammatoire cytokine IL-10, bleken niet alleen signifi cant verhoogd in HS huid, maar ook 
in de perilesionale huid. Deze cytokines waren in HS lesies duidelijk sterker verhoogd dan 
in psoriasis lesies. De cytokinen IL-2, IL-4, IL-5 en IFN-γ waren daarentegen vaak onmeetbaar 
laag. Deze resultaten suggereren dat geneesmiddelen gericht tegen TNF-α en IL-1β eff ectief 
zouden kunnen zijn voor behandeling van HS.
In hoofdstuk 3.2 onderzoeken wij of behandeling met de anti-TNF-α biologic adalimumab 
veranderingen in cytokinen en het ontstekingsinfi ltraat in HS huid teweeg brengt. Wij 
verbreedden onze kennis door het meten van verschillende cytokinen in HS huid van de 
betreff ende patiënten. Biopten van HS lesies werden afgenomen van 9 HS patiënten, voor 
start van de behandeling, en na 16 weken behandeling met adalimumab. Behandeling met 
adalimumab verlaagde voornamelijk de cytokinen IL-1β, CXCL9 en BLC, evenals het aantal 
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dendritische cellen, monocyten en macrofagen. Ook vond tijdens adalimumab behandeling 
afname plaats van het aantal T cellen en B cellen in de betreff ende biopten.
In hoofdstuk 3.3 wordt de aanwezigheid onderzocht van ontstekingscellen in normaal 
ogende perilesionale huid, net-ontstane HS ontstekingen, en chronische HS ontstekingen. 
Perilesionale HS huid laat verschillende afwijkingen zien, onder andere verstopping van de 
haarzakjes, psoriatiforme verbreding van de opperhuid en een toegenomen aantal ontste-
kingscellen. Nieuw gevormde HS ontstekingen worden gekarakteriseerd door een abcede-
rende neutrofi ele ontsteking met een aanzienlijke toename van macrofagen, monocyten en 
dendritische cellen. In de chronische fase neemt de grootte van de ontsteking toe en wordt 
in het bijzonder een toegenomen aantal B cellen en plasmacellen gezien. In alle HS stadia 
wordt een toegenomen aantal mestcellen gezien. Ook zien wij keratine resten van de opper-
huid diep in de huid en in reuscellen, als reactie hierop kan mogelijk een ontstekingsreactie 
plaatsvinden. Daarnaast zien wij losse keratinocyten en strengen van vitaal epitheel diep in 
de lederhuid, waar die normaal niet voorkomen, die mogelijk de basis zijn voor fi stelvorming.
In hoofdstuk 4.1 wordt de eff ectiviteit van een combinatietherapie bestaande uit de anti-
biotica clindamycine en rifampicine met verschillende duur en doseringen onderzocht. In 
dit kader werden 34 HS patiënten door ons behandeld met deze therapie. In 82% van de 
patiënten resulteerde deze behandeling in een verbetering van de aandoening en in 47% 
was zelfs geen andere behandeling meer nodig. Het maximale eff ect van de behandeling 
werd bereikt binnen 10 weken. Echter, in 62% van de patiënten, die geen andere behande-
ling nodig hadden, verergerde de ziekte weer na een periode van 5 maanden. Patiënten, 
die geen verbetering lieten zien, hadden over het algemeen een meer ernstige vorm van 
HS. Aangezien wij HS niet als een ziekte beschouwen die wordt veroorzaakt door bacteriën, 
denken wij dat de werking van deze antibiotica meer berust op ontsteking beperkende 
mechanismen dan bacteriedodende mechanismen. Uit deze resultaten concluderen wij 
dat deze combinatietherapie een veelbelovende therapie is voor HS. De optimale duur en 
dosering moeten nog nader worden onderzocht.
In hoofdstuk 4.2 onderzoeken wij de eff ectiviteit van de chirurgische methode deroofi ng.
Deroofi ng is een huidsparende chirurgische techniek waarbij het dak van de ontsteking 
wordt verwijderd en alle fi stels worden opgezocht met een sonde. 88 HS lesies werden op 
deze manier behandeld bij 44 patiënten. Slechts 17% van de plekken kwamen terug na 4,6 
maanden, wat voor HS een goed resultaat is. Patiënten waren tevreden met de procedure 
en beoordeelden deze met een 8 uit 10. 90% van hen zou deroofi ng aanraden aan andere 
patiënten. Wij stellen dat deroofi ng een eff ectieve, gemakkelijk uit te voeren chirurgische 
behandeling is voor milde tot matig ernstige HS.
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In hoofdstuk 4.3 onderzoeken wij de eff ectiviteit van colchicine in HS. Colchicine wordt 
gebruikt voor behandelingen van andere ontstekingsziekten, waarbij, net als in HS, het cyto-
kine IL-1β verhoogd is. Acht HS patiënten kregen 0.5 mg colchicine 2 maal daags gedurende 
1 tot 4 maanden. Gebruik van colchicine liet geen duidelijke verbetering in HS ernst zien, 
terwijl 3 patiënten misselijkheid als bijwerking meldden.
Hoofdstuk 5 beschrijft de belangrijkste bevindingen en conclusies uit hoofdstukken 2 
t/m 4 in de context van de beschikbare literatuur. Wij bespreken de mogelijkheid van een 
diermodel voor HS onderzoek, presenteren onze visie over hoe HS ontstaat, en zich ontwik-
kelt tot een chronische aandoening. Het hoofdstuk wordt afgesloten met suggesties voor 
toekomstig onderzoek naar HS.
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6-MP 6-mercaptopurine
AD Atopic dermatitis
AhR Aryl hydrocarbon receptor
ALA PDT Aminolevulinic acid photodynamic therapy
ALS Amyotrophic lateral sclerosis
AMP Anti-microbial peptide
APH1 Anterior pharynx defective 1
BID Twice a day
BLC B-lymphocyte chemoattractant
BMI Body mass index
Ca Cyproterone acetate
CARD15 Caspase recruitment domain family, member 15
CD Crohn’s disease
CES-D Center for epidemiologic studies depression scale
CI Confi dence interval
DAMP Damage associated molecular pattern 
DC Dendritic cell
DLQI Dermatology life quality index
DSM-IV Diagnostic and statistical manual of mental disorders version 4
EAE Experimental autoimmune encephalomyelitis
EE Ethinylestradiol
EOW Every other week
FDA Food and drug administration
FMF Familial Mediterranean fever
GSP German shepherd dog pyoderma
GWA Genome wide association
HLA Human leukocyte antigen
HS Hidradenitis suppurativa
IBD Infl ammatory bowel disease
ICD-10 International classifi cation of diseases-10
IFN Interferon
IL Interleukin
IMDM Iscove’s modifi ed Dulbecco’s medium
LHS Lesional hidradenitis suppurativa
LPS Lipopolysaccharide
MDI Major Depression Inventory
MDP Muramyl dipeptide
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MIG CXCL9
MMP Matrix metalloproteinase
NAMPT Nicotinamide phosphoribosyltransferase
NCT Nicastrin
Nd-Yag laser Neodymium-doped yttrium aluminium garnet laser
NK Natural killer 
NLR NOD-like receptor
NOD Nucleotide-binding oligomerization domain
OR Odds ratio
PAMP Pathogen-associated molecular pattern
PCOS Hyperandrogenic polycystic ovarian syndrome
PEN2 Presenilin enhancer 2
PGA Physician’s global assessment
PGP9.5 protein gene product 9.5
PHS Perilesional HS
PP Palmoplantar pustulosis
RA Rheumatoid arthritis
RBP4 Retinol binding protein 4
RCT Randomized controlled trials
SNP Single nucleotide polymorphism
Th T helper
TLR Toll like receptor
TNF Tumor necrosis factor
UC Ulcerative colitis
VEGF Vascular endothelial growth factor
QD Once a day
QoL Quality of life
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Dit proefschrift is mede tot stand gekomen door de inzet van vele vrienden en collegae. 
Graag wil ik een aantal mensen in het bijzonder bedanken.
Beste Jurr, bij jou is dit hele proefschrift begonnen. Je maakte mij enthousiast voor het vak 
dermatologie en de aandoening HS in het bijzonder. Ik zie mij nog als coassistent de eerste 
keer ’s avonds bij je thuis op bezoek komen om over HS te praten. Erg spannend om bij de 
specialist op bezoek te komen maar ik voelde mij al snel op mijn gemak en u werd jij. Jurr, 
hartelijk dank voor alles wat je voor mij gedaan hebt en de fi jne samenwerking zullen we in 
de toekomst voortzetten.
Beste Errol, Jurr stelde ons aan elkaar voor op het Deventer Ziekenhuis lustrumfeest. Ik, co-
assistent, met de wens dermatoloog te worden, jij professor experimentele dermatologie 
in Rotterdam: kan je je de spanning voorstellen? Tijdens mijn keuze coschap was je mijn 
begeleider en leerden wij elkaar beter kennen. Gelukkig deed je er alles aan om mij te laten 
terugkeren in het Erasmus MC. Waar ik je bijzonder voor wil bedanken is de ruimte die je mij 
gaf om mijn eigen hypothesen te formuleren en te onderzoeken. Ook heel bijzonder was 
immer je snelle respons of overleg, het maakte je niet uit of dit nu na het werk, ‘s avonds of 
zelfs ‘s nachts was. Mede door je ontspannen houding als promotor heb ik deze periode als 
een erg leuke tijd ervaren.
Beste Jon, voor mij ben jij DE wetenschapper. Ik wil je bedanken voor de grote bijdrage aan 
mijn wetenschappelijke vorming. De sessies op je kamer met het schoolbord en “dat was niet 
wat ik vroeg, geef nu eens kort antwoord op mijn vraag” waren zeer belangrijk. Hartelijk dank 
voor je altijd zeer kritische blik op mijn manuscripten, en je geduld met mijn grammatica en 
spellingsfoutjes.
Dear Gregor, I have always and still consider you as the international HS guru. Thank you for 
the great collaboration in the past and I trust in the future.
Beste Duco, het was altijd gezellig met jou op de OK in Delft, Voorburg of Leiden. Ik wil je 
hartelijk bedanken voor alle weefsels die voor mij hebt verzameld en onze prettige samen-
werking.
Beste Wim, hartelijk dank het verzamelen van weefsels in het Havenziekenhuis en de discus-
sies over behandelingen en pathogenese.
Rene en Eddy, bedankt voor jullie grote inzet bij mijn laboratorium experimenten.
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Beste professor Benner, bedankt voor het vertrouwen bij mijn aanstelling als promovendus 
op de afdeling Immunologie dit ondanks dat er geen lopende onderzoekslijn naar hidrade-
nitis was.
Beste Marjon en Deborah, zonder jullie hulp had ik de HS Humira trial nooit tot een goed 
einde kunnen brengen.
Ewout, Chris en de angels Lizenka en Armanda. We hebben met zijn allen een leuke en gezel-
lige groep gevormd als promovendi bij de immuno-derma. Bedankt voor jullie steun en hulp.
De overige coauteurs van mijn manuscripten wil ik graag bedanken voor hun inzet, betrok-
kenheid en kritiek.
Kim, bedankt voor je hulp als onderzoekstudent bij mijn projecten, je inzet is mij niet ontgaan.
Beste professor Neumann, dank voor de mogelijkheid mijn onderzoeken te verrichten op de 
afdeling Dermatologie en uw inspirerende onuitputtelijke dermatologische kennis.
De arts-assistenten van de Dermatologie, bedankt voor jullie interesse in mijn onderzoek en 
de prettige sfeer op de afdeling.
Al mijn collega’s op de immunologie en dan met name de unit immuunregulatie, maar ook 
Jeroen en Marja voor het uitvoeren van de cytokine arrays.
De HS patiëntenvereniging, ik ben vereerd mijzelf adviseur te mogen noemen en hoop op 
een nog lange vruchtbare samenwerking.
Mijn paranimfen, beste Minke, jij was ook getuige bij mijn huwelijk, en ik vind het fi ijn zo'n 
goede band met mijn zusje te hebben. Beste Lisette, in jouw enthousiasme over hidradenitis 
herkende ik mijzelf. Tijdens je keuzeonderzoek heb je hard gewerkt met enkele co-auteur-
schappen als resultaat. In januari zullen wij samen starten met de opleiding dermatologie en 
zullen dus gelukkig nog lang collega’s blijven.
De overige leden van de kleine en grote commissie, professor del Marmol, dr. Mekkes en 
professor Hovius dank ik voor het kritisch beoordelen van mijn proefschrift en deelname in 
de oppositie.
Mijn familie en schoonfamilie wil ik graag bedanken voor hun interesse in mijn werkzaam-
heden en steun.
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Lieve Leonie, zonder jou had ik dit proefschrift nooit tot een goed einde gebracht. Jij wist 
altijd de balans tussen werk en vrije tijd voor mij te bewaken.
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Hindrik Hessel van der Zee werd op 23 no-
vember 1979 geboren als zoon van Siebe en 
Marijke van der Zee-van Schie te Leiderdorp. 
Hij groeide op met een zus in Hazerswoude-
Dorp, Nijkerk en vanaf 1990 in Hillegom. In 
1997 behaalde hij het HAVO diploma en in 
1999 het VWO diploma aan het Fioretti col-
lege te Lisse. Dit zelfde jaar werd hij uitgeloot 
voor de studie geneeskunde en koos hij om 
bewegingswetenschappen te studeren aan 
de Vrije Universiteit te Amsterdam. In 2000 
kon hij alsnog met de studie geneeskunde 
starten aan de Rijks Universiteit Groningen. 
Na het behalen van het doctoraal diploma 
in 2006 verhuisde hij naar Deventer waar 
hij zijn coschappen liep in het Deventer 
Ziekenhuis. Hier leerde hij Dermatoloog dr. 
Jurr Boer kennen die hem enthousiasmeerde 
voor de dermatologie en de ziekte hidradenitis suppurativa in het bijzonder. In 2008 liep 
hij zijn keuze-coschap dermatologie in het Erasmus MC, Rotterdam en verhuisde naar Den 
Haag. In datzelfde jaar deed hij zijn artsexamen en ging aansluitend werken als arts-assistent 
op de spoedeisende hulp in het Ruwaard van Putten Ziekenhuis te Spijkenisse. In april 2009 
keerde hij terug in het Erasmus MC als arts-onderzoeker op de afdelingen Immunologie en 
Dermatologie en startte hij onder supervisie van profs. E.P. Prens J.D. Laman en R. Benner 
met het huidige proefschrift. Hij trouwde met Leonie van Wulften op 9 september 2010 en 
verhuisde naar Voorschoten. In januari 2012 zal hij starten met de opleiding tot dermatoloog 
in het Erasmus MC te Rotterdam. Zijn vrije tijd besteedt hij het liefst op de Waddeneilanden 
waar hij twee van zijn 3 hobby’s kan beoefenen, wedstrijdzeilen en sportvissen. Zijn andere 
hobby behelst de sportwagen Corvette.
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clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 
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Name PhD student: H.H. van der Zee
Erasmus MC Departments of Immunology and Dermatology
Research School: MolMed
PhD period: April 2008 till December 2011
Promotor(s): E.P Prens, R. Benner, J.D. Laman
Supervisor: E.P Prens
1. PhD training
Year Workload
(Hours/ECTS)
General academic skills
-  Biomedical english writing and communication
-  Writing successful grant proposals
-  BROK Cursus (Good clinical practice)
-  Cursus management voor promovendi en postdocs (NIBI)
2009
2009
2009
2009
4 ECTS
9 hours
20 hours
24 hours
Research skills
-  Biostatistics for clinicians
-  Introduction to clinical research
-  SPSS course
2009
2009
2010
1 ECTS
1 ECTS
16 hours
In-depth courses (e.g. Research school, Medical Training)
-  Molmed molecular diagnostics III
-  Course molecular medicine
-  Molmed molecular microbiology of infectious disease
-  Molmed annual course
-  3rd symposium and master classes on mucosal immunology
-  Immunologie cursus Lunteren
-  Cursus medische immunologie
-  Biomedical research techniques 7
2008
2008
2008
2008
2008
2008
2008
2009
16 hours
32 hours
8 hours
8 hours
16 hours
8 hours
16 hours
24 hours
Presentations (oral)
-  Problems of the current HS scoring systems, European Academy of Dermatology and 
Venereology, Paris, France
-  HS studies in Rotterdam, Skintermezzo, Rotterdam, The Netherlands
-  Werkbespreking Immunologie, Rotterdam, The Netherlands
-  De behandeling van HS, Skintermezzo, Rotterdam, The Netherlands
-  HS scoring system, American Academy of Dermatology AD, San Francisco, USA
-  How to help your HS patients, 5th Aegean Dermatology Symposium, Bodrum, Turkey
-  Clindamycin and rifampicin for HS, Wetenschapdag, Deventer Ziekenhuis, Deventer, The 
Netherlands
-  Werkbespreking Immunologie, Rotterdam, The Netherlands
-  Deroofi ng for HS, skintermezzo, Rotterdam, The Netherlands
-  HS treatment, hidradenitis suppurativa Vereniging, Utrecht, The Netherlands
-  A new HS score, European Academy of Dermatology and Venereology, Gothenburg, Sweden
-  Deroofi ng for HS, Dept. Surgery, Rotterdam, The Netherlands
-  Werkbespreking Immunologie, Rotterdam, The Netherlands
-  IL-1b, TNF-a and Il-10 elevated in HS, NVED, Lunteren, The Netherlands
-  Deroofi ng for HS, Jozefprijs, Deventer Ziekenhuis, Deventer, The Netherlands
-  Introduction and immunopathogenic mechanisms in HS pathology, EADV, Lissabon, Spain
-  Werkbespreking Immunologie, Rotterdam, The Netherlands
2008
2008
2008
2009
2009
2009
2009
2010
2010
2010
2010
2010
2011
2011
2011
2011
2011
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
Presentations (poster)
-  Poster NVED IL-1b elevated in HS lesions, NVED, Lunteren, The Netherlands
-  Immunohistological alterations in peri, early and chronic hidradenitis suppurativa, ESDR, 
Barcelona, Spain
2011
2011
1 ECTS
1 ECTS
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International conferences
-  European Academy of Dermatology and Venereology, Paris, France
-  American Academy of Dermatology, San Francisco, USA
-  5th Aegean Dermatology Symposium, Bodrum, Turkey
-  European Academy of Dermatology and Venereology, Berlin, Germany
-  European Academy of Dermatology and Venereology, Gothenborg, Sweden
-  European Academy of Dermatology and Venereology, Lissabon, Portugal
2008
2009
2009
2009
2010
2011
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
Seminars and workshops
-  Gata-3 in T-cell development and eff ector function, Rotterdam, The Netherlands
-  Auto immunity to neural antigens in MS, Rotterdam, The Netherlands
-  Interleukin-17 skin disorders, Rotterdam, The Netherlands
-  Transcriptional control of B-cell development, Rotterdam, The Netherlands
-  Ontstekingsziekten, Rotterdam, The Netherlands
2008
2009
2009
2009
2010
5 hours
5 hours
5 hours
5 hours
5 hours
Didactic skills
-  Teach the teacher 2008 16 hours
Other
-  Research meeting, Kopenhagen, Denmark
-  Research meeting, Dessau, Germany
-  Research meeting, Brussel, Belgium
-  Research meeting, Brussel, Belgium
-  HS session chair, European Academy of Dermatology and Venereology, Lissabon, Portugal
Occasional Reviewer for:
-  Dermatology
-  Ned Tijdschrift voor Geneeskunde
-  Journal American Academy Dermatology
-  Dermatology Treatment
-  Case Reports in Dermatology
-  Experimental Dermatology
-  Dermatologic Surgery
2008
2009
2010
2011
2011
2009
2010
2010
2010
2010
2011
2011
20 hours
10 hours
8 hours
8 hours
4 hours
4 hours
4 hours
4 hours
4 hours
4 hours
4 hours
2. Teaching activities
Year Workload 
(Hours/
ECTS)
Lecturing
-  Immunological lymediated skin diseases 2010-2011 10 hours
Supervising practicals and excursions
-  Casuistiek onderwijs 2de jaars geneeskunde studenten 2009-2011 100 hours
Supervising Master’s theses
-  Research thesis medical student Lisette de Ruiter
-  Research thesis medical student Kim de Winter
2010
2011
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CHAPTER 1
Figure 1. Prototypical hidradenitis suppurativa
 
Axillary HS in a man (source Dept. Dermatology, Erasmus MC).
Figure 3. Acne conglobata on the back of a man
Acne conglobata is characterized by severe eruptive nodulocystic acne without systemic manifestations 
(source Dept. Dermatology, Erasmus MC).
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Figure 4. Dissecting cellulitis of the scalp or perifolliculitis capitis et suff odiens
 
Dissecting cellulitis of the scalp is characterized by scarring alopecia with suppurating nodules and 
fi stulas (source Dept. Dermatology, Erasmus MC).
Figure 5. Pilonidal sinus at the gluteal cleft
Pilonidal sinus characterized by infl ammatory nodules and fi stulas caused by ingrown hairs (source Dept. 
Dermatology, Erasmus MC).
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Figure 6. Examples of HS by Hurley stage
a
b
c
a)  Hurley stage I HS in the axilla of a woman
b)  Hurley stage II HS in the axilla of a woman
c)  Hurley stage III HS in the groin of a man 
All images: source Dr. J. Boer, Deventer 
Hospital, The Netherlands.
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CHAPTER 2.2
Figure 1. Prototypical clinical photographs shown to patients
 
a b
a) Mild hidradenitis suppurativa in the axilla.
b) Severe hidradenitis suppurativa in the axilla.
CHAPTER 2.3
Figure 1. Left lower leg stump with fi stulas and follicular keratotic papules
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Figure 2. Detail of follicular keratotic papules on the medial side of the knee
Figure 3. Probed fi stula Figure 4. Extent of fi stulas after 
surgical deroofi ng and slight 
approximation by sutures
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CHAPTER 3.2
Figure 3. Immunohistochemical staining of CD11c+ dendritic cells in the clincally improved patient 6 in 
group 2: adalimumab EOW.
a
b
a) Week 0 b) Week 16.
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CHAPTER 3.3
Figure 2. Expression and distribution of keratin in HS lesions
a
b
a) Keratin fi bers and isolated detached keratinocytes (brown staining) in an abscess in a chronic HS lesion.
b) Single detached keratinocytes in the dermis (arrows) in a chronic HS lesion.
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Figure 2. (continued)
1
2
c
d
c) Free keratin fi bers (arrow 1) and detached keratinocytes (arrow 2) in the dermis in an early lesion.
d) Phagocytosed keratin fi bers and remnants in multinucleated giant cells, in an early lesion (indicated 
with arrows).
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Figure 3. Psoriasiform epidermal hyperplasia
a
b
a) Psoriasiform epidermal hyperplasia with parakeratosis overlying an infi ltrate in a chronic HS lesion. 
Basal epidermal keratinocytes frequently express Ki67, indicating proliferation.
b) The same sample adjacent to the infi ltrate shows less pronounced psoriasiform epidermal hyperplasia 
and fewer Ki67 positive keratinocytes.
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Figure 4. Strands of Ki67+ keratinocytes in the dermis in a chronic HS lesion
a
b
a) Keratinocytes, in an epidermal strand in the dermis in a chronic lesion (H&E stained).
b) Overview of the same HS lesion, Ki67 stained, with an epidermal strand in the dermis indicated by the 
square.
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Figure 4. (continued)
c
c) Higher magnifi cation of this epidermal strand showing multiple Ki67+ keratinocytes.
Figure 5. Scattered CD20 positive B cells, and a prototypical patch, creating ‘pseudo’ lymphoid follicles in 
a chronic HS lesion
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Figure 6. Increased number of tryptase positive mast cells in a chronic HS lesion
b
a
a) Tryptase positive mast cells in a chronic HS lesion.
b) Tryptase positive mast cells in healthy control skin.
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CHAPTER 4.2
Figure 1. Draining HS nodule, located in groin 
(Patient 1)
Figure 2. Blunt probe is inserted to explore extent 
of lesion (Patient 1)g
Figure 3. Sinus tracts can be unexpectedly long (Patient 2)
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Figure 4. The roof of the lesion is removed and left for healing by second intention, after removal of 
debris by curette (Patient 2)
Figure 5. Lesion healed into a cosmetically acceptable scar. Result after 1 year (patient 1)
 
Hessel BW.indd   206 11-Oct-11   10:37:47 AM
207
Color section
C
CHAPTER 4.3
Figure 1 Right groin of patient #1 with a PGA score of 1 (slight improvement)
a b
a) at baseline; b) at 4 months
CHAPTER 5
Figure 1. The back of a German shepherd dog with GSP (source Dr. M.A. Wisselink)
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Figure 3. Key histological and immunological alterations in early and chronic HS skin
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